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Abstract  
 
As part of cell division, the initiation of DNA replication is an important regulatory 
mechanism that maintains genomic stability over generations.  RECQL4 belongs to 
the RecQ DNA helicase family holding an important role in the initiation of DNA 
replication.  RECQL4 mutations can lead to disorders including type II Rothmund-
Thomson (RTS) syndrome.  These patients demonstrate predisposition to 
osteosarcoma (OS) development.  OS is a primary bone tumour showing extensive 
chromosomal instability. We hypothesise mesenchymal stem cells (MSC) 
differentiating to osteoblasts are particularly sensitive to RECQL4 mutations, which 
may lead to impaired differentiation and OS.  Our aim is to establish a direct link 
between the impairment of replication initiation, consequent chromosomal 
instabilities and deregulation in osteoblast differentiation, and OS development.  
 
A model that phenocopies the effect of RECQL4 mutations was established in 
ASC52telo cells to apply acute and chronic pressure on replication initiation using 
PHA-767491, which inhibits DDK that acts upstream of RECQL4 in replication 
initiation (PHA cells). We monitored cell viability and chromosomal instability 
characteristics in these cells, and RTS cell lines. To establish if PHA cells sustained 
differentiation capability, the cells were cultured using supplemented media for 
osteoblast and adipocyte differentiation, and were analysed by histochemical 
staining and immunofluorescence. Presence of DNA damage was quantified using 
γH2AX, and activation of the DNA damage response was assayed by western 
blotting. The cells were cultured in ultra-low attachment plates to test for anchorage-
independent growth, and further analysed by cell count, MTS and luminescence 
assays.  To identify protein-protein interactions of RECQL4, GFP-tagged RECQL4 
HeLa and U2OS cells were treated with SAHA, or hydroxyurea, pulled down with 
GFP-nanotrap, and analysed by mass spectrometry and western blot.  
 
We confirmed reduced proliferation rate while maintaining viability in PHA cells. 
Assaying mitochondrial membrane potential revealed no significant effect on 
mitochondrial function.  Successful differentiation of PHA treated MSCs into 
osteoblasts and adipocytes was confirmed. Expression of osteoblast differentiation 
markers: calcium, and RUNX2 was influenced by PHA. An increase was also 
observed in chronic PHA cells under normal medium, indicating malignant 
transformation.     Sustained DNA damage was shown in chronic PHA-767491 
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treated ASC52telo cells,  with a higher degree of CHK1 phosphorylation, 
anchorage-independent growth and reduced contact inhibition. 
 
We found that the RECQL4 mutated cell line AG05013tert was more sensitive to 
inhibition of replication initiation. Increase of DNA damage markers was observed 
in AG05013tert cells, but not in AG18375 and AG03587.  Presence of MCM10 and 
PP2A in RECQL4 complexes was confirmed, and novel interactions with HDX and 
EN-2 were found. 
 
Overall, we demonstrated that chronic interference with DNA replication initiation 
leads to sustained DNA damage with characteristics of genomic instability, activated 
DNA damage response that may become impaired over time, and may induce 
transformation.  
 
To further these studies, RECQL4 knockdown using lentiviral transduction in 
osteoblasts would verify the cellular changes we propose, which lead to 
chromosomal instabilities and OS development.  Novel protein interactions with 
RECQL4 could highlight new pathways with a direct and/or indirect role in 
tumourgenesis.   
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1 Introduction 
 
1.1 Cell division 
Humans begin as a single cell; the fertilised egg, and through cell division adults are 
built from around 1013 cells. During development, a large number of cells are 
produced, and the process is precisely regulated to ensure this and the generation 
of a variety of cell types.  The cell diversity is achieved through asymmetric cell 
division.  During asymmetric division, the daughter cells inherit different cellular 
components such as proteins and RNA, resulting in cellular heterogeneity, leading 
to divergent fates (Gönczy, 2008; Knoblich, 2010). Complex regulatory mechanisms 
are in place to achieve proliferation of eukaryotic cells.  The chromosomes are 
required to be duplicated precisely and segregated forming daughter cells to 
maintain genomic stability over generations.  The precise regulatory mechanisms 
ensure DNA replication is only restricted for occurrence once per cell cycle.  Failure 
of the process to occur accurately leads to the development of lethality and severe 
diseases, including cancer (Tanaka and Araki, 2011). Studies using Drosophila 
melanogaster and Caenorhabditis elegans models identified the basic molecular 
mechanisms behind asymmetric division (Gönczy, 2008).  The process requires 
coordination between spindle orientation and temporal events.  As part of the 
process partitioning-defective (par) proteins localise along a polarity axis 
asymmetrically which controls the orientation of the spindle and asymmetric 
localization of determinants of cell fate.  This inherited cell fate is only passed on to 
one of the two daughter cells (Fisher et al., 2012; Hoege and Hyman, 2013; 
Noatynska et al., 2013; Thompson, 2013).   
1.1.1 Cell cycle 
The cell cycle defines the process of cell division as a sequence of events leading 
to the rise of two genetically identical daughter cells. The cell cycle is regulated to 
ensure normal development of multicellular organisms. The initiation of the process 
is well maintained and regulated to ensure proper progression, and completion form 
one phase to the next. Once commenced, the completion of the cycle must follow. 
The cell cycle consists of four distinct phases, which includes G1 (Gap1), S (DNA 
synthesis), G2 (Gap2), and M phase  
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Figure 1.1-a). Each phase controls the process of the cell division progression, and 
the transition is tightly regulated by various kinases which will be discussed later.  
Cell cycle progression is monitored by checkpoints; G1/S, G2/M, and the spindle 
checkpoint located in M phase, to ensure faithful completion of steps prior to 
engaging in the next cell cycle phase. During S phase, genetic material is replicated. 
Chromosomes condense and segregate during M phase, equally distributing the 
genetic material forming daughter cells.  The M phase is complex, containing five 
steps; prophase, prometaphase, metaphase, anaphase and telophase.  Gap 
phases (G1 and G2) allow for cell growth and preparation for DNA synthesis. The 
G0 phase of the cell cycle allows the cell to go into quiescence.  It is an 
irreversible/reversible state of replicative dormancy, a period of cell cycle arrest to 
allow continuation, when progression is appropriate. Cell type and external stimuli 
can lead a cell into this state (Murray, 1993; Coudreuse and Nurse, 2010; Pagliuca 
et al., 2011; Bertoli et al., 2013; Foley and Kapoor, 2013). The duration of each 
phase of the cell cycle can be very variable. In mammalian cells, the cell cycle 
usually takes around 24 hours (Foley and Kapoor, 2013; Araujo et al., 2016). 
  
 
 
Figure 1.1-a Cell cycle division phases.  Cell division involves the tightly regulated, ordered events of the cell cycle.   A new 
cell cycle commits the cell for division and activates G1-S phase transcription.  The DNA is replicated during S phase, the 
chromosomes are condensed, sorted and passed on to the new daughter cells during M phase.  The GO phase is a state of 
irreversible or reversible. replicative dormancy (Quiescence) (Adapted from Foley and Kapoor, 2013). 
 
1.1.1.1 Cyclin-dependent kinases 
In higher eukaryotes, the restriction of replication  was initially described in 1974 
(Pardee, 1974; Blagosklonny and Pardee, 2002). This process occurs via the 
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sequential assembly of the replication initiation complex in G1, and the regulation of 
origin firing in S phase by cyclin-dependent kinases (CDK).  The activity of CDKs is 
dependent on the binding with cyclin protein family members (Tanaka and Araki, 
2011). The cyclin/Cdk complexes are a family of conserved heterodimeric 
serine/threonine kinases which are made of a regulatory subunit known as cyclins, 
and a Cdk which is the catalytic component.  In higher eukaryotes five Cdks 
(1,2,3,4,and 6), have been shown to be associated with cell cycle progression, 
including Cdk1 which is activated by A- and B-type cyclins, Cdk2 by E- and A-type 
cyclins, Cdk3 by C-type cyclins, and Cdk4 and Cdk6 by D-type cyclins (Stern and 
Nurse, 1996; Morgan, 1997; Malumbres and Barbacid, 2009; Uhlmann et al., 2011; 
Symeonidou et al., 2012). Interestingly, while there is some functional redundancy 
of some cyclin/Cdk complexes, Cdk1 is essential.  Studies have shown in yeast, 
mice and flies that Cdks are required for proliferation, survival, and have a role in 
polarity regulation as well (Coudreuse and Nurse, 2010; Noatynska et al., 2013). 
1.1.2 Replication initiation 
The initiation of DNA replication is an important regulatory step to ensure activation 
occurs appropriately to prevent over-replication, which would lead to possible 
heterogeneity and therefore loss of genome integrity, lethality and severe diseases, 
including cancer. In eukaryotes origins of replication initiate chromosomal DNA 
replication (Tanaka and Araki, 2011; Chen at al, 2018; Kang et al, 2018) 
1.1.2.1 Replication initiation; RECQL4 
During cell division, the onset of DNA synthesis requires the interaction of initiator 
proteins at the site of replication initiation, prior to the loading of the replication 
machinery.  These sites are referred to as replication origins (Leonard and Méchali, 
2013).  Replication origin activation a conserved chain of events.  The first step is 
called licensing, and generates the specific protein-origin DNA complex, the pre-
replicative complex (pre-RC) (see Figure 1.1-b) (Tanaka and Araki, 2011). The 
protein part of the Pre-RC comprises the hexameric origin recognition complex 
(ORC). The binding of ORC is followed by the recruitment of additional factors. The 
complex contains Cdc10-dependent transcript 1 (Cdt1), Cdc6, which further recruits 
the Mcm2–7 (Minichromosome Maintenance: MCM) replicative helicase (Tatiana 
and Bakkenist, 2018). The accumulation of Cdt1 promotes the formation of pre-RC 
(Ballabeni et al., 2013). During late mitosis, and G1 phase of the cell cycle the pre-
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RC assembles at origins by the loading of Mcm2-7 as an inactive helicase complex 
(see Figure 1.1-b).    
Initiation is the second step reaction that occurs at the transition from G0 to S cell 
cycle phase, activating the pre-RC (Tanaka and Araki, 2011).  Pre-RCs are 
activated by conversion into pre-initiation complexes (pre-ICs), via recruitment of 
initiation factors (Symeonidou et al., 2012), the Cdc7-Dbf4 (DDK), and S-phase 
cycling dependent kinases (S-CDK); Cdk2-cyclinE (see Figure 1.1-b)  (Labib, 2010). 
The origin firing is triggered by the phosphorylation events of DDK and S-CDK, 
which promotes the binding of the cdc45 initiator factor, in the presence of Mcm10, 
TopBP1 and the GINS complex (Labib, 2010). The protein Treslin associates with 
TopBP1 in a Cdk2-dependent manner, mediating the loading of Cdc45 onto the 
replication origins (Kumagai et al., 2010).  It has been suggested that the 
participation of RECQL4 in nuclear DNA replication occurs due to its N terminal 
domain, which resembles Sld2; a protein in yeast with a crucial role in DNA 
replication. The study by Ohlenschläger et al., (2012) demonstrated that the N-
terminus of RECQL4 adopts a fold, similar to that of homeodomains.  This domain 
serves as a DNA binding module and is also implicated in the interaction with human 
replication factor TopBP1. TopBP1 a key mediator crucially involved in DNA 
replication initiation and is involved in the formation of the active replicative helicase 
complex on replication origins, (see Figure 1.1-b) (Sanchez et al., 1999; 
Ohlenschläger et al., 2012; Tanaka et al., 2013). MCM10 interacts with RECQL4, 
enabling the localization of RECQL4 to the origins (Im et al., 2015), and the 
association of RECQL4 with the MCM2-7 complex (see Figure 1.1-b)  (Xu et al., 
2009b).  The MCM2-7 complex plays an important central role as the replicative 
DNA helicase by acting as a DNA unwinding enzyme both during DNA replication 
initiation and elongation (Labib et al., 2000; Forsburg, 2004). The process of 
unwinding the double-stranded DNA is catalysed by the replicative helicase 
Cdc45/MCM2–7/GINS (CMG) complex, the defining step in replication initiation 
(Muramatsu et al., 2010; Sengupta et al., 2013; Medagli et al., 2016) and leads to 
polymerase loading (Labib, 2010) (Figure 1.1-b).  For processive DNA synthesis; 
two sister replisomes are formed at each origin, and proceed bidirectionally along 
the DNA following the recruitment of additional replication factors to the CMG (Aria 
and Yeeles, 2019).  At the end of mitosis, the degradation of geminin is required for 
initiating a new round of licensing. Geminin is a negative regulator of licensing by 
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binding to Cdt1 (Figure 1.1-b) (Nishitani and Lygerou, 2002; Symeonidou et al., 
2012; Ballabeni et al., 2013).   
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Figure 1.1-b DNA replication licensing and the initiation steps, in budding yeast and human cells, based primarily on studies in budding yeast and analogies drown for human cells.     
At the late M and G1 phases of the cell cycle the sequential loading of ORC, Cdc6 and Cdt1proteins onto the chromatin recruits the MCM2-7 hexameric helicase to the replication origins, generating 
the assembly of pre-replicative complex (pre-RC). Other proteins associate with the DNA replication origins (Pre-IC assembly), and the formation of the preinitiation complex (Pre-IC) occurs 
following phosphorylation by DDK and CDK kinase.  This leads DNA unwinding and polymerase loading; Pol, α Pol ε and Pol δ, initiating DNA replication (Moiseeva and Bakkenist, 2018) 
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1.1.2.2 Impaired DNA replication initiation can lead to oncogenesis 
The faithful transfer of the genome and viability from the parental cell onto the 
daughter cells is a very elaborately controlled mechanism (Lau et al., 2007).  
Eukaryotes have evolved regulation at several stages, which safeguards the 
process of DNA replication initiation, DNA repair, and checkpoints that are critical 
for replication precision. This ensures the prevention of erroneous genomic 
instabilities and aneuploidy, which has been found a common trait in most cancers 
(Lengauer et al., 1998; Depamphilis et al., 2006; Duesberg et al., 2006; Lau et al., 
2007). Defects in DNA replication have been shown to be a result of direct inhibition 
or the abrogation of checkpoint and repair mechanisms. Furthermore, studies have 
shown a link between replication initiation proteins and oncogenesis, as illustrated 
in (Figure 1.1-c) (Lau et al., 2007).  The lack of or impaired function of pre-RC 
proteins in the relevant cell cycle phases may give rise to different phenotypes, 
which could lead to possible therapeutic and diagnostic developments (Lau and 
Jiang, 2006; Lau et al., 2007).  
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Figure 1.1-c Impairment of Pre-RC/DNA replication proteins and its involvement in oncogenesis.  Impaired function of 
pre-RC proteins can result in incomplete DNA replication leading to cell death or chromosomal instability by reducing licensed 
origins.  De-regulation can lead to re-firing, which if undetected can lead to subsequent amplifications and aneuploidy (Lau et 
al., 2007). 
 
1.2 RECQL4 
RECQL4 belongs to the family of RecQ DNA helicases. There are five members of 
this family in humans: WRN, BLM, RECQL4, RECQL1, and RECQL5 (Figure 1.2-a) 
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(Kitao et al., 1999b; Croteau et al., 2012b).  The RecQ helicase family is highly 
conserved, and along with other proteins such as BRCA1 and BRCA2 have been 
termed ‘the guardians of the genome’ due to their involvement in DNA metabolism 
related processes including repair, homologous recombination or replication fork 
restart, replication, transcription, and chromatin organization (Croteau et al., 2012b; 
Larsen and Hickson, 2013; Nahhas et al, 2018). The RECQL4 gene was first cloned 
and mapped to chromosome 8q24.3 by Kitao et al (1999a). RECQL4 is a small gene 
of 6.5 kb, with 21 exons and with most introns less than 100 bp in length (Kitao et 
al., 1999a; Wang et al., 2002a). The gene encodes a 1208 amino acid protein. 
Unlike other human RecQ helicases, RECQL4 lacks the RecQ carboxy-terminal 
(RQC), and helicase RNaseD C-terminal (HRDC) domains (Figure 1.2-a) 
(Ohlenschläger et al., 2012).  
 
 
 
 
Figure 1.2-a Structural organization of human RecQ helicases. RecQ helicase members possess a highly-conserved 
helicase domain (pink). The nuclear localization signal (greyish-blue) is present mostly at the C-terminus, RECQL4 is an 
exemption, which has two nuclear targeting sequences (NTS1 and NTS2) that are present at the N-terminus. The N-terminus 
of RECQL4 shows sequence similarity with the Sld2 protein in yeast that is important for DNA replication and cell viability. A 
putative mitochondrial targeting sequence is present at the N-terminus of RECQL4.  The location of some of the known 
RECQL4 mutations are depicted. * Mutations shared by RTS and BGS (Adapted image, from Croteau et al., 2012; Sidorova 
and Monnat., 2015.   
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1.2.1 Biochemical activity of RECQL4 
Studies have highlighted roles and functions of RECQL4, including DNA strand-
annealing activity and ATPase activity activated by ssDNA. RECQL4 has also been 
shown to be involved in DNA repair (Yin et al., 2004; Macris et al., 2006; Maire et 
al., 2009) and is capable of unwinding various DNA structures (Xu and Liu, 2009a).  
RECQL4 was thought not to possess DNA helicase activity, unlike other members 
of the RecQ helicases (Yin et al., 2004; Macris et al., 2006). However, RECQL4 was 
shown to possess in vitro 3′→5’ helicase activity by other authors, which might have 
been masked by strand annealing activity (Xu and Liu, 2009a; Capp et al., 2010; 
Croteau et al., 2012b; Larsen and Hickson, 2013). It has been suggested that there 
is a second helicase activity harboured at the 400 amino-terminal amino acid by a 
study by Xu and Liu, (2009), even in the absence of notable nucleotide binding and 
helicase motifs (Xu and Liu, 2009a).  
1.2.2 RECQL4 localisation 
Northern blotting analysis showed high expression in human thymus, testis, and 
placenta, with moderate expression in the heart, brain, colon, and the small 
intestines.  Peak of expression is seen at S-phase of the cell cycle (Yin et al., 2004; 
Dietschy et al., 2009; Croteau et al., 2012a).  Within the RecQ helicase family, 
RECQL4 is the only known to be found both in the nucleus and cytoplasm (Yin et 
al., 2004; Petkovic et al., 2005; Burks et al., 2007). It localizes predominantly to the 
nucleoplasm, with fraction to telomeres and nucleolus, and more recently found 
inside the mitochondria  (Croteau et al., 2012a).  A study by Burks et al., (2007), 
identified two nuclear targeting signals located in the N-terminus;  NTS1 amino acids 
37–66 and NTS2 amino acids 363-492, of RECQL4 (Burks et al., 2007).  The 
acetylation of RECQL4 by histone acetyltransferase p300 has been shown to lead 
to localisation of RECQL4 to the cytosol from the nucleus (Dietschy et al., 2009).   A 
study by Chi et al., (2012) reported the identification of nuclear exporting signals 
pNES2 and pNES3 at the C-terminus. Diminished cytoplasmic localization was 
observed following pNES2 deletion.  They also found that in the presence of 
functional pNES2 RECQL4 cytoplasmic fraction was enriched following the addition 
of ubiquitination tail at the C-terminus.   Using immunofluorescence Chi et al., (2012) 
demonstrated cytoplasmic RECQL4 to be located within the mitochondria, 
suggesting a regulatory role in mitochondrial DNA (mtDNA) copy number 
maintenance.   An increase in mtDNA copy number was demonstrated in HEK293 
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cells following RECQL4 expression elevation, while RECQL4 knockdown in U2OS 
cells resulted in a decrease in mtDNA copy number.   In RECQL4 deficient human 
fibroblasts and RECQL4 suppressed cancer cells mitochondrial superoxide 
production and a decrease in repair function was reported following oxidative DNA 
damage, further demonstrating the role of RECQL4 in mitochondrial stability (Chi et 
al., 2012). The intracellular distribution and dynamic relocalization of RECQL4 to 
sites of DNA damage has suggested a possible contribution to the phenotypes, and 
associated heterogeneity, which has been found in RECQL4-associated diseases 
(Croteau et al., 2012a). 
1.2.3 Mutations in the RECQL4 gene 
Almost half of the mutations in RECQL4, representing missplicing, nonsense, or 
frameshift mutations, occur before or in regions coding for the helicase domain 
suggesting that the helicase domain is critical for accurate function of the protein 
(Siitonen et al., 2009; Larizza et al., 2010; Kohzaki et al., 2012).  Most of the 
mutations are predicted to cause a truncated protein (Kitao et al., 1998; Larizza et 
al., 2010; Wang et al., 2017a).  
DT40 cells with homozygous deletions of the RECQL4 gene failed to proliferate, 
however rescue was achieved by ectopic expression of the N-terminal Sld2-like 
domain leading to proliferation.  This suggests that the C-terminus, including the 
helicase domain is not essential for cell proliferation (Abe et al., 2011).  However, 
other studies suggest the C-terminus as well as the helicase domain to be a 
requirement for DNA replication (Sangrithi et al., 2005; Matsuno et al., 2006; Capp 
et al., 2009).  The knockout of the Recql4 gene entirely, or the part encoding the 
Sld2-like N-terminus has been found to lead to embryonic lethality in mice and flies 
(Hoki et al., 2003; Sangrithi et al., 2005; Matsuno et al., 2006; Xu et al., 2009a).   
 
RECQL4 mutations (Figure 1.2-a) give rise to autosomal recessive overlapping 
diseases in humans: Rothmund–Thomson syndrome (RTS, OMIM #268400) 
RAPADILINO (RAPA, OMIM #266280), and Baller–Gerold syndrome (BGS, OMIM 
#218600). The majority of mutations detected have been found to be 3’ to the codon 
of amino acid 496 (Larizza et al., 2010).  The loss  of helicase domain causes a 
severe phenotype reminiscent of RTS (Mann et al., 2005). Studies have suggested 
that the mutations found within the RECQL4 protein in RTS individuals permit partial 
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activity (hypomorphic), even though the expression may be detected at very low 
levels (Ouyang et al., 2008).  
 
1.2.3.1 Baller-Gerold (BGS) syndrome 
BGS is inherited in an autosomal recessive manner and was first described in 1950. 
Its hallmark presentations include radial aplasia/hypoplasia and craniosynostosis.  
Craniofacial manifestations are not seen in all patients (Petkovic et al., 2005; Van 
Maldergem et al., 2006). The Hallmark feature of RTS, poikiloderma, is also found 
in patients with BGS (Petkovic et al., 2005). The most frequent mutations of 
RECQL4 are the R1021W missense, and the 2886 delta T frameshift mutations of 
exon 9 (Van Maldergem et al., 2006).  
1.2.3.2 RAPADILINO syndrome 
RAPADILINO is an autosomal recessive disease, involving RECQL4 mutations, and 
was originally described in Finland in 14 patients.  The acronym RAPADILINO 
stands for the characteristic clinical features often presented: RAdial hypo-/aplasia, 
Patellae hypo-/aplasia and cleft or highly arched PAlate, DIarrhoea and DIslocated 
joints, LIttle size and LImb malformation, NOse slender and NOrmal intelligence.  
Patients most commonly represent in-frame deletions of exon 7, which is thought 
not to affect the helicase domain (Siitonen et al., 2003). Interestingly, while there 
are overlaps in RTS and RAPADILINO symptoms, joint dislocations and patellar 
hypo/aplasia, found to be more common in female RAPADILINO patients, are not 
characteristic to RTS (Kellermayer et al., 2005; Van Maldergem et al., 2006).  
Around 7% have been found to develop tumours, mainly lymphomas and 
osteosarcoma (Kellermayer et al., 2005; Siitonen, 2008). 
1.2.3.3 Rothmund Thomson Syndrome (RTS) 
RTS was first described by Rothmund in 1868, characterising it as a familial 
occurrence of skin changes with bilateral juvenile cataracts.  In 1936 Thompson 
reported subsequent cases, and in 1957 it was suggested by Taylor that these were 
of the same disease (Rothmund, 1868; Thomson, 1936; Taylor, 1957). RTS is a 
rare autosomal recessive genodermatosis, therefore both parents of proband are 
obligate heterozygotes, leaving the siblings a 25% chance of being affected, 25% 
chance of not being carriers, and a 50% chance of being carriers but asymptomatic.  
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RTS patients appear to be phenotypically and genetically heterogeneous (Wang et 
al., 2003; Larizza et al., 2006; Larizza et al., 2010).   
Recurrent RECQL4 mutations have been found to include exon 9 c.1573delT 
(p.Cys525AlafsX33), which accounts for around one-third of RTS mutations. This 
mutation was found in compound heterozygous patients from multiple ethnic 
backgrounds (Wang et al., 2003; Larizza et al., 2010; Croteau et al., 2012b). The 
amino-terminal region has an essential functional role in the cell, although not 
necessarily for cell viability but can lead to severe phenotype reminiscent of RTS if 
lost (Kitao et al., 1999b; Ichikawa et al., 2002; Hoki et al., 2003; Mann et al., 2005).  
RTS patients have been found to have common phenotypes caused by mutations 
that target the helicase domain or the C-terminal region, suggesting the C-terminus 
acts as one unit (Kohzaki et al., 2012).  
1.2.3.3.1 Symptoms 
Pathological changes of the skin are the main hallmark characteristic presentation 
seen in RTS patients (Larizza et al., 2010). Poikiloderma, a skin rash seen in RTS 
patients, usually presented around the age of 3-6 month and typically the pattern of 
spread involves the cheeks, and then to other extremities, sparing the trunk and 
abdomen. The rash is sun-sensitive with redness and blisters, involving patches of 
skin.  The patient may develop variable pigmentation, atrophy; areas of thinning of 
the skin, and telangiectases; small clustering of blood vessels under the skin. This 
presentation is a crucial criterion for diagnosing RTS (Pujol et al., 2000; Wang et al., 
2001; Beghini et al., 2003; Larizza et al., 2010). Ectodermal dysplasia is often seen 
in type I RTS (Larizza et al., 2010).   Ectodermal dysplasia was previously defined 
as a congenital disorder presenting with alterations in at least to ectodermal 
structures including the hair, teeth, nails, or sweat glands (Freire-Maia, 1971). The 
classification has been modified to include gene defects and clinical manifestations 
(Visinoni et al., 2009).  Sparse or absent hair, eyelashes and eyebrows is a common 
feature. In a cohort of 41 RTS sufferers, 50% and 73% of the patients presented 
with sparse, brittle, thin or absent scalp hair and sparse hair on eyelashes and/or 
eyebrows, respectively (Wang et al., 2001).  Poorly formed and dystrophic nails 
(Larizza et al., 2010), and dental abnormalities were first described in the early study 
of 1868, and are also common features (Rothmund, 1868).   
Ocular lesions are often present, with rapid onset of bilateral cataracts is the most 
common ocular sign (Nathanson et al., 1983; Stinco et al., 2008).   
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Rothmund-Thomson syndrome does not appear to show cognitive impairment 
(Larizza et al., 2010), however, one patient has been recorded in the literature with 
sensorineural deafness (Beghini et al., 2003).   
Haematological signs have been reported, ranging from myelodysplasia to aplastic 
anaemia, and leukaemias have also been identified (Rizzari et al., 1996; Knoell et 
al., 1999; Porter et al., 1999; Narayan et al., 2001; Pianigiani et al., 2001).  
The loss of or underdeveloped bone and reduced growth syndromes leading to 
patterning-like phenotype are often referred to as “dysostoplasias”.  They can occur 
following genetic defects leading to defects in mesenchymal condensation and/or 
differentiation (Mundlos and Olsen, 2002). Radial ray defects appear to follow all 
three overlapping RECQL4 mutation disorders; BGS, RTS, and RAPADILINO 
(Siitonen et al., 2003; Larizza et al., 2006; Van Maldergem et al., 2006; Burks et al., 
2007; Larizza et al., 2010).  An early review has reported about 68% of the patients 
were found to display skeletal anomalies, including frontal bossing, saddle nose and 
abnormalities of the long bones (Vennos et al., 1992; Wang et al., 2003).  A latter 
study of 28 subjects found around 75% of patients with RTS presented at least one 
skeletal abnormality (Mehollin-Ray et al., 2008).  In at least two-third of patients low 
birth weight, slow weight gain, and linear growth deficiency are present, and they 
are proportionally small (Wang et al., 2001).  Those patients without RECQL4 
mutations and RTS appear to share some similar symptoms including skeletal 
abnormalities, however, those patients with RECQL4 mutations and RTS show a 
higher percentage of presenting with small stature, sparse brows or lashes, and 
radial ray defects (Radial hypo/aplasia and/or aplastic/hypoplastic thumbs.  The 
symptoms of RTS patients have been shown to involve highly proliferative cells, 
including developing teeth, nails, skin, intestines and blood (Larizza et al, 2010; 
Wang and Plon, 2019).  Involvement of RECQL4 in DNA replication initiation could 
explain this, suggesting RECQL4 may be important for viability of highly proliferative 
cells. The dysfunction of RECQL4 could lead to reduced cellular proliferative 
potential, leading to tissue damage and a lower potential for tissue regeneration, 
and the development of pathological disorders, such as RTS (Lu et al, 2014).   
1.2.3.3.2 Diagnosis 
The symptoms of RTS are relatively non-specific, leading to clinical diagnostics 
criteria to be variable.  Clinical diagnosis is therefore based on the time of onset, 
spreading, and clinical presentation of the characteristic poikiloderma.   The 
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probability of an RTS diagnosis, according to is determined by an atypical rash and 
the presence of two of the following signs: short stature, congenital bone defects, 
sparse hair found on the scalp, eyebrows, and eyelashes, abnormalities of the teeth 
and nails, cataracts, and hyperkeratosis. RTS diagnosis is usually considered in 
patients with osteogenic sarcoma, especially if presenting with skin changes 
(Nahhas et al, 2018; Wang and Plon 2019).  RTS molecular genetic tests currently 
include sequence analysis/mutation scanning to identify point mutations in the 
RECQL4 gene, and deletion/duplication analysis for the detection of partial or whole 
genome deletions in cytogenetic testing.  Lymphocytes or skin fibroblasts can reveal 
chromosome 8 abnormalities: trisomy 8, tetrasomy 8q, partial 8q duplication, and 
isochromosome 8q (Wang and Plon, 2016). It has been suggested that primary 
defects of the replication and repair functions of RecQ helicase mutant cells, 
chromosomal instability is a secondary occurrence (Bachrati and Hickson, 2008).  
Chromosomal instabilities are not a hallmark feature, however, to act as an adjunct 
to clinical diagnosis, nevertheless, when found it appears as distinctive mosaic 
aneuploidies and isochromosomes (Larizza et al., 2006).  
1.2.3.3.3 Subtypes 
There are two subtypes of RTS based on molecular and clinical analysis: type I and 
type II. Type I is characterised by poikiloderma, ectodermal dysplasia, and juvenile 
cataracts and shows no RECQL4 mutations on gene analysis. The aetiology of 
these cases is unknown, gene mutations have not been associated. Those patients 
with type II RTS have documented RECQL4 mutations with an associated risk of 
malignancy, and characterised further by poikiloderma and congenital bone defects 
(Wang et al., 2003; Larizza et al., 2010; Croteau et al., 2012b). Mutations may 
render the RECQL4 protein in RTS individuals partially active, even though the 
expression may be detected at very low levels (Ouyang et al., 2008).  It is unclear if 
the two types of RTS represent different syndromes demonstrating similar clinical 
features, or the possibility of involving different genes linking to the same pathway 
(Larizza et al, 2010), suggesting a link between RECQL4 and cancer predisposition 
in RTS patients. 
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1.2.4 RTS and cancer predisposition 
Cancer is a developmental process, and cancer cells are formed following complex 
cell transformation, often due to mutations or DNA-rearrangements which 
undermine the former cellular phenotype.  This generates a cell population with 
large variability in gene expression, chromatin organisation, and interactome 
composition formation (Huang et al., 2009b; Greaves and Maley, 2012; Huang, 
2013; Wang et al., 2013a; Wang et al., 2013b) 
RTS patients can present with multiple malignancies, in particular osteosarcoma 
(Dick et al., 1982; Varughese et al., 1992; Drouin et al., 1993).  Studies have shown 
susceptibility can also be induced by chemotherapy (Simon et al., 2010; Carlson et 
al., 2011). Around two thirds of patients with mutations in RECQL4 have RTS (Wang 
et al, 2003; Siitonen et al., 2009; Larizza et al, 2010; Croteau et al, 2012).   A clinical 
cohort study looked at 41 RTS patients and found 30% diagnosed with 
osteosarcoma (Wang et al., 2001). The median age of diagnosis of osteosarcoma 
is 11 years in RTS patients, which is slightly lower than those in general public 
without RTS (Lindor et al., 2000; Wang et al., 2001), suggesting RTS as a premature 
aging syndrome that may lead to cell susceptibility to OS (Croteau et al., 2012b; 
Larsen and Hickson, 2013). Proliferative defects could lead to tissue damage and 
reduced regeneration, leading to many of the symptoms associated with RTS (Lu et 
al, 2014). This could also link the age of OS development occurring in younger 
patients in those with RTS (Lindor et al., 2000; Wang et al., 2001).  RTS type II 
patients have demonstrated a second peak of incidence of OS in the elderly (Unni, 
1996; Dorfman and Czerniak, 1998).  OS in older patients have also demonstrated 
worse prognosis (Longhi et al., 2008).  Epithelial tumours including squamous cell 
and basal cell carcinomas, Bowens disease, and melanoma of the skin have also 
been demonstrated in some RTS patients (Wang et al., 2001; Wang et al., 2003; 
Howell and Bray, 2008).  Skin malignancy may be related to skin sensitivity, and 
use of sunscreen protection is recommended (Kiss and Anstey, 2013; Morales‐
Sánchez et al., 2016). The development of skin cancers can occur at any age, 
however, often presented earlier in RTS patients (Stinco et al., 2008).  Interestingly, 
many RTS patients develop more than one tumour of the same or of different type.  
This supports RTS as a cancer predisposition syndrome (Hees et al., 1996; Stinco 
et al., 2008).  
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The burden of cancer correlates with the increase of the age of the population 
(Jones et al., 2012).  The biological functions of the association of aging and cancer 
is not yet fully understood. Aging leads to physiological deterioration which 
contributes to the development of some human cancers (Kennedy et al., 2014), and 
could be a driver of the significance risk of cancer development seen on premature 
aging diseases (Figure 1.2-b). 
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Figure 1.2-b– Schematic linking premature/normal aging and cancer development. Mutations can lead to premature aging syndromes. Key hallmarks of aging include; telomere attrition, mitochondrial dysfunction, 
genomic instability, loss of proteostasis, epigenetic alterations, stem cell exhaustion, cellular senescence, deregulated nutrient sensing, and altered intercellular communication.  This could lead to cell susceptibility 
driving cancer development (Anisimov, 2009; López-Otín et al., 2013).  
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1.3 Mesenchymal stem cells 
The first report of MSCs was in 1867 by pathologist Julius Friedrich Cohnheim, who 
described them as fibroblastoid, adherent, and extravasated cells at sites of injury 
(Cohnheim, 1867).  Later, these ossifying cells were isolated in cell culture, and 
reported as a plastic-adhering colony forming cell population, originally harvested 
from bone marrow (Friedenstein et al., 1970).  In 1990 they were found to exhibit 
the ability of multipotent differentiation, and from then referred to as mesenchymal 
stem cells, capable of osteoblastic, adipocytogenic, and chondrogenic potential 
(Caplan, 1991).  Mesenchymal stem cells (MSCs) are now widely available, have 
few ethical concerns, low immunogenicity, and multi-lineage differentiation potential 
(Figure 1.3-a) (Jung et al., 2012; Wang et al., 2014).  
 
 
Figure 1.3-a Mesenchymal stem cell multipotentiality. Mesenchymal stem cells (MSCs) are able to differentiate into 
mesodermal, ectodermal, and endodermal lineages (Ullah et al., 2015). Adapted from (Uccelli et al., 2008). 
 
There are many sources of MSCs (Crisan et al., 2008; Choudhery et al., 2013; Patel 
et al., 2013).  MSCs can be isolated efficiently from bone marrow (Pittenger et al., 
1999), amniotic fluid (Scherjon et al., 2003; Tsai et al., 2004), amniotic membrane 
(Cai et al., 2010), dental tissue (Huang et al., 2009a; Seifrtová et al., 2012), 
endometrium (Schüring et al., 2011), peripheral (Ab Kadir et al., 2012), and adipose 
tissue (Wagner et al., 2005; Zhang et al., 2006), to name a few.  The bone marrow 
is often utilised for isolating multipotent MSCs, however, the harvest procedure is 
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highly invasive, and the quantity, differentiation potential, and lifespan has been 
reported to decline with age (Nishida et al., 1999; Mueller and Glowacki, 2001; 
Stenderup et al., 2003).  Adipose tissue is easier to obtain as less invasive then 
many other sources, such as the bone marrow.  Adipose tissue has been identified 
with relatively high abundance of stem cells (Dicker et al., 2005; Fraser et al., 2006).  
Large quantities of adipose tissue can be isolated following liposuction, therefore 
attractive for requirements of large scale productions of MSCs (Zuk et al., 2002; 
Wang et al., 2014).  MSCs from different sources have been shown to demonstrate 
variations on proliferation rates, and suggested that human umbilical cord 
mesenchymal stem cells (HUC-MSCs) have highest proliferation potential 
(Choudhery et al., 2013; Wang et al., 2014).  However, these are more difficult to 
obtain, compared to adipose derived cells.  The success of isolation has also been 
reported to be variable (Erices et al., 2000; Goodwin et al., 2001; Mareschi et al., 
2001; Wexler et al., 2003; Bieback et al., 2004; Kögler et al., 2004; Lee et al., 2004).    
MSCs hold typical characteristics, such as fibroblast like morphology, formation of 
fibroblastoid colony-forming units, differentiation ability, and expression of certain 
classical markers. MCSs have been found to be positive for markers CD44, CD105, 
CD73, and CD90, and negative for CD3, CD14, CD19, CD34, and CD45 
(Choudhery et al., 2013; Wang et al., 2014). However, studies have found some 
controversy, with different marker expression seen (Kern et al., 2006). MSCs are 
defined by the International Society for Cellular Therapy as holding specific 
characteristics.  The criteria include: exhibiting plastic adherence, specific set of cell 
surface markers (as listed above), and have the ability to differentiate in vitro into 
adipocytes, chondrocytes and osteoblasts (Dominici et al., 2006; Bourin et al., 
2013).   
 
The ability to differentiate is dependent on MSC type (Cohen and Chen, 2008), 
involving signalling pathways and transcription factors promoting lineage selection.  
Some of these well regulated pathways include Wnt (Clevers et al., 2014; Park et 
al., 2015), Hedgehog (Spinella-Jaegle et al., 2001; Deng et al., 2008; Fontaine et 
al., 2008), Notch (Deng et al., 2008; Lin and Hankenson, 2011; Shimizu et al., 2011; 
Song et al., 2015), chemical factors, and physical factors; ECM, integrins, cell 
shape, external mechanical forces, geometric structures such as contractile 
cytoskeleton (Engler et al., 2006; Chen et al., 2016).  
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1.3.1 Bone formation 
The bone holds many roles in the human body. Functions of the bone include the 
maintaining of calcium levels in the blood, establishing and maintaining the 
mechanical support of soft tissue, and skeletal structure; growth and support, acting 
as levers in muscle action, supporting the process of haematopoiesis, acting as a 
hold surrounding the brain and spinal cord. Bone tissue is unlike other tissue, in 
respect to its ability to regenerate rather than heal (Marzona and Pavolini, 2009).  
Bone is a very dynamic form of tissue that undergoes a constant state of remodelling 
under normal conditions, in response to changes that include hormone levels, 
growth factors, and mechanical load. The efficiency of bone structure is dependent 
on the biochemical properties of different bone components (Ducy et al., 2000).  
There are three main types of bone cells: osteoblasts, osteocytes and osteoclasts, 
which work collectively coordinating bone maintenance (Curtis et al., 2016).  There 
is a finely regulated balance in bone structure formation that involves the deposition 
of bone extracellular matrix (ECM), hydroxylapatite [Ca5(PO4)3(OH)] crystals on the 
collagen fibres, by differentiated osteoblasts and resorption by osteoclast  
Boonrungsiman et al., 2012; Luukkonen et al, 2019).  Osteocytes occupy single 
lacunae and hold an extensive network of dendritic processes.  They act as a 
mechanosensory system around Haversian canals allowing communication 
between neighbouring osteocytes directly via Cx43 at gap junctions, or through 
endocrine, paracrine (receptor activator of nuclear factor-kappa B ligand (RANKL)) 
and autocrine signalling factors, crucial for bone modelling and remodelling    
(Yellowley et al., 2000; Curtis et al., 2016). Defects in osteoblasts be it qualitative or 
quantitative, acquired or inherited, would lead to disruption of bone maintenance 
causing many pathophysiological presentations, such as short stature, bone 
fragility, osteoporosis, and metabolic bone disease (Ducy et al., 1999).    
Macrophages hold a known role in repair and inflammation.  Interestingly, they are 
also found within the developing marrow cavity in normal bone.  Macrophages, like 
osteoclasts are of monocytic lineage. The function of macrophages in the bone is 
not fully understood, as they have not been found to co-localise with osteoclasts 
(Godwin et al., 2013).  They may promote osteoblast differentiation leading to repair 
and maintenance of bone density (Vi et al., 2015).   
Throughout life this maintenance is achieved through the process of continuous 
tissue renewal known as remodelling (Figure 1.3-b), which occurs asynchronously 
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throughout the skeleton at basic multicellular units. During childhood there is a 
positive balance, which reaches a peak of bone mass in early adulthood (Ducy et 
al., 1999; Hernandez et al., 2003).  This is followed by a period of stability before a 
negative balance occurs in older age, leading to a greater activity of osteoclasts and 
bone loss (Zebaze et al., 2010). In adults the BMU (basic multicellular unit) takes 
around 3 weeks with 3 to 4 months for the formation response, resulting in about 5-
10% of the skeleton is replaced each year, and the replacement of the whole adult 
human skeleton takes around 10 years (Frost and Straatsma, 1964; Parfitt, 1980; 
Harada and Rodan, 2003).  
 
 
Figure 1.3-b The sequential stages of bone remodelling.  Activation; signal via osteocytes or endocrine signals osteoclast 
precursors the remodelling site.  Resorption; the bone matrix is resorbed by fully differentiated and mature osteoclasts which 
adhere to the mineralized bone matrix, and secrete protons and proteases, such as cathepsin-K, and matrix metalloprotease 
9 (MMP9). The membrane-rich ruffled border dissolves the mineral phase of the bone and releases proteases to further 
degrade the organic phase.  A ‘sealing zone’ is formed where they adhere tightly to the matrix confining to the lacuna, and 
allows efficient bone degradation. The reversal stage; the removal of most osteoclasts, Mesenchyme derived osteoblasts then 
rebuild this resorbed bone by producing mineralized matrix.  Termination phase (Quiescence) ends the differentiation of 
osteoblasts and the bone surface is maintained until further remodelling is signalled (Duong et al., 1998; Coxon and Taylor; 
Bellido et al., 2014; Georgess et al., 2014). Adapted from (Everts et al., 2009; Siddiqui and Partridge, 2016) 
 
Skeletal growth occurs from the beginning of development in foetal life to second 
decade during longitudinal growth. This requires the process of modelling which 
differs from remodelling that occurs throughout life.  The cells hold the same roles, 
however, the bone is formed at the sites that have not undergone resorption (Figure 
1.3-c).   The changes generated in the size and shape of the bone follow the 
widening of long bones at the periosteal surface, and the development of medullary 
cavity due to resorption at the endosteal surface (Sims and Martin, 2014).  The 
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development of bone is referred to as osteogenesis. The skeleton is formed from 
three distinct lineages: the somites generating the axial, the lateral plate mesoderm 
generating the limb, and the cranial neural crest forming the branchial arch and 
craniofacial bones and cartilage. Bone formation involves the transformation of 
existing mesenchyme tissue forming bone tissue, directly referred to as 
intramembranous ossification; and forming post differentiation into cartilage, which 
is replaced by bone; termed endochondral ossification.  In humans in long bones, 
endochondral ossification forms outwards in both directions from the centre of the 
bone.  The cartilage ends of the long bones are called epiphyseal growth plates.  
The bone continues to grow, if these areas produce chondrocytes, which are 
required to proliferate and push out the cartilaginous ends of the bone (Gilbert, 
2000). Intramembranous ossification involves mesenchymal cells condensing and 
differentiating into osteoblasts directly, which deposit the osteoid matrix leading to 
calcification, and form an outer fibrous membrane surrounding the bone known as 
the periosteum.  The inner surface of the periosteum is highly cellular, while the 
peripheral surface is rich in vascular and neural sympathetic network, mesenchymal 
progenitor cells differentiating into osteoblasts, fibroblasts and osteogenic 
progenitor cells that also form an osteoid matrix, which therefore leads to layers of 
bone formation (Squier et al., 1990; Gilbert, 2000; Dwek, 2010).   The inner layer 
has also been referred to as the cambium and found to be essential for bone growth 
(Ito et al., 2001; Bilkay et al., 2008) that involves bone elongation and modelling 
(Dwek, 2010). The cambium becomes thinner with age, and in adults the periosteum 
is only a thin layer of tissue of which envelopes the bone structure (Allen et al., 
2004).  Following terminal differentiation of osteoblasts, osteocytes become trapped 
within the bone matrix and are the most abundant cell within the bone.  The lifespan 
of these cells is long, reported at around 25 years (Polig and Jee, 1990; Mulhern 
and Van Gerven, 1997; Franz‐Odendaal et al., 2006). However, other factors 
influence this, such as bone age and cell location from the surface of remodelling 
(Parfitt et al., 2000; Qiu et al., 2002).   
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Figure 1.3-c Schematic diagram of the interior of a typical long bone showing the growing proximal end with a growth 
plate and a distal end with the epiphysis fused to the metaphysis (Jee, 1988; Zoetis et al., 2003).  During growth (dashed 
lines) (I), the external shape of the metaphysis is maintained, (II).  A constant length of the metaphysis is achieved by resorbing 
central trabeculae at the border between the metaphysis and the diaphysis (III). At the diaphysis level, the outer bone size 
expands through periosteal apposition (IV). The marrow cavity enlarges through endocortical resorption (V) (Rauch, 2012).  
The growth plate is divided into three well-defined zones, which disappears after puberty (Karimian et al., 2011). The resting 
zone contains embedded single cells or pairs of small, uniformly round in shape, and generally quiescent cells (Ballock and 
O'keefe, 2003; Melrose et al., 2008). Immediately beneath this zone lies the proliferative zone, the chondrocytes are flatten, 
and begin to divide forming parallel to the bone alignment, and synthesize collagen of types II and XI (Ballock and O'keefe, 
2003). In the hypertrophic zone, the chondrocytes are larger in shape and more swollen, here they initiate terminal 
differentiation. The cells demonstrate reduced cell division, an increase in alkaline phosphatase activity and the synthesis of 
large amounts of various elements of the ECM, including type-X collagen. Elongation occurs until adulthood, when the 
epiphyses fuse by ossification (O'keefe et al., 1994; Scheuer and Black, 2000; Karimian et al., 2008; Karimian et al., 2011). 
Image adapted from (Jee, 1988; Karimian et al., 2011; Rauch, 2012; Alman, 2015).  
 
The regulation of MSC differentiation into osteoblasts and adipocytes have been 
implicated in conditions which relate to defective bone remodelling (Horwitz et al., 
1999; Kawai et al., 2012; Pino et al., 2012). An increase of bone marrow adiposity 
has been seen in conditions relating to bone loss, such as aging and pathological 
conditions (Justesen et al., 2001; Moerman et al., 2004; Dudley-Javoroski and 
Shields, 2008; Bredella et al., 2011; Cao, 2011; Motyl et al., 2011; Cohen et al., 
2012; Mcgee‐Lawrence et al., 2016). In support of our hypothesis, studies have 
suggested impaired differentiation in the osteogenic, or chondrocyte pathway may 
play a role in OS development (Taitz et al., 2004; Walkley et al., 2008; Wagner et 
al., 2011; Mutsaers et al., 2013; Sun et al., 2014). 
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1.4 Primary bone malignancies 
1.4.1 Ewing sarcoma 
Ewing sarcoma is an example of a pediatric solid tumour of the bone, derived from 
mesenchymal cells (Riggi et al., 2005; Chen et al., 2015). Specific initiation by 
chromosomal translocations have been reported in Ewing sarcomas, including the 
t(11;22)(q24:q12) that generates the EWS-FLI1 fusion protein (Tirode et al., 2014) 
the most frequent oncogenic driver (Chen et al., 2015).  Ewing sarcoma presents 
with a peak incidence in adolescence, but unlike OS, a second peak is not seen in 
the elderly (Damron et al., 2007).  The development of Ewing is thought to be 
prenatal, whereas OS appears to show a link between bone growth during puberty 
in its aetiology (Parkin et al., 1988; Stiller, 2007).  Both commonly demonstrate fibro-
osseous lesions (Lee et al., 2012).    
1.4.2 Osteosarcoma  
Osteosarcoma (OS) is the most common primary bone cancer.  The incidence of 
OS appears to show a bimodal distribution, the first peak is associated with rapid 
growth of the skeletal system, occurring during adolescence (Mirabello et al., 2009; 
Yamaguchi et al., 2015).  This is highlighted also as females present earlier than 
males, which is linked to the earlier development age seen in females (Mirabello et 
al., 2009). The second peak occurs in the elderly (Yamaguchi et al., 2015). 
OS mostly occurs in the metaphyseal areas (91%) of long bones of the extremities, 
including lower end of femur, upper end of the tibia, upper end of humerus, and the 
upper end of the femur (descending order). Only around 9% are seen in the 
diaphysis. A common site is the knee joint. The involvement with other sites of non-
long bone are less common, but the occurrence appears associated with an 
increase with age (Kaya et al., 2000; Bielack et al., 2002; Cleton-Jansen et al., 2009; 
Fletcher, 2014; Kundu, 2014). The characteristic radiological feature of OS is the 
sun-burst appearance with periosteal lifting with a Codmans’ triangle formation, 
identified by x-ray.  There is usually further evidence of new bone formation in soft 
tissue with a permeative pattern of destruction of bone (Resnick, 1995; Dorfman 
and Czerniak, 1998; Fletcher, 2014; Kundu, 2014).    
The classification of osteosarcoma is based on the predominant cell lineage, and 
the extracellular matrix produced by the malignant cells (Fletcher, 2014). The most 
common primary osteosarcoma is osteoblastic (osteoid matrix) accounting for about 
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50%, chrondroblastic (cartilaginous tissue) about 25%, and fibroblastic (fibrous 
tissue) about 25%. Other primary classifications include small cell, telangiectatic, 
low grade central, and surface osteosarcomas; parosteal, periosteal, and high-
grade surface.  There are further unusual types which demonstrate similar biological 
behaviour to conventional osteosarcoma such as osteoblastic osteosarcoma-
sclerosing type, chondroblastoma-like osteosarcoma, and clear-cell osteosarcoma, 
to name a few (Huvos, 1993; Broadhead et al., 2011a; Hameed et al., 2011; Tesser-
Gamba et al., 2012; World Health, 2013; Fletcher, 2014; Kundu, 2014).   Cases of 
multicentric OS (OSMC) have been reported (Sim et al., 1992; Varughese et al., 
1992; El-Khoury et al., 1997; Miozzo et al., 1998; Spurney et al., 1998; Pujol et al., 
2000; Wang et al., 2001; Leonard and Méchali, 2013), which refers to the tumour 
occurring at multiple sites with the absence of pulmonary metastases.  This is further 
classified as synchronous if more than one lesion is found, and metachronous if a 
new tumour is found at new site (Currall and Dixon, 2006).  There appears to be an 
increased risk of OSMC in RTS patients reported in the literature (Hicks et al., 2007; 
Cabral et al., 2008; Stinco et al., 2008; Larizza et al., 2010). Asymptomatic 
osteosarcoma has been reported; however, most patients present with symptoms 
related to location of lesion (Yamaguchi et al., 2015). The most likely cell type of OS 
origin is the osteogenic cell lineage, as they are prevalent in the bone 
microenvironment. Interestingly, OS occurs more commonly at the sites of bone 
growth, suggesting proliferation of osteoblastic cells may acquire mutations required 
for transformation (Rosenberg, 2010). Studies have suggested MSC under 
osteoblast commitment were the cells of origin, however, although only present at 
low incidence, early mesenchymal progenitors targeted with specific mutations 
could also generate OS. This suggested the micro-environment signals may be a 
contributing factor. The level of tumour differentiation did not relate to the level of 
cell of origin differentiation.  Supporting epigenetic differentiation mechanisms could 
be involved, particularly in mature osteoblasts during tumour initiation (Calo et al., 
2010; Rodriguez et al., 2013; Chan et al., 2014; Quist et al., 2015). Undifferentiated 
MSCs may lead to OS following oncogenic events (Mohseny et al., 2009; Lemos et 
al., 2015). 
Current treatment for OS involves a combination of adjuvant and neoadjuvant 
chemotherapy, and surgery (Hong at al, 2013; Harrison et al 2018).  Survival rate of 
osteosarcoma has remained fairly unchanged over the past 20 years (Bishop et al., 
2016). Around 70% of patients with osteosarcoma and no metastasis at diagnosis 
Page | 27  
 
will have a 5-year survival rate, which falls to <30% in patients with metastasis, or 
<20% reoccurrence following remission, following current treatments. Around 80% 
of patients will develop or present with radio-graphically undetectable micro-
metastases (Marina et al., 2004; Chou et al., 2005; Daw et al., 2006; Tang et al., 
2008; Li et al., 2014). The survival rates appear similar between RTS patients and 
non-RTS patients (Hicks et al., 2007). A study demonstrated some patients with 
RTS and osteosarcoma led to remission following appropriate multimodal therapy, 
although survival rates still low overall.  Treatment was advised as the same as 
sporadic OS, with the exception of chemotherapy, as increased toxicity has been 
seen in RTS patients; this would need additional monitoring and altering on the 
patients response (Hicks et al., 2007; Zils et al., 2015). Better understanding could 
improve treatment developments (Gorlick, 2002; Kundu, 2014; Cui et al., 2016). 
Early metastasis is often seen, and often the main reason for the poor prognosis 
with OS (Ta et al., 2009; Tesser-Gamba et al., 2012; Botter et al., 2014).   
1.4.2.1 Cell cycle dysregulation and OS 
Dysregulation of cell cycle checkpoints has been demonstrated in many tumours 
(Hartwell and Kastan, 1994; Taylor and Mckeon, 1997; Bower et al., 2010).The 
deregulation of mitotic checkpoint control is thought to be an underlying cause of 
chromosomal instabilities (Savage and Mirabello, 2011; Martin et al., 2012). The 
tumour suppressor Phosphatase and tensin homolog (PTEN) supresses 
unscheduled mitotic checkpoint complex to maintain chromosomal stability (Choi et 
al., 2017), as a regulator of cyclin D and PI3K-Akt signalling (Weng et al., 2001). 
The loss of PTEN may aid tumour growth and expansion in the bone (Xi and Chen, 
2017). Nuclear α-thalassemia/mental retardation X-linked (ATRX) has multiple 
roles, including histone modifications and transcription (Ratnakumar and Bernstein, 
2013). In childhood cancers mutation in the epigenetic regulator ATRX  is common, 
with around 29% of osteosarcomas (Chen et al., 2014a). The loss of ATRX can lead 
to an upregulation of transcription, aberrant epigenetic alterations, and DNA 
damage at telomeres (Wong et al., 2010; Heaphy et al., 2011a; Lovejoy et al., 2012). 
The phosphoinositide 3-kinase (PI3K/Akt) pathway is known to be an important cell 
survival pathway in OS (Cenni et al., 2004; Inoue et al., 2005; Díaz-Montero et al., 
2006).  Akt regulates several downstream targets, enabling OS cell growth and 
survival (Chirgwin and Guise, 2000).     
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1.4.2.2 OS and known gene involvements 
To date, 14 main drivers have been described that may account for around 87% of 
cases of osteosarcoma; some novel in the context of osteosarcoma (ATRX, FANCA, 
NUMA1 and MDC1), some known including RECQL4, TP53, and RUNX2 (Kovac et 
al., 2015). Altered expression of genes associated with cell adhesion, DNA repair, 
and cell cycle progression may also be involved in the development of OS (Yang 
and Wang, 2016), a few of which will be discussed in more detail below.   
1.4.2.2.1 P53  
P53 belongs to a family of transcription factors, encoded by TP53 gene in humans. 
P53 holds an important role in the regulation in MSC differentiation, including 
osteogenic (Kim et al., 2014; Li et al., 2015), maintaining genomic stability (Lane 
and Crawford, 1979; Levine et al., 1991), regulation of cell cycle (El-Deiry et al., 
1992), apoptosis (Shaw et al., 1992), senescence (Yonish-Rouach and Resnitzky, 
1991), and metabolism (Berkers et al., 2013).  Around 50% of human cancers were 
reported to hold P53 mutations (Olivier et al., 2010; Robles and Harris, 2010).   P53 
mutations appear to be a significant oncogenic driver in OS (Diller et al., 1990; 
Helman and Meltzer, 2003; Mirabello et al., 2015; Velletri et al., 2016).  Next 
generation sequencing approaches have identified a specific translocation event in 
the first intron of the TP53 tumour suppressor gene in the majority of OS cases, 
leading to the inactivation of TP53 in almost all osteosarcomas (Chen et al., 2014a).  
A high level of genomic instability is seen in OS cells with P53 mutations 
(Overholtzer et al., 2003; Liu et al., 2009). The lack of P53 in MSCs may lead to 
disruption of differentiation into mature osteoblasts as a consequence of the 
upregulation of Runx2 and Osterix, establishing impaired bone remodelling, and an 
osteosclerotic phenotype, demonstrated in mice (Lin et al., 2009; Solomon et al., 
2014; Zambetti, 2014). The bone tumour microenvironment could signal MSCs 
lacking or having mutant P53 to promote OS development (Cheng et al., 2014; 
Alfranca et al., 2015). RECQL4 has been found to interact with P53 (De et al., 2012; 
Xavier et al., 2014; Lu et al., 2015).  Interestingly, an increase of P53 protein levels 
have been reported in RTS cells (Davis et al., 2013).  
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1.4.2.2.2 RECQL4 and tumour development 
The mechanisms behind tumorigenesis and association with mutations in RECQL4 
remain unknown (Lin et al, 2017).  The most common cause of death in patients 
presenting with RECQL4 mutations is cancer (Croteau et al., 2014; Lu et al., 2017).  
Overexpression and amplification of RECQL4 has been reported in colorectal 
cancer (Buffart et al., 2005), furthermore, a study by Lao et al, (2013) found 
RECQL4 and BLM expression are significantly increased in colorectal cancer cells 
(CRCs), when compared to matched normal colonic mucosa and in contrast to 
RECQL and RECQL5.  The study indicates the possibility of increased expression 
of BLM and RECQL4 to support the ability of CRC cells to tolerate genotoxic stress 
(Lao et al., 2013). RECQL4 expression is also increased in metastatic prostate 
cancer cell lines (Su et al., 2010).  The loss of RECQL4 expression has been shown 
to lead to the accumulation of double-strand breaks, while following knockdown 
tumourigenicity (in vivo) and invasiveness (in vitro) was shown to decrease in 
metastatic prostate cancer cells (Su et al., 2010), These data suggest that RECQL4 
might be an important factor in the pathogenesis and tumorigenesis of CRC and 
prostate cancer (Su et al., 2010; Lao et al., 2013). Overexpression and amplification 
of RECQL4 has also been reported in breast cancer (Thomassen et al., 2009), late 
stage laryngeal squamous cell carcinomas (Saglam et al., 2007) as well as in 
sporadic osteoblastomas (Maire et al., 2009).  Thomassen et al, (2009) even 
suggests RECQL4 to be a potential metastasis promoting gene in breast cancers. 
Yong et al, (2014), found frequent amplifications of RECQL4, however, did not find 
associations between these amplifications and late stage oral squamous cell 
carcinomas (OSCCs). Despite significant amplifications were shown, the expression 
of RECQL4 was not shown to be affected in the samples (Yong et al, 2014).  
1.4.2.2.2.1 RECQL4 and OS 
RECQL4 expression is found abundantly in actively forming bone; in osteoblasts 
lining the trabecular surface, bone lining cells, and in chondrocytes of the growth 
plate. RECQL4, therefore, may have an important role in bone growth (Delagoutte 
and Von Hippel, 2003; Siitonen, 2008; Ng et al., 2015).  A correlation has been 
shown between the presence of pathogenic variants of RECQL4, low bone mineral 
density, and a history of increased fracture risk in RTS patients (Cao et al., 2017), 
and risk of OS development (Mehollin-Ray et al., 2008).     RECQL4 has been found 
to be a requirement for skeletal development through interaction with p53 (Lu et al., 
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2015).  In conditional mouse models, disruption of Recql4 function in skeletal cells 
leads to bone abnormalities, such as osteoporosis, however, it would appear not to 
always lead to OS development but may lead to OS susceptibility (Lu et al., 2015; 
Ng et al., 2015), and the type of mutation may be an influencing factor. In Recql4-
deficient mice (Recql4HD), Lu et al, (2014) found evidence of bone marrow and/or 
haematological defects indicating possible senescence of bone marrow cells. 
Interestingly, some RTS patients have shown to have progressive leukopenia, 
chronic microcytic hypochromic anaemia, myelodysplasia, aplastic anaemia and 
leukaemia (Larizza et al, 2010); disorders that are associated with the dysfunction 
of bone marrow (Kohzaki et al., 2012), suggesting that RECQL4 deficiency may lead 
to bone marrow dysfunction. RECQL4 expression may be up-regulated by RANKL 
during osteoclast differentiation (Mccardle, 2013).  RANKL has been shown to 
facilitate the migration of cancer cells into the bones (Jones et al., 2006),  while high 
levels of RANKL in osteosarcoma leads to poor response to preoperative 
chemotherapy (Lee et al., 2011b).  The increase in the generation of osteoclasts 
resulting in the resorption of normal bone is also a part of OS pathogenesis and 
aggressiveness (Bathurst et al., 1986; Avnet et al., 2008; Broadhead et al., 2011b), 
which could be linked to high levels of RANKL observed (Mori et al., 2007).  RANKL 
pathway has been found to be crucial for tumourigenic osteolysis, and allows tumour 
expansion (Chirgwin and Guise, 2000). An association has also been made with 
over-expression of RECQL4 in osteosarcoma tumours and an increase in genome 
instability (Maire et al., 2009; Thomassen et al., 2009). Interestingly, in sporadic 
osteosarcoma somatic mutations of RECQL4 have not been detected (Martin et al., 
2014).  
1.4.2.2.3 RUNX2 and cancer 
The mammalian Runx family of transcription factors, which includes RUNX1, 
RUNX2, and RUNX3, have an important role in cell fate determination into specific 
lineages (Komori, 2010; Ito et al., 2015).  The RUNX genes encode the α subunits 
of PEBP2/CBF (polyomavirus enhancer-binding protein 2/core binding factor) 
transcription factors required for skeletal development (Wang et al., 1993; Yoshida 
et al., 2002). The key role of RUNX2 is in the regulation of osteoblast differentiation, 
therefore maintaining bone, bone development, and maturation (Komori, 2007).  
RUNX2 is regulated by Vitamin D (Lim et al., 2010; Martin et al., 2010; Hoshino et 
al., 2015; Garimella et al., 2017).   Patients with OS present aberrations in vitamin 
D regulatory system and sub optimal vitamin D levels (Lee at al., 2013; Kurucu et al 
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2019). Vitamin D targets the RUNX2 pathway, specifically inhibiting genes required 
for cell cycle, proliferation, survival, interactions, cytoskeletal dynamics, migration, 
and invasion, reported in an OS cell line (Garimella et al., 2017).    
RUNX2 may increase the expression of prometastatic RUNX2 target genes, 
including integrins, focal adhesion kinase, PTHrP, VEGF, bone sialoprotein (BSP), 
osteopontin and survivin (Van Der Deen et al, 2012; Rustamov et al, 2019). RUNX2 
has been shown to be overexpressed in metastatic breast cancer cells, leading to 
the promotion of transcription of genes such as MMP and VEGF, which are involved 
in migration and invasiveness (Javed et al., 2005). RUNX2 has been shown to act 
in rapidly proliferating tumour cells in the bone microenvironment through the 
promotion of PTH or PTHrP mediated antiapoptototic effects.  RUNX2 expression 
here appears to be pro-survival for the tumour cells, promoting tumour growth. To 
aid this RUNX2 also induces survivin expression (Bellido et al., 2003).  In OS, many 
growth factors have been reported to activate RUNX2, promoting RUNX2 
phosphorylation directly, or indirectly.  Survivin is an important biomarker in OS, and 
recently Runx2 has been shown to activate survivin and Bcl2 which inhibits 
apoptosis, aiding in tumour cell survival (Lim et al., 2010). The overexpression of 
RUNX2 can generate osteopenia and fractures as receptor activator of NF-κB ligand 
(RANKL) expression is increased, leading to stimulation of osteoclast activity (Liu et 
al., 2001; Gupta et al., 2012)  In OS cell lines, RUNX2 may also regulate the focal 
adhesion pathway by mediating genes, such as TLN1 and FAK (Van Der Deen et 
al., 2012).  
Interestingly, RUNX2 has also been implicated in osteomimicry which promotes 
breast and prostate cancer metastasis to the bone (Akech et al., 2010; Brubaker et 
al., 2003; Leong et al., 2010).  Osteomimicry is the ability of cancer cells to behave 
like bone cells, assuming osteoblast like phenotype.  This has been demonstrated 
by breast and prostate cancer cells expressing bone matrix proteins, alkaline 
phosphatase, and molecules involved in the cross talk between osteoclasts and 
osteoblasts (Gonzalez-Suarez et al., 2010; Rucci and Teti, 2010).  
1.4.2.3 OS and bone dysregulation  
OS commonly occurs in the metaphysis region, and the most common primary site 
of OS is the distal femur (Girish et al., 2012; Haynes et al., 2017; Kumar and Singh, 
2017).  During bone growth, the metaphyseal cortex of the distal radius appears thin 
and porous.  The observed cortical porosity may be an influential factor to the 
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increased rates of distal fractures seen in puberty (Parfitt, 1994).  Cortical porosity 
refers to the average fraction of the void volumes within the volume of the cortical 
bone (Kalkwarf et al., 2011; Zebaze et al., 2013).   An early study suggests the 
incomplete trabecular coalescence as the main process leading to fragility, rather 
than bone remodelling (Rauch et al., 2007), as rapid modelling drift of the 
metaphyseal cortex occurs (Rauch, 2012).  This could suggest, however, the lack 
of osteoblast involvement to recover the situation (Rauch, 2012). Another study has 
suggested mechanical loading cycles leading to the coalescence of metaphyseal 
trabeculae, which may link to the metaphyseal cortical thickness and porosity 
(Tanck et al., 2006; Rauch, 2012).  Further factors which may be involved include 
the short life cycle of metaphyseal trabeculae. Pathological fractures can present at 
diagnosis or form during treatment in patients with OS, with an incidence of around 
5-12% (Chandrasekar et al., 2012).   
1.5 The DNA damage response and genome instability 
A fundamental pre-requisite for life involves completeness and integrity of genomic 
information (Utani et al., 2010). DNA damage is a generic term which is used to 
describe DNA modifications with the ability to generate cell death response, in 
particular apoptosis. If DNA damage is not repaired or does not lead to apoptosis, 
loss of genomic stability can follow the genomic alterations (Roos and Kaina, 2013).  
1.5.1 DNA damage 
DNA damage can originate from exogenous and endogenous (internal) sources. 
Endogenous sources can be related to physiological processes, such as during 
replication following DNA mismatches, and DNA strand breaks can follow abortive 
topoisomerase I and II activity.  DNA lesions can also occur due to damage arising 
from hydrolytic reactions, and methylation (Valko et al., 2006). Double-stranded 
DNA breaks (DSBs) can also arise following V(D)J recombination and 
immunoglobulin gene class switch recombination (CSR) during development of the 
adaptive immune system leading to induced chromosome breakage (Dudley et al., 
2005; Daniel and Nussenzweig, 2013). Inflammation and infection recruits 
macrophages and neutrophils to the site, and reactive oxygen and nitrogen 
compounds are produced (Kawanishi et al., 2006).  This can lead to DNA single-
strand breaks (SSBs), DSBs or base damage (Khanna and Jackson, 2001).    
Further examples include oxidative DNA damage (Li et al., 2002), lipid peroxidation 
(Esterbauer et al., 1990), propano adducts (Hecht et al., 2001), etheno adducts 
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(Chung et al., 1996),  endogenous alkylating agents (Holliday and Ho, 1998), and 
endogenous oestrogens (Yager and Leihr, 1996), to name a few.   
A major environmental risk of exogenous sources comes from ultra-violet light.  A 
common cancer-causing reagent prevalent today includes tobacco (Doll and Peto, 
1981; Pfeifer et al., 2002; Wogan et al.; Gao et al., 2014; Wei et al., 2014).  
Exogenous and endogenous sources can be influenced by an interaction between 
them, leading to DNA damage and diseases, such as cancer (Jackson and Loeb, 
2001).   
1.5.2 Hallmark features of genomic instability  
Genomic instability refers to a range of alterations of DNA from single nucleotide to 
whole chromosomal changes. Based on the level of genetic disruption genomic 
instabilities are typically divided into three categories.   
Nucleotide instability (NIM) is characterised by high occurrence of nucleotide 
deletions, base substitutions, and insertions. NIM occurs due to replication errors 
and impairment of nucleotide excision repair and base excision repair pathways.  
This form may be less common, however can lead to dramatic phenotypes.  An 
example is germline mutations in XPC that lead to Xeroderma pigmentosum, an 
autosomal recessive disease.  It is characterised by impaired nucleotide excision 
repair and sensitivity to UV light and often skin cancer (Al-Tassan et al., 2002; 
Dworaczek and Xiao, 2007).  
A microsatellite is a tract of repetitive DNA which leads to the repeats of specific 
DNA motifs ranging between 2 to 5 base pairs, at typically 5 to 50 times (Turnpenny 
and Ellard, 2016).  They can occur at various locations within the genome, and 
demonstrate a high mutation rate and diversity, establishing microsatellite instability 
(MIN). MIN usually originates from defects in mismatch repair genes (Weissenbach 
et al., 1992; Ionov et al., 1993; Geiersbach and Samowitz, 2011).   
Chromosomal instabilities (CIN) involve the increased rate of loss or gain of entire 
or part of chromosomes and can be categorised as numerical (N-CIN), and 
structural (S-CIN), although with some overlapping features (Cisyk et al., 2014). N-
CIN can occur as a result of defects in chromosomal segregation, and S-CIN can 
follow aberrant genomic rearrangements and chromosomal breakages, which can 
include duplications, translocations, and deletions (Rajagopalan et al., 2003), and 
usually but not always alterations to gene copy numbers.  S-CIN can form as a result 
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of ineffective DNA damage response mechanism often in response to exogenous 
insults that cause errors in replication (Bayani et al., 2003).  
In cancer cells some of the mechanisms involved in maintaining genomic stability 
can be disrupted, which leads to genomic instability and can contribute to the 
malignant transformation of these cells through, for example, the amplification of 
oncogenes or drug-resistance genes (Utani et al., 2010). CIN frequently leads to 
karyotypic complexity in tumours which is associated with high expression levels of 
survival and tissue invasion genes, and decreased expression of cell cycle and DNA 
repair regulators (Roschke et al., 2008).  It is thought that around 90% of human 
cancers exhibit chromosomal abnormalities and aneuploidy (Lengauer et al., 1997; 
Gagos and Irminger-Finger, 2005). CIN is related to poor prognosis and drug 
resistance (Gagos and Irminger-Finger, 2005; Carter et al., 2006; Walther et al., 
2008; Lee et al., 2011a).  The underlying mechanism of CIN in sporadic cancers is 
not yet fully understood, partly due to the wide range of genes that can give rise to 
CIN following disruption of normal processes, demonstrating the heterogeneous 
nature found in sporadic cancers.   
Importantly for the work presented in this thesis, a study found an association of 
CIN, and in particular errors in chromosomal segregation leading to centrosome 
aberrations, to be a feature of OS development (Al-Romaih et al., 2003; Ottaviani 
and Jaffe, 2009).  Osteosarcoma has a high level of genetic and cytogenetic 
heterogeneity, not just between patients but also within the same patient (Selvarajah 
et al., 2008). RECQL4 mutations can lead to replicative stress and genomic 
instability (Burrell et al., 2013; Flach et al., 2014; Zeman and Cimprich, 2014).  
Interestingly, a relationship of RECQL4 overexpression and S-CIN development in 
osteosarcomas has been reported (Bayani et al., 2007; Maire et al., 2009). MIN has 
been demonstrated in several cancers (Wang et al., 2005; Sheng et al., 2006; 
Weisenberger et al., 2006; Geigl et al., 2008), and reported in a few OS tumours as 
well (Heinsohn et al., 2007; Ahmed et al., 2012).         
1.5.3 Single stranded DNA 
Single-stranded DNA is an ubiquitous and a very important intermediate structure 
formed throughout the cells’ life cycle.  It is therefore crucial that single-stranded 
DNA is protected from DNA damage.  Replication protein A (RPA) is the main 
ssDNA binding protein in eukaryotes, and has many roles required for ssDNA 
formation, including DNA replication, recombination, DNA damage checkpoints, and 
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DNA repair mechanisms (Zou et al., 2006).  During DNA damage response RPA is 
required for the formation of γH2AX foci (Anantha et al., 2007) and RAD51 foci 
(Anantha et al., 2008).  
1.5.4 Double stranded DNA break  
DNA double strand breaks (DSB) are the most dangerous type of DNA lesions, as 
they can lead to the loss of large chromosomal regions (Chang et al., 2017). DSBs 
can also occur following two single-strand breaks in close proximity, or following 
DNA damage response during DNA replication (Khanna and Jackson, 2001), but 
many other mechanisms are also involved, both physiological and pathological 
(Lieber, 2016). If not repaired these lesions can block transcription and genome 
replication, and can lead to serious consequences such as mutations and genome 
aberration resulting in  reduced cell viability (Valko et al., 2006). 
1.5.5 DNA repair pathways 
In eukaryotes, the DNA damaged response (DDR) aids in maintaining genomic 
stability following DNA damage. The site of the lesion on the DNA can alter 
subsequent response mechanism.  The DNA damage response pathway is a 
complex, well-organised pathway comprising biochemical signalling and effector 
pathways that functions to repair and restore the original configuration of DNA, 
following damage (Kavanagh et al., 2013), involving many proteins with variable 
roles, including detectors, mediators and effectors (Sancar et al., 2004).   
Defects in DNA repair have been shown to strongly link to predisposition to cancer, 
neurodegeneration, immune deficiency and aging (Coon and Benarroch, 2018; 
Gorgoulis et al, 2018).  RECQL4 has been shown to participate in a range of DNA 
repair pathways (Petkovic et al., 2005; Fan and Luo, 2008; Schurman et al., 2009; 
Shamanna et al., 2014), and mutations may cause impairment of these pathways 
following DNA damage.   
1.5.5.1 DNA damage response pathways  
The DNA damage response pathways include the PI 3-kinase-related kinase (PIKK) 
family of proteins Ataxia telangiectasia mutated (ATM) and Ataxia telangiectasia 
and RAD 3-related (ATR).  These act as detectors and initiate the DNA damage 
response. DSBs activate ATM, and ssDNA, which may arise during replication fork 
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stalling or collapse following endogenous and exogenous induced lesions in S 
phase, bound by RPA and ATRIP activates ATR (Friedel et al., 2009).    
Mediator proteins include breast cancer 1, early onset (BRCA1), Mediator of DNA 
damage checkpoint 1 (MDC1) and p53 binding-protein 1 (53BP1), following 
phosphorylation by ATM or ATR.  These processes are aimed to stop cell cycle 
progression, and to activate proteins required for DNA repair, (Podhorecka et al., 
2010).  This can further a response to effector proteins such as RAD51, checkpoint 
kinase-1 (CHK1), checkpoint kinase-2 (CHK2) and p53 (Kobayashi, 2004).  There 
have been two characterised pathways of the DNA damage response involving 
CHK1. The ATM/ATR-CHK1/CHK2-Cdc5s pathway is reversible and demonstrates 
a fast response to DNA damage. CHK1, a key distal signal transducer, is activated 
by ‘proximal transducers’ ATR, and to some extent ATM, and other PI3 kinase like 
proteins, activating DNA damage “sensor” proteins linked with “mediator” proteins 
(Dai and Grant, 2010).  The second pathway is the p53-dependent pathway, which 
is a much slower response and is irreversible. It involves Chk1/Chk2 with ATM/ATR 
phosphorylating p53 or MDM2, which subsequently promotes the stabilization of 
p53 (Zhou and Bartek, 2004; Dai and Grant, 2010). 
1.5.5.2 Homologous recombination 
Relatively benign DNA lesions found during G1 or G2 phase in a repair-competent 
cell can generate DSB during DNA replication (Nagaraju and Scully, 2007; 
Petermann and Helleday, 2010).  If a break occurs during the S phase of the cell 
cycle, DSBs are formed at blocked replication forks, which are usually repaired by 
homologous recombination between sister chromatids that is an error-free but 
complex repair pathway (Figure 1.5-a).  Following damage recognition, the intact 
homologous strand of DNA is detected, and is transported near the lesion. The 
broken ends undergo 5’→3’ end resection, and the liberated 3’ single-stranded tail 
invades the intact neighbouring sister chromatid. Using the complementary strand 
of the intact sister chromatid the broken end is extended by DNA polymerase, 
copying the missing information from the template into the broken chromatid.  The 
DNA strand is separated following ligation and the DNA is restored via the 
dissolution pathway resulting in non-crossover outcome, or holiday junction 
resolution resulting in non-crossover or cross over outcome in equal probability 
(Pâques and Haber, 1999; San Filippo et al., 2008; Krejci et al., 2012).  Other 
pathways include synthesis-dependent strand annealing (SDSA) favoured during 
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mitosis, and break induced replication (BIR) involving the formation of replication 
fork in a D-loop structure (Krejci et al., 2012).  
  
 
Figure 1.5-a A schematic of the execution step of homologous recombination repair (HR) of double-stranded DNA 
breaks (DSB).  The DNA at the break site is resected, the degradation of one strand at both sides of the break at 5’→3’ 
direction exposes the DNA as a single stranded DNA with 3’ tail, and coated with RPA. It recruits RAD52 interacting with 
RAD51. The resected ssDNA nucleoprotein filament tail engages in active strand invasion.  Strand exchange and DNA 
synthesis follows the dissociation of RAD51 exposing the 3’-OH, and newly synthesised DNA is ligated forming a double 
Holiday junction. Separation of the double Holiday junction can be via dissolution, or resolution that can follow different paths, 
producing either a crossover or a non-crossover end product (Cromie et al., 2001; West, 2003; Krejci et al., 2012). 
 
ATM/ATR signalling is important for the phosphorylation of proteins involved in 
homologous recombination, including BRCA1, BRCA2, WRN, BLM, and FANCD2 
(Roos and Kaina, 2013).  Following DNA damage leading to DSB, ATM 
phosphorylates CHK2 (checkpoint kinase-2) at Thr68 (Matsuoka et al., 2000).  ATM 
is a homodimeric serine/threonine protein kinase and normally is in an inactive state.  
Recruitment to the break by the MRE11/NBS1/RAD50 (MRN) complex results in its 
activation by auto-phosphorylation at Ser1981 (Bakkenist and Kastan, 2003).  ATR 
phosphorylates CHK1 (checkpoint kinase-1) at Ser345 in response to stalled DNA 
replication forks (Guo et al., 2000), which occur following lesions due to replication 
blockage or interstrand crosslinks preventing DNA synthesis due to modifications 
on DNA template. Detection of stalled forks and transduction of the signal requires 
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the ATR-ATRIP complex, TopBP1 (DNA topoisomerase 2-binding protein 1) and 
the 9-1-1 complex (Ward and Chen, 2001).  CHK1 and CHK2 phosphorylate the 
transcription factor p53 at Ser20 (Shieh et al., 2000), which is a key decision-making 
step  between DNA repair and apoptosis (Oda et al., 2000; Roos et al., 2007).  
1.5.5.3 Non-homologous end-joining 
In a cell that is not replicating, an alternative route is taken outside of late S and G2 
phases, when homologous recombination is the dominant pathway to repair double-
stranded breaks: non-homologous end joining repair (NHEJ) repairs DSBs, not 
restricted by cell cycle phase (Figure 1.5-b).  HR is essentially error free, while NHEJ 
is mostly error-prone potentially leading to mutations (Lieber, 2010).  The cause of 
DSB and cell cycle phase influences the repair process chosen. NHEJ does not 
require the homologous template for the repair of the DNA. NHEJ is capable of 
repairing a wide range of DNA-end configurations, which can however lead to the 
repaired DNA junctions containing mutations (Chang et al., 2017).  An important 
step is the recognition and binding of the Ku heterodimer to the DSB (Mari et al., 
2006; Uematsu et al., 2007), which acts as a scaffold and recruits other factors such 
as DNA-PKcs (Uematsu et al., 2007),  X-ray cross complementing protein 4 
(XRCC4) (Mcelhinny et al., 2000; Mari et al., 2006; Costantini et al., 2007), DNA 
Ligase IV (Costantini et al., 2007), XRCC4-like factor (XLF) (Yano et al., 2008), and 
Aprataxin-and-PNK-like factor (APLF) (Grundy et al., 2013). DNA-PKcs is a member 
of phosphatidylinositol-3 (PI-3) kinase-like kinase family (PIKK), similar to ATM and 
ATR (Abraham, 2004; Bakkenist and Kastan, 2004).  
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Figure 1.5-b DSB repair by NHEJ pathway. The DSB initiates the recognition of the DNA end, the NHEJ complex is 
assembled at the DSB.  The DNA ends form a bridge by Ku heterodimers (Ku70/Ku80), leading to end stability, and 
processing. The gap generated is filled in by processing enzymes, and the ends are ligated by XRCC4/LigIV. The dissolution 
of the NHEJ complex follows as DNA strands are repaired (Davis and Chen, 2013).  Adapted from (Pardo et al., 2009).   
 
Chromatin structure appears to be an important context of the choice and 
completion of DSB repair pathway selection, which was first suggested following a 
study which investigated UV induced DNA damage and repair following nucleotide 
excision repair (Cleaver, 1977).  Histone H2AX, a variant form of histone H2A, is 
phosphorylated on serine 139 of the C terminal tail following DNA damage, such as 
ironizing radiation (IR), forming gamma-H2AX (H2AX). The H2AX site seems to 
be a target of the nuclear DNA damage PI3 kinase-like signalling kinases, ATM, 
ATR, and DNA-PKcs, dependent on source and timing of DNA damage (Rogakou 
et al., 1998; Rogakou et al., 1999; Bonner et al., 2008; Kinner et al., 2008). The 
presence of γH2AX foci is a widely used marker for the detection of DNA damage 
and repair or to determine the effectiveness of radiation treatment and cancer 
therapies (Celeste et al., 2003b; Bonner et al., 2008; Mariotti et al., 2013).  It has 
also been suggested that H2AX may also be important in allowing repair proteins 
to access damaged DNA regions and remodelling chromatin process, and may have 
a role in processes of apoptotic cell death (Baritaud et al., 2012).  Chromatin 
Page | 40  
 
complexity affects the selection and rate of DNA repair processes.  Slowly repaired 
DNA may be in regions of heterochromatin, where prolonged chromatin relaxation 
takes much longer for intermediates to reach the break sites. ATM is crucial for this 
by activating KAP1, a KRAB- associated protein that forms foci and colocalizes with 
H2AX.  Repair in heterochromatic regions occurs primarily in G2 phase by HR, and 
DSBs in euchromatic regions is repaired by NHEJ (Ziv et al., 2006; Goodarzi et al., 
2010; Jakob et al., 2011; Goodarzi and Jeggo, 2012).  
1.5.5.4 Telomeres are disguised double-stranded breaks  
Normal somatic cells hold a finite proliferative capacity termed the molecular clock 
(Harley et al., 1992; Wright and Shay, 1992; Cong et al., 2002), also referred to as 
the Hayflick limit (Hayflick and Moorhead, 1961; Hayflick, 1965). Warson and 
Olovnikov hypothesized that DNA would be progressively lost at the ends of 
chromosomes as the cell divides.  Telomeres, initially reported in the late 1930s 
(Blackburn, 2001), act as essential regulators of both cell life span and chromosomal 
integrity (Hahn, 2003). Telomeres are repetitive DNA sequences (TTAGGG/ 
AATCCC) located at the ends of linear chromosomes.  In normal cells, these shorten 
during each cell division cycle, in vitro, and with age in vivo, leading to replicative 
mortality via senescence, as the cell reaches the Hayflick limit known as stage 1 
(M1) (Shay and Wright, 2004; Shay and Wright, 2019).  If the cell is able to avoid 
this trigger by inactivating p53, it leads to further proliferation and telomere loss until 
stage 2 (M2) is reached.  M2 has been shown to lead to cell death following the 
critically short and dysfunctional telomeres.  Further cell survival can be achieved 
following the escape of this crisis by the activation of telomerase (Cong et al., 2002). 
Telomeres are also important structures in the protection of DNA ends from 
degradation, stem cell self-renewal, and DNA replication attrition (Burrow et al., 
2017), as they play a role in the cell cycle, DNA replication, MMR processes involved 
in maintaining chromosomal stability, relating to cell pluripotency and self-renewal 
(Kapinas et al., 2013).  Telomeres end in a 3' overhang, known as the G-strand 
overhang, which bends back on itself and anneals with the complementary 
sequences in the 5' end of the opposite strand, displacing part of the 5' end in a D-
loop and creates a telomere or T-loop (Figure 1.5-c). T-loops facilitate the formation 
of a higher order structure mediating the end capping by masking telomeric DNA 
ends from recognition by the DNA repair system as a double-stranded break 
(Espejel et al., 2002). Regulating factors of telomerase-mediated telomere 
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elongation include the telomere-binding protein TRF1 (Telomeric Repeat Binding 
Factor-1), a negative regulator of telomere length, interacting with POT1 (Protection 
Of Telomeres-1; a single-stranded telomeric DNA-binding protein) (Sfeir et al., 
2009).  TRF2 assists in the formation of the T-loop, and maintains the secondary 
structure of the telomere to stabilize the T-loop and protects from unscheduled 
nucleolytic processing. TRF2 also interacts with the human Repressor Activator 
Protein-1/Telomeric Repeat Binding Factor 2 Interacting Protein (RAP-1/TERF2IP), 
and the MRN complex, which is implicated in response to DNA damaging agents 
(Wang et al., 2004; Doksani et al., 2013).  The Ku complex has a role in the repair 
of DSB and localizes to the telomere (Chai et al., 2002; Tsai et al., 2002; Hahn, 
2003). Further proteins involved in the T-loop stabilization and maintaining telomere 
includes TRF1-interacting Ankyrin-related ADP-ribose polymerase (TANK) (Sbodio 
and Chi, 2002), TRF1-Interacting Nuclear Factor-2 (TIN2) (Ye et al., 2004), and 
heterogeneous nuclear ribonucleoproteins such as Heterogeneous Nuclear 
Ribonucleoprotein-A1 (HNRPA1) (Ishikawa et al., 1993), and Heterogeneous 
Nuclear Ribonucleoprotein-A2/B1 (HNRPA2B1) (Kamma et al., 2001; Chai et al., 
2002; He and Smith, 2009).   Exogenous activation of telomerase is an in vitro 
method for immortalization of cell lines, and it can lead to unlimited proliferation 
capacity (Cong et al., 2002).  
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Figure 1.5-c Formation of T-loop. The T-loop is formed as both strands of chromosome join by an early point in a double-
stranded DNA by 3’ strand end invading the strand pair and forming a D-loop (Greider, 1999; Griffith et al., 1999).  The T-loop 
is stabilised with additional proteins; TANK:TRF1-interacting, Ankyrin-related ADP-ribose polymerase, TIN2;TRF1-Interacting 
Nuclear Factor-2, HNRPA1; Heterogeneous Nuclear Ribonucleoprotein-A1, and HNRPA2B1; Heterogeneous Nuclear 
Ribonucleoprotein-A2/B1.  This image is a modification of QIAGEN’s original (Qiagen, 2018). 
 
In cancer cells, a common feature involves the activation of telomere maintenance 
mechanisms, enabling the cells to avoid telomere shortening checkpoint, allowing 
the cell to continue to divide, and overcome replicative senescence. Telomere 
maintenance in tumours involves two mechanisms in humans, either telomerase 
activation (TA), or alternative lengthening of telomeres (ALT) (Granger et al., 2002; 
Maser and Depinho, 2002; Artandi and Depinho, 2009; Cesare and Reddel, 2010; 
Shay and Wright, 2011). It is thought around 85% of carcinomas maintain telomeres 
using TA, with the synthesis of new telomeric DNA via telomerase; a holoenzyme, 
comprising functional telomerase RNA (hTR), and telomerase reverse transcriptase 
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catalytic subunit (hTERT) (Feng et al., 1995; Nakamura et al., 1997; Granger et al., 
2002; Shay and Wright, 2006). In around 5-15% of human cancers, in the absence 
of TA, the cancer cell can utilise ALT via homologous recombination (Henson et al., 
2002).  This process involves the elongation of telomeres via recombination 
(Bechter et al., 2003).  In early studies, OS cells interestingly have been reported to 
demonstrate both TA and ALT with even expressions, unlike other cancer cells 
(Bryan et al., 1997; Scheel et al., 2001).  However, ALT appears to be more 
prevalent in OS (Scheel et al., 2001; Heaphy et al., 2011b).  
Telomeres have been found to hold additional functions to suppress the DNA 
damage response via telosome.  This prevents potentially lethal telomere fusion, 
translocation, and genomic instability which can form following DSB repair at 
telomeres (Burgess, 2013).  Interestingly, many proteins involved in DNA repair also 
have a functional role in telomeres (Marcomini and Gasser, 2015).  The interaction 
of nucleoprotein complexes on telomeric DNA aids the maintenance of telomere 
integrity. Following disruption of shelterin components, which can lead to exposure 
of the DNA structures at the ends of disrupted telomere, a DNA damage response 
may follow.  The shelterin complex consists of six major proteins, TRF2, TRF1, 
POT1, TPP1, Rap1, and TIN2 (Palm and de Lange, 2008). The shelterin complex 
protects chromosomal ends from erosions.  POT1–TPP1 complex has been found 
to compete with the CST (CTC1, STN1, and TEN1) complex which terminates 
telomerase activity (Chen et al., 2012). In particular, TRF2, is thought to perform an 
important role in the protection of telomeres from erosion by binding to telomeric 
repeats to form the T-loop (Palm and De Lange, 2008) (Figure 1.5-c). The Loss of 
TRF2 protein and the consequent disruption of the shelterin complex, both 
expression and activity has been shown to induce telomere shortening, DNA 
damage response, chromosomal instability, and replicative senescence (Oh et al., 
2003; Denchi and De Lange, 2007; Okamoto et al., 2013).  Telomere shortening 
leads to reduced TRF2 (Saha et al., 2013). On the other hand, artificially increased 
TRF2 have been found to develop a delay in the onset of senescence (Karlseder et 
al., 1999). It has been suggested TRF1 and TRF2 activity via telomere length may 
play a role in initial transformation phases, and tumourigenesis (Matsutani et al., 
2001; Nakanishi et al., 2003; Nijjar et al., 2005; Oh et al., 2005; Muñoz et al., 2006).  
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1.5.5.5 Base excision repair 
A common form of endogenous DNA damage includes base modifications (Lindahl, 
1993), that can lead to alterations of base pairing, and if not repaired, can lead to 
mutagenesis (Gelfand et al., 1998).  A primary repair mechanism of oxidative lesions 
is base excision repair (BER) (Croteau et al., 2012b), and often follows ROS induced 
damage.  There are two main pathways (Figure 1.5-d) short patch and long patch 
BER (Kim and M Wilson Iii, 2012). The pathway mainly repairs non-bulky small 
nucleotide lesions, the excision and replacement of incorrect bases such as uracil, 
or damaged bases such as 3-methyladenine or 8-oxoG generated by alkylation or 
oxidation, respectively (Kim and M Wilson Iii, 2012).   The initiation occurs following 
at least one of distinct glycosylases (NTHL1, NEIL1, NEIL2, NEIL3 MPG, TDG, 
UNG, MUTYH, OGG1, MPG, MPD4 and SMUG1), depending on the type of the 
lesion, and further influences the choice of pathway (Fortini et al., 1999).  Other 
influential factors include the cell type, and the availability of BER factors (Narciso 
et al., 2007; Bauer et al., 2011; Tichy et al., 2011).  Short-patch BER requires 
specific repair proteins which are not necessary for replication, and therefore, the 
process shows efficiency in proliferating and non-proliferating cells.  Following 
initiation by DNA glycosylase, further steps require AP-endonuclease APE1, DNA 
polymerase β (Pol β), and DNA ligase I or III (LIG1/3) (Krokan and Bjørås, 2013).  
poly(ADPribose) polymerase 1 (PARP1) and XRCC1 may also participate, but has 
been suggested these may not always be involved (Hanssen‐Bauer et al., 2011).  
The long-patch repair pathway has been found to primarily take place in proliferating 
cells, and to a large extent utilises replicative proteins during the process by APE1, 
including, PCNA, FEN1, DNA polymerase δ/ε and LIG1.  However, this is dependent 
on proliferative state of the cell. Pol β is found to be used in non-proliferating cells 
with primarily Pol δ/ε in proliferating cells (Akbari et al., 2009; Svilar et al., 2011). 
The core steps of BER (Figure 1.5-d) are excision of the base, incision, end 
processing, repair synthesis, and gap filling and ligation. A variation of proteins 
utilised downstream of the base excision is dependent on the short-patch repair with 
a single nucleotide gap is generated, filled and ligated, or long-patch repair with a 
gap of 2-10 nucleotides is generated and filled (Lindahl, 2001; Almeida and Sobol, 
2007; Fortini and Dogliotti, 2007; Robertson et al., 2009; Svilar et al., 2011; Wallace 
et al., 2012).    
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Figure 1.5-d The core steps of BER.   The DNA glycosylase excises the damaged base producing an abasic or AP site.  
The DNA backbone is cleaved by AP enonuclease at 5’, generating a 5’ deoxyribose phosphate end and a free 3’OH end. 
During short-patch repair DNA polymerase β (Pol β) adds a nucleotide to the 3’-OH end and removes the 5’-deoxyribose 
phosphate group. Then DNA ligase (LIG3+ XRCC1) joins the ends to form an intact strand. Long-patch repair: DNA 
polymerase δ or ε (Pol δ or ε) acting with RFC and PCNA adds 2-8 nucleotides to the 3’-OH group, while displacing the 5’-
deoxyribose phosphate group and further nucleotides to generate a flap. The flap endonuclease FEN1 removes the flap, then 
ligase (LIG1) joins the ends. Image adapted from (Schärer, 2003).  
 
1.5.5.6 Nucleotide excision repair 
A lesion on the transcribed template strand can lead to stalling of RNA polymerase 
inducing nucleotide excision repair (NER) (Hu et al, 2017). In mammals, Nucleotide 
excision repair (NER) (Figure 1.5-e) usually occurs following UV induced DNA 
damage (Lu et al., 2017).  It is the main pathway for removing bulky DNA lesions 
caused by UV, and environmental mutagens, and some chemotherapeutic agents 
(Friedberg et al., 2005; Schärer, 2013).    
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Figure 1.5-e Schematic of the core NER reaction. (A)  Damaging agents induce bulky DNA lesions that destabilize duplex 
DNA, leading to DNA helix distortion. (B) In GG-NER, XPC-HR23B recognize the lesions and binds the undamaged strand 
opposite, stabilizing the DNA bend.  (C) TFIIH is recruited and interacts with XPC-RAD23B.  (D) TFIIH in an ATP dependent 
manner, unwinds the DNA helix.  One subunit (here XPD) encounters the chemically modified base, while XPB (second 
helicase subunit) continues unwinding the DNA.  (E) Stalling at the lesion allows the formation of “preincision” complex with 
the recruitment of XPA, RPA, and XPG. (F)  ERCC1-XPF interacts with XPA and is recruited to the complex, creating a dual 
incision; 5’ by ERCC1-XPF and followed by the incision at 3’ by XPG.  (G) RPA remains bound to ssDNA facilitating the 
transition to repair synthesis by Pol δ and Pol κ or Pol ε and associated factors; PCNA and RFC.  (H) The sealing of the nick 
of DNA completes the repair synthesis, by DNA ligase IIIα/XRCC1 or DNA ligase I (LIG1, shown here) completes the process 
(Gillet and Schärer, 2006; Schärer, 2013). Image adapted from (Gillet and Schärer, 2006).   
 
The NER pathway recognises UV induced DNA damage by dual incision with XPG 
and XPF-ERCC1 endonucleases, leading to a region of ssDNA about 22-35 
nucleotides long.  This region is then coated with RPA.  Further, this can trigger the 
GG-NER-dependent ATR activation for repair (Marteijn et al., 2014).  The initiation 
of NER can occur by two subpathways; global genome NER (GG-NER), and 
transcription-coupled NER (TC-NER) (Gillet and Schärer, 2006; Hanawalt and 
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Spivak, 2008). TC-NER is more specific and acts on lesions in the transcribed strand 
of active genes, whereas GG-NER can act at any location of the genome.   The GG-
NER specific factor XPC-RAD23B, and sometimes the UV-damaged DNA-binding 
protein initiate the GG-NER pathway.  RNA polymerase stalled at lesions initiate the 
TC-NER pathway, with the aid of TC-NER specific factors, such a CSA and XAB2.  
The core NER factors are crucial for each pathway for the completion of the excision 
process (Tubbs et al., 2009; Latypov et al., 2012; Schärer, 2013).  During the 
synthesis step of NER damage signalling can be triggered under certain 
circumstances.  These occasions can include too high damage load, the inhibition 
of repair synthesis following nucleotide depletion or inhibition of polymerases 
(Hanasoge and Ljungman, 2007; Matsumoto et al., 2007; Marteijn et al., 2009; 
Overmeer et al., 2011), and if the incision at 3’ does not occur.  The signalling follows 
the replacement of EXO1 with XPG (Schärer, 2013).  The NER intermediate forms 
a ssDNA which is coated with RPA which binds ATRIP/ATR, activating the ATR 
kinase (Zou and Elledge, 2003; Novarina et al., 2011).  A signal cascade with MDC1, 
RNF8, 53BP1, and BRCA1 forms chromatin marks including the phosphorylation of 
γH2AX (Marteijn et al., 2009; Schärer, 2013).  The NER pathway demonstrates 
heterogeneity, which occurs due to the molecular mechanisms involved, and the 
crosstalk between other processes.  The NER pathway is able to repair a wide range 
of structurally unrelated DNA lesions, such as cyclobutene-pyrimidine dimers, and 
lesions generated by UV, chemical adducts, intrastrand crosslinks and ROS 
(Marteijn et al., 2014).   
1.5.6 Involvement of RECQL4 in processes of DNA repair  
Patients with RTS cells were found to show sensitivity to DNA damaging agents, 
suggesting an implication of RECQL4 within the DNA damage response (Cabral et 
al., 2008; Fan and Luo, 2008; Jin et al., 2008).  Studies have investigated RECQL4 
mutant cells in response to genotoxic agents, however, results have been varied, 
possibly due to different primary cells and assays utilised (Lu et al., 2014a).   Some 
of the agents include ionizing radiation, UV, topoisomerases inhibitors, and 
chemotherapy agents (Werner et al., 2006; Cabral et al., 2008; Fan and Luo, 2008; 
Jin et al., 2008; Singh et al., 2010; Crevel et al., 2012; Kohzaki et al., 2012).  Viable 
RTS patient fibroblasts were shown to undergo irreversible growth arrest following 
the recovery from damage caused by oxidative stress, with significantly reduced 
DNA synthesis (Werner et al., 2006).   
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RTS patient cells show chromosomal instabilities, mainly mosaicism and 
isochromosomes (most often 8, 7 and 2 trisomies) (Ying et al., 1990; Orstavik et al., 
1994; Wang et al., 2001; Beghini et al., 2003; Larizza et al., 2006). In mouse 
embryonic fibroblasts aneuploidy and an increase in premature centromere 
separation was observed, leading to chromosomal instability (Mann et al., 2005).  
Sister chromatid segregation errors were also seen by others (Dietschy et al., 2007), 
and it was suggested to reflect the activity of RECQL4 in the N-end rule pathway 
(Yin et al., 2004).  In lymphocytes of RTS patients, chromosome breaks also occur 
frequently (Der Kaloustian et al., 1990; Lindor et al., 1996; Miozzo et al., 1998; Grant 
et al., 2000), although a few exceptions have been seen (Kerr et al., 1996; Beghini 
et al., 2003). Spontaneous breaks have been found to occur in skin fibroblasts as 
well (Vennos et al., 1992; Miozzo et al., 1998).  
Following induction of DNA double-stranded breaks (DSBs) in human cells, 
endogenous RECQL4 was found to interact with RAD51; they co-localize and form 
a complex at sites representing homologous recombination repair. It is proposed 
RECQL4 could resolve aberrant DNA structures formed during DNA replication, and 
recombinational repair processes, or signal interactions with other proteins during 
these processes, suggesting a potential reason for genomic instability found in RTS 
cells and the predisposition to cancer (Petkovic et al., 2005). Silencing of RECQL4 
also led to reduced RAD51 foci numbers in cells treated with ionizing radiation, and 
an increase of PARP inhibitor sensitivity was shown.  Further to this, RECQL4-
slienced cells were sensitive to cisplatin induced DNA damage  repair via HR,   
suggesting reduced HR repair ability following DSB  (Santarpia et al., 2013).   
PARP-1 is a single-strand break repair protein and is activated by a wide variety of 
DNA damaging agents. PARP-1 also modulates cellular sensitivity to γ-irradiation 
and holds an important role in BER (Bohr, 2002).  Woo et al (2006) found an 
interaction of RECQL4 and poly(ADP-ribose) polymerase-1 (PARP-1). The study by 
Schurman et al, (2009) found RECQL4 regulates BER capacity directly and 
indirectly.  They showed the colocalization of RECQL4 with key factors in BER; 
APE1 and FEN1 following H2O2 induced oxidative DNA damage. Interestingly, RTS 
cells were shown to express an upregulation of BER pathway genes, but fail to 
respond as normal cells under the same oxidative stress conditions (Schurman et 
al., 2009). 
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RECQL4 is also thought to coordinate with BLM in DNA replication and DNA repair, 
and the interaction has been shown to be stronger in S-phase and following ionizing 
radiation.  BLM has many cellular roles including involvement in homologous 
recombination (Singh et al., 2012).  The intracellular distribution and dynamic 
relocalization of RECQL4 to sites of DNA damage has suggested a possible role to 
the phenotypes, and associated heterogeneity, which has been found in RECQL4-
associated diseases (Croteau et al., 2012b).  Studies have highlighted functional 
roles of RECQL4 associated with aging and cellular senescence, oxidative DNA 
damage repair, telomere maintenance and mitochondrial dysfunction. Genomic 
instability and cellular senescence can be caused by the disruption of normal 
replication and transcription (Croteau et al., 2012b).  
 
RECQL4 may interact with Xeroderma pigmentosum group A (XPA) demonstrated 
by GST-pulldown assay, as part of the NER pathway.  A further increase of 
interaction was observed in cells under UV irradiation (Fan and Luo, 2008).  A study 
demonstrated co-immunoprecipitation of RECQL4 with the Ku70/Ku80 heterodimer  
and the depletion of RECQL4 in human cells has been suggested to decrease NHEJ 
activity (Shamanna et al., 2014). 
Interestingly, increased fragility of telomeric ends have been found in RTS patient 
cells and human cells following RECQL4 knockdown.  Human RECQL4 has been 
shown to localise to telomeres and interact with the shelterin protein telomeric 
repeat-binding factor 2 (TRF2), and TRF1. On telomeric D-loops, RECQL4 has been 
shown to interact and stimulate WRN activity.  RECQL4 has been demonstrated to 
be able to resolve telomeric D-loops also, which is a requirement for replication at 
the telomeres (Ghosh et al., 2012).  WRN, BLM, and RECQL4 appear to be more 
active at telomeric D-Loops containing 8-oxoguanine base lesions, results of 
oxidative damage. The unwinding of D-Loops containing thymine glycol (Tg) lesions 
have been shown to be a preference of RECQL4 (Ferrarelli et al., 2013). Therefore, 
RECQL4 appears to have an important role in maintaining telomeric stability.  
Mutations in RECQL4 could therefore lead to the dysfunction of telomeres, which is 
involved in tumour suppression and progression (Xu et al., 2013). RTS patient cells 
were shown to have an elevated level of fragile telomeric ends (Ghosh et al., 2012).   
A study by Yin et al (2004), reported an interaction between RECQL4 and cytosolic 
ubiquitin ligases UBR1 and UBR2, which have a function in the N-end rule pathway 
involving protein ubiquitination and degradation (Yin et al., 2004).  
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1.6 Aims of project 
RECQL4 mutations in RTS patients lead to genomic instabilities, in particular 
chromosomal instabilities. We hypothesise that differentiating osteoblast become 
increasingly sensitive to DNA lesions, leading to malignant transformation.  Using a 
cellular system that interferes with the initiation of DNA replication, and therefore 
recapitulates defects in RECQL4 mutated cells we aim to determine the cellular 
changes this may generate during osteocyte differentiation of mesenchymal stem 
cells.  To achieve interference with replication initiation during osteogenic 
differentiation we follow two related approaches: 
1) We utilize PHA-767491, a specific inhibitor of DDK at sub-lethal concentrations 
to put a continuous pressure on the initiation machinery in proliferating and 
differentiating mesenchymal stem cells. DDK acts upstream of RECQL4 
recruitment, and we hypothesise that its inhibition can copy the phenotypes of 
RECQL4 impairment in a system that is simple to establish and maintain. 
2) While RTS fibroblasts cell lines are readily available from cell repositories, 
RECQL4 mutated mesenchymal stem cells are not. We aim to establish an 
immortalized MSC cell line in which RECQL4 is depleted by lentiviral transduction 
of shRNA. 
RECQL4 holds a critical role in predisposing RTS patients to OS development, 
perhaps directly or indirectly.  We aim to identify RECQL4 interacting partners that 
may lead to understanding important interactions or pathways, which may enable 
the development or sensitizing of cells to tumorigenesis in RECQL4 mutated cells.   
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2 Materials and Methods 
2.1 Stock solutions  
Chemical reagents made up following manufacturer’s protocols.  Cell culture 
reagents were prepared in a Thermo Scientific Safe 2020 class II biological safety 
cabinet. Unless otherwise stated procedures were performed at room temperature. 
All solutions were made with Milli-Q® ultra-pure water with a resistivity of about 18 
MΩ/cm.   
2.1.1 Stock solutions and chemical reagents 
Table 2.1-a Stock solutions and buffers 
Stock solutions Composition 
 
Fixing solution with 4% 
paraformaldehyde 
 
 
Permeabilising solution 
 
IF Blocking buffer 
 
1X PBS 
 
 
1X PBS-Tween 20 
 
Oil red O stock solution 
 
Oil red O working 
Solution 
 
Alizarin Red S staining 
solution 
 
Alcian blue staining 
solution 
 
Destaining solution 
 
Membrane blocking 
buffer 
 
WB blocking buffer      
 
WB blocking buffer 
BSA       
 
Anti-fading mounting 
medium 
 
Acid stripping 
 
 
Pulldown lysis buffer 
 
 
 
 
 
2x lysis solution 
 
Prepared with the 9 x dilution of Formaldehyde (Sigma 36.5-38% F8775; 4% final concentration) 
in 250nM HEPES (4-(2-hydroxyethethyl)-1-piperazineethanesulfonic acid; Life Technologies, 
2013a). Made up with distilled water. 
 
0.3% Triton X-100 (Sigma-Aldrich 93422) (v/v) in 1X PBS 
 
10% FBS 0.1% Triton-X100 (Sigma-Aldrich 93422), (v/v) in 1X PBS 
 
1X phosphate buffered saline tablet (Gibco® PBS Tablet, Thermo Fisher Scientific BR014G), 
per 100ml H2O, 0.01M.  
 
1X PBS, 0.1% (v/v) Tween-20 (Sigma-Aldrich).   
 
300mg Oil Red O (Thermo Fisher Scientific, 15244664) in 99% isopropranol 
 
Oil red O stock  solution was diluted in distilled H2O in 3:2, stirred for 10 minutes. Filtered before 
use. 
 
2g Alizarin Red S (Santa Cruz Biotechnology, sc-205998), dissolved in distilled H2O, pH 
adjusted to 4.3. Stored in dark. 
 
10mg Alcian blue (Santa Cruz Biotechnology, sc-214517) dissolved in a mixture of 60ml of 
absolute ethanol and 40ml Acetic acid (98%). 
 
Mixture of 120ml of absolute ethanol and 80ml Acetic acid. 
 
5% non-fat milk (w/v) in 1x PBS Tween 20, or 5% (w/v) BSA in 1x PBS Tween-20; stirred for 30 
minutes 
 
2% (w/v) non-fat milk in 1x PBS Tween-20 
 
2% (w/v) BSA in 1x PBS Tween 20 
 
 
For 1 ml: 1 µl  Para-phenylenediamine (10mM), 49 µl pure water, 50 µl 1M TRIS pH 7.4, and 
900 µl Glycerol 
 
4M HCl in distilled H2O 
 
 
1ml phosphosafe (Sigma-Aldrich), 30µl 5M NaCl (Melford D23735 7647-14-15), 10µl 
phosphatase inhibitor #3 (Sigma-Aldrich, P0044 lot-033M4020V), 10µl phosphatase inhibitor #2 
(Sigma-Aldrich, P5726), 10µl phosphatase inhibitor cocktail (Sigma-Aldrich, P8340 lot- 
033M4023V), 40µl 25x complete mini (1 tablet in 420 µl H2O), (Roche 11836153001), 1µl 1M 
DTT, 10µl PMSF phenylmethanesulfonyl fluoride solution (Sigma-Aldrich, 93482).  
 
25mM Tris-HCl (pH7.6), 150mM NaCl, 1% NP-40, 1% sodium-deoxycholate, 0.1% SDS. 
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Protease inhibitor 
cocktail 
 
 
Protein lysis buffer  
 
stock 
 
 
Western blotting lysis 
buffer 
 
TBE buffer 10x 
 
Agarose gel 0.8% 
 
25 x Tris-Glycine buffer 
 
 
 
Criterion gel running 
buffer (10x) 
 
Invitrogen gel running 
buffer 
 
Invitrogen Nupage 
Novex LDS sample 
buffer (4x) 
 
Membrane transfer 
buffer 
 
2x RealTime-Glo™ 
 
 
PHA-767491 (PHA) 
 
 
NEBuffer 2  
 
 
1 mini complete tablet in 1ml deionised water. 
 
 
 
5ml 2x lysis solution, 100 µl 10mM Sodium fluoride (NaF), 500 µl 5mM Sodium pyrophosphate  
 
(NaPPi), and 3ml MiLLiQ water. 
 
 
420 µl Protein lysis buffer stock and 71.4 µl protease inhibitor cocktail.  
 
 
Tris (1M)-borate (1M)-EDTA (0.02M) (ThermoFisher Scientific)  
 
0.32g agarose gel in 40ml TBE 1x 
 
18.2g Tris base (12mM) (Melford B2005) 
90g Glycine (96mM) (Fisher Scientific, BP381-1 130837 
To 500ml with deionised water 
 
30g Tris Base (Melford B2005), 144g Glycine (Fisher Scientific, BP381-1 130837), 10g SDS 
(pH 8.3) in 1000ml deionised H2O diluted 1x.  
 
NuPAGE MOPS SDS (20x) NP001 25ml in 500ml H2O. 
 
 
Glycerin, Sulfuric acid, monododecyl ester, lithium salt (NP0008, ThermoFisher Scientific) 
 
 
 
40ml 25x Tris-Glycine buffer, 760ml deionised H2O, 200ml methanol.  
 
 
NanoLuc ® Enzyme was equilibrated to 37℃.  1000x MT cell viability substrate and 1000x 
NanoLuc ® Enzyme was added to media and mixed well.   
 
PHA-767491 (Sigma-Aldrich, PZ0178), dissolved in DMSO (Dimethyl Sulfoxide; Santa Cruz 
Biotechnology, sc-358801).  
 
10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl₂, 1 mM DTT (pH 7.9@25°C) 
 
Table 2.1-b Nucleic acid stains 
Cell stain  Colour Dilution     Cell 
permeability 
Mounting 
media  
Detection Excitation
/Emission 
(nm) 
Molecular 
formula 
 
Hoechst 1mg/ml 
(Sigma-Aldrich, 
33258) 
 
 
DAPI (4’, 6-
diamidino-2-
phenylindole; Life 
Technologies). 
 
 
Vectashield 
mounting medium 
with DAPI (Vector, 
H-1200) 
 
 
Blue  
 
 
 
 
Blue 
 
 
 
 
 
Blue             
 
1: 20000 
in H2O 
 
 
 
1: 20000 
in H2O 
 
 
 
 
- 
 
Cell-
permeable 
 
 
 
Cell-
Impermeable 
 
 
 
 
Cell-
Impermeable 
 
 
Anti-fading 
mounting 
medium  
 
 
Anti-fading 
mounting 
medium  
 
 
Fluorescent 
 
 
 
 
Fluorescent 
 
 
 
 
 
Fluorescent 
 
 
352/461 
 
 
 
 
358/461 
 
 
 
 
 
360/460 
 
C25H37Cl3N6
O6 
 
 
 
C16H17Cl2N5 
 
 
 
 
 
C16H17Cl2N5 
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Table 2.1-c Primary antibodies.   WB – Western blot, IF – Immunofluorescence  
Antigen Dilution     Clonality  Raised in 
/ isotype 
Immunogen kDa 
 
Tubulin 
WB 
 
RECQL4 (Cell Signalling 
Technology, 2814) 
WB 
 
 
 
Ki-67 (Dako, M7240) 
IF, WB 
 
 
 
RUNX2 (Santa Crux, M-70 
sc-10758) 200μg/ml 
IF 
 
 
 
 
 
 
 
Phospho CHK-1 (Bethyl  
A300-163A), (1mg/ml) 
WB 
 
 
 
 
 
 
 
HDX (Aviva  Systems, 
QC11406, ARP39),  
(1µg/ml), WB 
 
 
 
 
 
HDX (Abcam, 94475), 
(1µg/ml), WB 
 
γH2AX, (Abcam, phospho-
2139, ab2893n, 1mg/ml), IF 
 
TRF2 (Novus Biologicals  
NB100-56506, 1mg/ml), IF 
 
53BP1, (Novus Biologicals, 
NB100-305, 1mg/ml), WB 
 
PP2A A subunit (PP2a), (Cell 
Signalling 2039s), WB 
 
MCM10 (Proteintech, 12251-
AP), WB 
 
Chk-1 (Santa Cruz, sc-
7898), WB 
 
Engrailed homolog 2 (EN2), 
(Thermo Fisher Scientific, 
PA5-28953, 1mg/ml), WB 
 
 
1:5000 in WB 
blocking buffer 
 
1:1000 in WB 
blocking buffer BSA 
 
 
 
 
1:300 in IF blocking 
buffer  
 
 
 
1:300 in blocking 
buffer -IF 
 
 
 
 
 
 
 
 
1:250  
in WB blocking buffer 
BSA 
 
 
 
 
 
 
 
1:500  
in WB blocking buffer 
BSA 
 
 
 
 
 
1:1000 WF blocking 
buffer BSA 
 
1:500 IF blocking 
buffer 
 
1:500 IF blocking 
buffer 
 
1:5000 in WB 
blocking buffer BSA 
 
1:1000 in WB 
blocking buffer BSA 
 
1:800 in WB blocking 
buffer BSA 
 
in WB blocking buffer 
BSA 
 
1:10,000 in WB 
blocking buffer BSA 
 
Monoclonal 
 
 
Polyclonal 
 
 
 
 
 
Monoclonal 
Clone-MIB-1 
 
 
 
Polyclonal 
 
 
 
 
 
 
 
 
 
Polyclonal 
 
 
 
 
 
 
 
 
 
Polyclonal 
 
 
 
 
 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Monoclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Polyclonal 
 
 
Mouse 
 
 
Rabbit 
 
 
 
 
 
Mouse, 
IgG1κ 
 
 
 
Rabbit 
IgG  
 
 
 
 
 
 
 
 
Rabbit 
IgG 
 
 
 
 
 
 
 
 
Rabbit 
 
 
 
 
 
 
 
Rabbit 
 
 
Rabbit 
 
 
Mouse 
 
 
Rabbit 
 
 
Rabbit 
 
 
Rabbit 
 
 
Rabbit 
 
 
Rabbit 
 
 
 
 
Synthetic peptide 
corresponding to 
amino acids near the 
amino terminus of 
human RECQL4 
 
Human recombinant 
peptide corresponding 
to a 1002 bp Ki-67 
cDNA fragment  
 
Epitope corresponding 
to amino acids 294-
363 RUNX2 mouse 
origin 
PQVATYHRAIKVTVD
GPREPRRHRQKLDD
SKPSLFSDRLSDLGR
IPHPSMRVGVPPQNP
RPSLNSAPSPF 
 
phosphorylated 
synthetic peptide, 
which represented a 
portion of human 
Checkpoint Kinase 1 
(GeneID 1111) around 
serine 317 according 
to the numbering given 
in entry NP_001265.1 
 
Synthetic peptide 
sequence derived 
from: 
MNLRSVFTVEQQRIL
QRYYENGMTNQSKN
CFQLILQCAQETKLD
FSVVRT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCM10 fusion protein 
ag2899 
 
50 
 
 
150 
 
 
 
 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
77 
 
 
 
 
 
 
 
 
220 
 
 
62 
 
 
97-
105 
 
56 
 
 
30 
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Table 2.1-d Secondary antibodies.  
Secondary antibody Dilution Clonality  Raised in 
 
Alexa-fluor 488 anti-rabbit, 
(invitrogen, A11008) 
1:500 in IF blocking buffer   Goat 
Alexa fluor 555 anti-mouse, 
(Invitrogen, A21422) 
1:500 in IF blocking buffer   Goat 
Anti-Rabbit Horseradish 
Peroxidase, (Millipore, 12-
348) 
1:5000 in WB blocking 
buffer/ WB blocking buffer 
BSA 
Polyclonal Goat 
Anti-Mouse Horseradish 
Peroxidase (Millipore 
AP501P) 
1:5000 in WB blocking 
buffer/ WB blocking buffer 
BSA 
Polyclonal Goat 
Anti-Goat Horseradish 
Peroxidase (Millipore 
AP180P) 
 
1:10,000 in WB blocking 
buffer/ WB blocking buffer 
BSA 
 
Polyclonal 
 
Donkey  
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Table 2.1-e Cell lines and culture details. DMEM - Dulbeccos modified minimal essential medium (Gibco™, 
Thermo Fisher Scientific).  EMEM - Eagle’s Minimum Essential Medium (Gibco™, Thermo Fisher Scientific).  
MEM α -  Minimum Essential Medium alpha (Gibco™, Thermo Fisher Scientific).  FBS – fetal bovine serum 
(Gibco™, Thermo Fisher Scientific).   
Cell line Species/det
ails 
Tissue/cell 
type 
Disease/mutati
on 
Growth 
medium 
Freezing 
medium 
Obtained 
 
HeLa LacZeo 
TO (HeLa) 
 
Human 
 
Cervical 
 
Carcinoma 
 
DMEM with 10% 
FBS  
 
Antibiotic 
(complete 
media) + 1%  
penicillin/strepto
mycin 
 
DMEM + 
20% Foetal 
calf serum + 
10% DMSO 
 
 
Stephen 
Taylor, 
University of 
Manchester 
U2OS Flp-In™ 
T-REx™ 
(U2OS) 
Human  Osteosarcoma DMEM with 10% 
FBS 
 
Antibiotic 
(complete 
media) + 1%  
penicillin/strepto
mycin  
DMEM + 
20% Foetal 
calf serum + 
10% DMSO 
 
Catherine 
Miller, 
University of 
Manchester 
AG05013htert 
immortalized 
Human, 
male, 10 
years of age 
Skin,fibroblast RTS/RECQL4 DMEM 
with 10% FBS  
DMEM + 
20% Foetal 
calf serum + 
10% DMSO 
 
Coriell Cell 
Repositories 
HS68htert 
immortalized 
Human, 
male, new 
born 
Skin,fibroblast aspartoacylase 
deficiency; 
possible 
Canavan 
disease 
DMEM  
with 15% FBS  
DMEM + 
20% Foetal 
calf serum + 
10% DMSO 
 
Immortalisati
on 
performed 
by CRUK 
Cell 
Cervices at 
Clare Hall 
MRC5 
 
Human Lung, 
fibroblast 
  
DMEM 
with 10% FBS  
 
DMEM + 
20% Foetal 
calf serum + 
10% DMSO 
 
 
(ATCC® 
CCL-171™) 
ASC52telo 
htert 
immortalized 
Human adipose 
derived 
mesenchymal 
stem cells 
 MesenPRO 
RS™ Medium kit 
(Thermo Fisher 
Scientific)  
MesenPRO 
RS™ 
Medium 
(Thermo 
Fisher 
Scientific) + 
10% DMSO 
 
ATCC® 
SCRC 
4000™) 
P13 
AG03587 Human, 
Caucasian, 
male, 7 
years of age. 
Fibroblast, RTS EMEM with 15% 
FBS, 
EMEM with 
15% FBS + 
10% DMSO 
 
Coriell Cell 
Repositories 
AG18375 Human, 
Caucasian, 
male, 22 
years of age. 
Fibroblast RTS/RECQL4 
Osteosarcoma 
at 21 years of 
age.  
MEM α +10% 
FBS 
MEM α 10% 
FBS + 10% 
DMSO 
 
Coriell Cell 
Repositories 
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Table 2.1-f siRNA details 
siRNA  Target sequence 
 
AllStars Non-
Targeting 
(NT), 
(Qiagen, 
1027280),  
 
No homology to 
any known 
mammalian 
gene.  
 
Non-targeting  
 
RECQL4 
siRNA (pool), 
(Qiagen) 
 
#1SI03091732  
#2 SI00061866  
#3 SI00061859  
#4 SI00061852  
 
Entrez gene 9401 
 
 
 
RECQL4 
siRNA #9 
  
5’-cagggugugggaacgaggauu-3’ 
RECQL4 
siRNA#10 
  
5’ aggcuagggcagugacug auu-3’ 
 
HDX 
(Qiagen) pool 
 
HS cxorf43 8 
(5104269097) 
HS cxorf43 5 
(5103160745) 
HS cxorf43 7 
(5104257617) 
HS HDX 1 
(5105393444) 
 
 
Entrez gene 139324 
 
Table 2.1-g Delivery agent to DNA ratio 
Delivery system Ratio reagent:DNA (PEYFP-C1 at 200ng) 
 
Fugene 6 
 
2:1 
 
3:1 
 
3:2 
 
4:1 
Lipofectamine 2000 2:1 3:1 3:2 4:1 
 
Table 2.1-h Control plasmid 
Plasmid Type Promoter Size 5’sequencing 1 
primer 
Tag 1 Constitutive Viral 
 
pEYFP-
C1 
 
Mammalian 
expression 
 
CMV 
 
4700 
 
5'd[CATGGTCCTGCT
GGAGTTCGTG] 
 
EYFP 
(Nterm) 
 
Constitutive 
 
Nonviral 
 
Table 2.1-i concentrations of plasmid for inoculation 
 Plasmid and vector Soc medium Ratio 
 
10 µl  
 
40 µl 
 
1:4 
20 µl 30 µl 2:3 
50 µl - - 
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Table 2.1-j Digest mix 
Digest 
 
NcoI 
 
XhoI  
 
Hinfl 
3µl plasmid DNA or empty vector 5µl plasmid DNA or empty vector 5µl plasmid DNA or empty vector 
1µl 10x BSA 1µl 10x BSA 1µl 10x BSA 
1µl 10x NEB3 (Biolabs B72035) 1µl 10x NEB4 (Biolabs B70045) 1µl 10x NEB3 (Biolabs B72035) 
0.5µl NCOI (10 n/ µl)  0.5µl digest (Biolabs R01465) 0.5µl digest (Boehringer monheim 13607322-43) 
4.5µl H2O 2.5µl H2O 2.5µl H2O 
Incubated at 37℃ for 2 hours  Incubated at 37℃ overnight Incubated at 37℃ overnight 
 
Table 2.1-k RECQL4 oligonucleotides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1-l Annealing mix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oligonucleotides 
Concen
tration Sequence 
 
9 Top - Sh 
RECQL4_9 (Sigma-
Aldrich 8017856206 
0010 403) 200µm 
5’CCGGCACAGGGTGTGGGAACGAGGACTCGAGTCCTCGTTCCCACA
CCCTGTGTTTTTG-3’ 
9 Bottom - Sh 
RECQL4_9 (Sigma-
Aldrich 8017856206 
0020 403) 200µm 
5’AATTCAAAAACACAGGGTGTGGGAACGAGGACTCGAGTCCTCGTTC
CCACACCCTGTG-3’ 
10 Top - Sh 
RECQL4_10 
(Sigma-Aldrich 
8017856206 0030 
403) 200µm 
5’CCGGAGAGGCTAGGGCAGTGACTGACTCGAGTCAGTCACTGCCCT
AGCCTCTTTTTTG-3’ 
10 Bottom - Sh 
RECQL4_10 
(Sigma-Aldrich 
8017856206 0040 
403) 200µm 
5’AATTCAAAAAAGAGGCTAGGGCAGTGACTGACTCGAGTCAGTCACT
GCCCTAGCCTCT-3’ 
ML Protocol (A)  Addgene Protocol (B) (modified)  
TE pH 8.0 
100 mM MgCl2 
200 pmol of Top oligo (200 µM) 
200 pmol of Bottom oligo (200 µM) 
43µl 
5µl 
1µl 
1µl 
 
H2O 
NEBuffer 2 10x 
200 pmol of Top oligo (200 µM) 
200 pmol of Bottom oligo (200 µM) 
 
43 µl 
5 µl 
1µl 
1µl 
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Table 2.1-m Ligation Reagent mix 
 Empty vector RECQL4 9 (A) RECQL4 9 (B) RECQL4 10 (A) RECQL4 10 (B) 
 
PLK0.1 (93.5ng/µl 
 
1µl 
 
1µl 
 
1µl 
 
1µl 
 
1µl 
10x annealed insert - 0.5µl 0.5µl 0.5µl 0.5µl 
T4 ligase  0.2µl 0.2µl 0.2µl 0.2µl 0.2µl 
10x ligase buffer 1µl 1µl 1µl 1µl 1µl 
10x BSA 1µl 1µl 1µl 1µl 1µl 
H20 6.8µl 6.3µl 6.3µl 6.3µl 6.3µl 
Adenosine 
triphosphate (ATP) 
0.1µl 0.1µl 0.1µl 0.1µl 0.1µl 
 
Table 2.1-n PCR amplification mix 
PCR amplification mix component Volume per reaction 
Amplification grade water To final volume (25µl) 
GenePrint® 10 5X Master Mix 5µl 
GenePrint® 10 5X Primer Pair Mix 5µl 
template DNA (10ng) Up to 15µl 
Total reaction volume 25µl 
 
2.2 Cell Culture  
All cell culture procedures were performed in a clss II Thermo Scientific Safe 2020 
Biological safety cabinet.  Separate solutions were used between cell lines to reduce 
the risk of cross contamination.  Cells were incubated in a Panasonic MCO-19A1C-
PE humidified cell culture incubator, CO2 controlled at 5%, at 37℃. All solutions 
were equilibrated to 37℃ before usage in a Grant waterbath. 
2.2.1 Cell maintenance 
Cells were maintained in 25cm2 T-flasks in 5ml of suitable medium (Table 2.1-e) at 
around 80-90% confluency (2-4 days).   
For passaging and seeding, the media was removed using aspiration, and the cells 
were washed with 1x PBS. 500µl 1x trypsin-EDTA (0.25% trypsin, 0.53mM EDTA, 
Gibco) in 1x PBS was added to detach the cells, for 5-10 minutes at 37 ℃. Detached 
cells were re-suspended in suitable media (Table 2.1-e)  and the cells were counted 
before each assay, seeding, and passaging by haemocytometer or a BioRad TC20 
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cell counter. Desired cell density was seeded onto plate wells, or in 25cm2 T-flask 
for continual culture.  If required during culture, cell growth was recorded using 
phase contrast images taken with a Nikon eclipse T5100 and DN100 camera.   
2.2.2 Freezing 
The cells were detached from the culture vessel using trypsin-EDTA, as previously 
described, and were placed in separate conical tubes and centrifuged down at 
1000rpm for 5 minutes. The medium was carefully removed leaving the cells at the 
base of the 15ml conical centrifuge tube.  Light tapping was applied to mix the 
remaining cells and suitable 1ml freezing medium was added (Table 2.1-e).  The 
suspension was transferred into cryo-vials and stored via slowly cooling to -80℃, 
then transferred to vapour phase of a liquid nitrogen container.  
2.2.3 Recovery 
The cells were rapidly thawed by placing in a 37℃ water bath for 2 minutes, to 
prevent the formation of water crystals. The cells were suspended in 10 ml media 
then centrifuged down at 1000rpm for 5 minutes and the freezing media (Table 
2.1-e) was removed by aspiration.  The cells were re-suspended in the appropriate 
growth media (Table 2.1-e) and transferred to a 25cm2 T-flask.  
2.2.4 Proliferation titration  
Cells were harvested as previously described, were seeded at suitable densities 
and incubated at 37°C. At various time points the cells were harvested as previously 
described and counted.  The cells were viewed using Nikon Eclipse TE2000 inverted 
stage microscope.  
2.2.5 ASC52telo differentiation ability 
ASC52telo cells were seeded at 5000 cells per cm2 on 24 well plate.  The cells were 
allowed to reach around 80% confluency (control cells).  The cells were treated with 
selected differentiation media: chondrocyte differentiation (StemPro chondrocyte 
kit, Thermo Fisher Scientific), osteocyte differentiation (StemPro osteogenesis kit, 
Thermo Fisher Scientific), and adipocyte differentiation (StemPro adipocyte kit, 
Thermo Fisher Scientific). Medium was changed every 3 days. Full differentiation 
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was expected following at least 21 days of culture. Differentiation was confirmed 
with histochemical staining.   
2.2.5.1 Adipocyte differentiation detection - Oil red o  
Following cell incubation for adipocyte differentiation (21 days, unless stated 
otherwise), the medium was aspirated gently; the cells were not allowed to remain 
dry for no longer than 30 seconds. All rinsing was carried out gently, in order not to 
disturb the monolayer.  The cells were washed with 1x PBS, and fixed in 4% fixing 
solution (Table 2.1-a) for 10 minutes at 4℃.  The fixing solution was then removed 
and 1x PBS washes performed 2 times.  The cells were washed with distilled H2O.  
60% Isopropanol was added to cover the cells for 5 minutes.  This was removed 
and 2ml of Oil red O working solution (Table 2.1-a), was added to cover the cells for 
5 minutes. The solution was removed and the cells washed with tap water until 
running clear.  2ml of Harris haematoxylin (Thermo Fisher Scientific) counterstain 
was added for 1 minute and rinsed with warm tap water.  The cells were observed 
using transmitted light microscopy, the nuclei staining blue, and the lipid droplets 
staining red.   
2.2.5.2 Osteoblast differentiation detection - Alizarin red S 
Following cell incubation for osteoblast differentiation (21 days, unless stated 
otherwise), the medium was aspirated gently.  All rinsing was carried out gently, in 
order not to disturb the monolayer.  The cells were washed with 1x PBS, and fixed 
in 4% fixing solution (Table 2.1-a) for 10 minutes at 4℃.  The fixing solution was 
then removed and 1x PBS washes performed 2 times. The cells were washed with 
distilled H2O, and Alizarin Red S staining solution (Table 2.1-a), was added to cover 
the cells for 5 hours.  The plate was wrapped in foil to protect from light.  The solution 
was carefully removed and cells washed 4x with H2O and maintained in 1x PBS.  
The cells were observed using transmitted light microscopy, extracellular calcium 
deposits staining orange-red.   
2.2.5.3 Chondrocyte differentiation detection – Alcian blue 
Following cell incubation for chondrocyte differentiation (21 days, unless stated 
otherwise), the medium was aspirated gently. The cells were washed with 1x PBS, 
and fixed in 4% fixing solution (Table 2.1-a) for 10 minutes at 4℃.  The fixing solution 
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was then removed and 1x PBS washes performed 2 times.  The cells were washed 
with distilled H2O and Alcian blue staining solution was added to cover the cells 
overnight.  The staining solution was carefully removed and the cells were washed 
2x with destaining solution (Table 2.1-a) for 20 minutes each time.  The cells were 
maintained in 1x PBS and observed using transmitted light microscopy.  Cartilage 
stains dark blue.  
2.2.6 Anchorage-independent growth  
ASC52telo cells were seeded at 2000 cells per well in Costar flat bottom ultra-low 
attachment surface non pyrogenic (3474) 96 well plate. The cells were incubated as 
indicated in the legend of the respective figures.  Every 3 days the plate was 
centrifuged at 1000rpm, the media was carefully removed leaving 20ul on the cells.  
The cells were re-suspended in media under the same conditions with/without 
treatment (PHA-767491). MTS assay (Section 2.2.7.2) was performed at indicated 
days.  
2.2.7 Cell quantification and viability analysis  
2.2.7.1 Cell quantification  
Cell quantification was performed before each assay to seed cells at desired 
density, and for analysis of cell proliferative rate. Obtained cell suspension was 
mixed with Trypan blue at a 1:1 ratio to measure cell viability, was added to a clean 
haemocytometer, and viewed using Nikon Eclipse TE2000 inverted microscope with 
10x objective. In total 8 quadrants were used to provide a mean. The mean was 
calculated, and the cell concentration was expressed as n x 105. Alternatively, a Bio-
Rad TC20 automated cell counter was used with a cell suspension prepared (see 
Table 2.1e). 
2.2.7.2 MTS viability assay 
The procedure was carried out in dark conditions.  MTS solution was prepared using 
MTS (CellTiter 96® -A Queous MTS Reagent Powder, Promega), dissolved in 1x 
PBS and mixed with the electron coupling reagent phenazine methosulfate (PMS), 
(Sigma-Aldrich, P9625).  Cells were seeded at appropriate densities in 96-well plate 
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and following incubation the media was replaced with 100ul fresh media and 20ul 
of MTS/PMS solution was added to the culture medium at a final concentration of 
1.9 mg/ml MTS and 44 μg/ml PMS in 1x PBS, and cells were incubated for 3 hours 
at 37°C.  Post incubation, the coloured product generated by viable cells was 
measured at 490 nm and quantified using a Spectra Max Plus (Molecular Devices) 
plate reader with Softmax pro 5.2 software.  
For drug treatments, the drug was added 24 hours following cell seeding and 
maintained throughout the assay until MTS/PMS was added. 
2.2.7.3 RealTime-Glo™ MT assay 
ASC52telo cells were seeded at 5000 cells per cm2 on a 96 well plate in triplicates, 
and treated as required. A well was left blank either side. The cells were incubated, 
and the media was changed every 3 days.  On day 21 fresh media was added, 2x 
RealTime-Glo™ was added to the wells in media to form 1x concentration, and 
incubated for 1 hour. The plate was covered with PCR film to reduce contamination 
to cells, covered with tin foil to protect from light during incubation. Luminescence 
was read using Hidex Chameleon plate reader. The plate was returned for 
incubation and on day 24 the RealTime-Glo™ MT assay was repeated, and cells 
returned for incubation.  To analyse the cells further an MTS assay (Section 2.2.7.2) 
was performed on day 28.     
2.2.8 PHA-767491 titration 
A suitable concentration of PHA-767491 (pyridin-4-yl)-6,7-dihydro-1H-pyrrolo[3,2-
c]pyridin-4(5H)-one; Sigma-Aldrich, PZ0178), was determined in a range of cell 
lines to establish mild proliferation inhibition. Cells were harvested as previously 
described, and seeded at 2000 cells per well in a 96-well plate and incubated for 24 
hours. Wells with media alone were used as background control.  Media was 
replaced with 100ul fresh media containing a range of PHA-767491 concentrations 
after the cells had safely attached to the substrate.  The cells were incubated for 7-
10 days and an MTS assay performed as described previously.  
A PHA-767491 model (PHA model) (Figure 2.2-a) was generated to establish 
ASC52telo cell lines which would represent: 1) short term treatment (referred to as 
‘acute’); 2) continuous, prolonged treatment (‘chronic’); 3) cells released from 
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chronic treatment for the duration of experiment (‘chronic recovery); 4) and 
untreated cells (no treatment) in low and high passage cells.  Low passage chronic 
PHA treatment started at P+6, high passage chronic PHA treatment started at P+13. 
Cells treated with PHA for a period of time and through a number of passages prior 
to further plating were deemed ‘chronic’.  
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Figure 2.2-a A schematic showing ASC52telo cells and various culture conditions that established a model of PHA-767491 treatment.  ASC52telo cells were passaged and maintained 
under PHA-767491 at 1.5µm as per model.  ‘Chronic’ represents cells under treatment during culture that continued throughout any further analysis. ‘Acute’ represents cells without treatment 
under culture but the addition of PHA-767491 during assays.  ‘Recovery’ cells were treated during culture but no treatment during further analysis.  
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2.2.9 Titration of selection reagents 
Optimum selection concentration of Blasticidin-S® (Thermo Fisher Scientific) in 
HeLa and U2OS cells had been previously determined to be 4µg/ml and 15µg/ml, 
respectively. 
HeLa and U2OS cells were seeded into petri dishes containing 10ml DMEM medium 
(Table 2.1-e) with Blasticidin-S® (Thermo Fisher Scientific) as above and 
concentrations of Hygromycin B (Calbiochem, 400053) varying between 0 µg/ml 
with 50µg/ml increments and incubated for 2 and 3 weeks.  The cells were observed 
microscopically using Nikon Eclipse TE2000 inverted stage microscope for the rate 
of cell growth / cell death to determine an appropriate concentration of Hygromycin 
B with the Blasticidin-S® co-treatment. The optimal concentration of Hygromycin B 
for co-selection was found to be 225 µg/ml (45 µl in 10ml medium) in HeLa cells, 
and and100 µg/ml (20 µl in 10ml medium) in U2OS cells.  
2.2.10 Transfection 
2.2.10.1 siRNA transfection 
All siRNA transfections were performed as reverse transfections, under RNAse-free 
conditions, and conducted in 96 well plates. For one well of the 96-well plate 0.1 µl 
DharmaFECT 1 (Dharmacon) delivery reagent was diluted in 9.9µl OptiMEM 
medium (Gibco, Thermo Fisher Scientific), and 0.5µl 2µM siRNA (Table 2.1-f) was 
diluted in 9.5µl OptiMEM. The diluted reagents were mixed via vortexing and 
incubated at room temperature for 5 minutes.  Following incubation the transfection 
reagents (diluted siRNA and diluted transfection reagent) were combined, mixed, 
and incubated at room temperature for 20 mins, then placed into the wells. Cell 
suspension of 12,000 cells per well was set up and 80µl was added to each well. 
The reagent mixes and cell suspension were scaled up as required for the number 
of wells. The media was topped up 18 hours post transfection and incubated for 
further 2 days.  Whole cell protein was extracted (Section 2.3.1) and further analysis 
was performed. 
2.2.10.2 Optimisation of plasmid transfection 
HeLa LacZeo cells were seeded at 1x105per well onto glass coverslips in 24 well 
plate and incubated overnight.  The cells were transfected with variety of ratios 
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(Table 2.1-g) of delivery agent : plasmid DNA, using either Fugene 6 (Promega), or 
Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific), and pEYFP-C1 control 
plasmid (Table 2.1-h). For Lipofectamine 2000, 6 hours post transfection the media 
was removed and replaced with media alone, while additional media was added to 
Fugene 6 wells. Analysis was performed 72 hours post transfection. 
2.2.10.3 Plasmid transient transfection 
1x105 HeLa or U2OS cells were seeded into wells of a 24 well plate and incubated 
overnight. The medium was then replaced with 500 µl fresh medium. 300 ng of 
plasmid DNA diluted in OptiMEM (Gibco, Thermo Fisher Scientific) was mixed with 
Lipofectamine 2000 at a ratio of 3:1 Lipofectamine 2000 to DNA, and incubated at 
room temperature for 25 minutes.  A 100 µl aliquot of the transfection mix was added 
into the appropriate wells and incubated for 6 hours. 6 hours post transfection 
additional 500 µl medium (Table 2.1-e) was added to each well, and incubated for 
72 hours, until analysis. 
2.2.10.4 Co-transfection for inducible expression 
For the generation of stable cell lines the FlipIn / FRT site-specific recombination 
system was used. The host cell lines, HeLa-LacZeo and U2OS-FLIPINTREX, 
contain a single-copy integrated FRT recombination site, which is utilized by the 
FLP recombinase. The FLP recombinase is introduced into the system via the co-
transfection of the pOG44 plasmid (Invitrogen, Thermo Fisher Scientific). 
HeLa-LacZeo and U2OS-FLIPINTREX cells were seeded onto 10cm plates and 
cultured to reach around 50% confluency. 800ng of pXPfrtto-RECQL4-Emerald 
maxiprep plasmid DNA (2.6.5) (4294.5ng/µl) was mixed with 7.2µg pOG44 (1940.1 
ng/ µl) to reach a ratio of 9:1 in OptiMEM and allowed to stand for 5 minutes. 
Lipofectamine 2000 transfection reagent was diluted in OptiMEM to allow a ratio 3:1 
with DNA reagent, mixed well, and allowed to stand for 5 minutes at room 
temperature. The diluted plasmids and the Lipofectamine reagent were mixed well 
and allowed to stand at room temperature for 25 minutes then added to the cells 
drop-wise and incubated for 5 hours.  Post transfection the medium was removed 
and was replaced with 10ml of fresh medium. The transfected cell population was 
selected for correct integration and Tet repressor expression with Blasticidin-S® 
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(Thermo Fisher Scientific) and Hygromycin B (Calbiochem, 400053), at 
concentrations determined previously.  
2.2.11 Verification of inducible Emerald-GFP tagged RECQL4 
Emerald-GFP tagged RECQL4 clones (in HeLa-LacZeo and U2OS-FLIPINTREX 
hosts) under selection were maintained in 6 well plates to reach around 90% 
confluency.  The cells were harvested using trypsin as previously described and 
seeded at suitable density onto ethanol sterilised glass coverslips in 1ml medium 
(Table 2.1-e).   Doxycycline at 2 µg/ml was added to the wells and incubated for 3 
days. Fixing, mounting and analysis was performed as described in section 2.4. 
2.3  Protein isolation and analysis 
2.3.1 Whole cell protein extraction 
Adherent cells (ASC52telo) were allowed to reach around 80% confluence, for 
approximately three days.  The cell medium was removed from the dishes using an 
aspirator, and cells were washed x3 with 1X Phosphate Buffered Saline (PBS).  
Remaining PBS was aspirated.  An appropriate amount of cold lysis buffer 
supplemented with protease and phosphatase inhibitors was added for 5 minutes 
at 4 ℃.  The lysate was then collected and was transferred into a new 1.5ml micro-
centrifuge tube and sonicated with 4x 5 second bursts at 18 microns of amplitude 
(Soniprep 150, MSE).  The cells were then centrifuged at 13,000 rpm for 20 minutes 
at 4℃ to sediment the cell debris, and the lysate was transferred to a new 1.5ml 
micro-centrifuge tube and stored at -80℃. 
2.3.2 Protein quantification 
Protein concentration of whole cell lysate was determined by Bradford assay.  For 
each sample 1 µl was assayed in 4 µl of H2O in 96-well plate. Bovine Serum Albumin 
(BSA, Sigma-Aldrich, A9647) 0-2mg/ml was used as standards at 5 µl per well. 250 
µl of Quick Start Bradford 1x dye (Bio-Rad, 500-0205) was added to each well, and 
was incubated for 5 minutes in tin foil to protect from light. Absorbance was read at 
595nm using Infinite® M200 Tecan or spectra Max Plus Molecular Devices plate 
reader with Softmax pro 5.2 software.  
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2.3.3 Sodium dodecyl sulphate polyacrylamide gel (SDS page) 
Proteins were separated by electrophoresis using polyacrylamide gel. Depending 
on the number of parallel samples either a small or a large gel was run. A small 
Novex NuPage 4-12% Bis-Tris pre-cast gel was run in an XCell sureLock Mini-Cell 
tank with 1x Invitrogen NuPage MOPS SDS running buffer. A large Criterion TGX 
pre-cast 4-15% gel was run in a Criterion cell (Bio-Rad) in 1x Criterion gel running 
buffer (Table 2.1-a). Protein concentrations in each lysate were determined (Section 
2.3.2) and normalised to the most dilute sample to maintain equal loading.  To 
denature the proteins each lysate was heated at 100℃ for 5 minutes with 1x Nupage 
Novex LDS sample buffer (Table 2.1-a) and allowed to cool on ice.  The gel was run 
at 100v for 2.5 hours (Nupage) or 120v for 1.5 hours (Criterion). Following the 
separation of the proteins the gel was either cut (Section 2.3.4) and sent for mass 
spectrometry, or western blot was performed (Section 2.3.5). 
2.3.4 Gel section cutting 
Sections of the gel previously ran by SDS page (Section 2.3.3), were then cut 
according to ladder markings. To help maintain sterility and to avoid keratin 
contamination, equipment was cleaned with ethanol and Teknon 100.  The sections 
were stored in micro-centrifuge tubes, at -80℃, and sent for mass spectrometry 
analysis.   
2.3.5 Western blotting 
To identify specific proteins extracted from cells a western blot was performed.  The 
proteins were separated by size using SDS-page (2.3.3), transferred onto 
Amersham Hybond ECL nitrocellulose membrane (RPN303D GE-Healthcare) and 
were blocked in membrane blocking buffer (Table 2.1-a) for 1 hour.  Targeted 
proteins were marked using appropriate primary and secondary antibodies: the 
membrane was incubated overnight at 4 °C with primary antibodies in blocking 
buffer (Table 2.1-c), sealed in a polyethylene bag on a rotary wheel.  Unbound 
antibody was removed in 5x washes for 10 minutes each in PBS Tween-20. A 
targeted horseradish peroxidase-conjugated secondary antibody (Table 2.1-c) was 
then applied for 1 hour at room temperature sealed in a polyethylene bag on a 
rocking platform. Unbound antibody was removed in 5x washes for 10 minutes each 
in PBS Tween-20. The signal from targeted protein was detected using an enhanced 
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chemiluminescence detection kit: ECL substrate BioRad (Bio-Rad,170-5060s) for 5 
mins, or Pierce™ ECL Western Blotting Substrate (Thermo Scientific Fisher ™) for 
1 minute. The signal was captured on film and developed using an Xograph 
Compact x4, or imaged using Bio-Rad ChemiDoc™ MP imaging system (Bio-Rad) 
with Image lab 4.1 software. Band densities were measured using ImageJ software, 
and normalized to Tubulin to express relative density where appropriate.  
2.3.6 Stripping and re-probing 
The membrane previously probed was stripped to allow re-probing with different 
antibody.  The membrane was placed into stripping solution (Table 2.1-a) for 30 
minutes on a rocking platform, followed by 2x washes in 1xPBS-Tween.  The 
membrane was then blocked and appropriate antibody applied as described above 
(Section 2.3.5).   
2.3.7 Immunoprecipitation of GFP-RECQL4 fusion proteins  
Cells expressing Emerald-GFP tagged RECQL4 in a doxycycline inducible manner 
were established in HeLa and U2OS background. HeLa GFP-RECQL #2 and U2OS 
GFP-RECQL4 #15 cells were recovered.  Confluency was established in selection 
medium (Table 2.1-e).  The cells were then detached as previously described and 
re-seeded into separate 3x 10cm petri dishes for each cell line with medium (Table 
2.1-e). GFP-RECQL4 expression was induced with the addition of 2ug/ml 
doxycycline and the cells were allowed to establish confluency.  The cells were then 
trypsinised and transferred into 8 x 10 cm petri dishes separately for each cell line 
and incubated overnight.  Late evening the following day the cells were treated as 
follows: 2 of the petri dishes of each cell line were treated with 2µm Suberoylanilide 
hydroxamic acid (SAHA); 2 were treated with 4mM hydroxyurea; two were left 
untreated, and the final two with Dimethyl Sulfoxide (DMSO) and incubated for 18 
hours. The medium was then removed and on ice using 3ml of cold PBS the cells 
were detached by scraping and transferred into 15ml falcon tubes. The falcon tubes 
were then centrifuged at 1,000rpm for 5 minutes at 4℃.  The supernatant from each 
tube was carefully removed and the pellet was re-suspended in 5ml cold PBS, and 
centrifuged at 1,000rpm for 5 minutes at 4℃.  The supernatant was carefully 
removed and the pellet was re-suspended in 1ml cold PBS and transferred into 
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separate 1.5ml micro-centrifuge tubes. These were then centrifuged again at 
1,000rpm for 5 minutes at 4℃, and the supernatant discarded.  
GFP-tagged proteins were isolated via immunoprecipitation using Chromotek GFP-
trap®_A. The pellet was flicked to mix well before the addition of lysis buffer to each 
and allowed to rotate on a rotary wheel at 4℃ 20rpm for 1 hour.  Following 
incubation, the crude lysate was centrifuged at 13,000rpm for 30 minutes at 4℃.  
The supernatant was transferred to new 1.5ml micro-centrifuge tubes on ice.  50µl 
of the cell lysate was diluted with 50µl 4x LDS-sample buffer with 13mM DTT and 
heated at 100℃ for 5 minutes, allowed to cool on ice before storage at -80℃ for 
western blotting (input).  25µl of GFP-trap®_A beads were equilibrated with 500µl 
of ice cold dilution buffer for each sample in 1.5ml micro-centrifuge tubes. The tubes 
were centrifuged at 2700xg for 2 minutes at 4℃, and the supernatant was discarded; 
this process was repeated a further 2 times. The cell lysate was then added to the 
appropriate 1.5ml micro-centrifuge tube containing the beads.  They were then 
rotated on a rotary wheel for 2 hours at 12rpm at 4℃. Following incubation, the tubes 
were centrifuged at 2000xg for 2 minutes at 4℃.  The supernatant was then 
transferred to new 1.5ml micro-centrifuge tubes.  From this a 50 µl of aliquot was 
diluted with 50µl 4x LDS-sample buffer with 13mM DTT and heated at 100℃ for 5 
minutes, allowed to cool on ice and stored at -80℃ for western blotting (cleared 
lysate).  The remaining supernatant was discarded.  The beads were then washed 
with 500µl ice cold dilution buffer and centrifuged at 2000xg for 2 minutes at 4℃, the 
supernatant discarded, and the wash step repeated.  The beads were then re-
suspended in 4x LDS-sample buffer with 13mM DTT and heated at 95℃ for 10 
minutes, allowed to cool on ice before storage at -80℃.   SDS page, gel section 
cutting, and western blotting was performed as described above (Sections 2.3.3, 
2.3.4, 2.3.5, respectively).  
2.4 Epifluorescent microscopy 
Glass coverslips (Thermo Fisher Scientific 12392128, MNJ-500, 13mm), were 
sterilised in 70% ethanol and allowed to dry in wells of a 24-well plate.  Cells were 
seeded at appropriate concentrations with suitable media and cell treatments, on 
the glass coverslips. The cells were incubated and allowed to reach around 70-90% 
confluency. Then the medium was removed using aspiration and the cells were 
washed with 1x PBS.  The cells were fixed in 4% paraformaldehyde for 12 minutes 
on ice. The fix was removed, and the cells were washed in PBS 5 times. The cells 
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were then permeabilised for 20 minutes on ice and then blocked (IF blocking buffer) 
for 1hr at 37°C (Table 2.1-a).  Primary antibody (Table 2.1-c) was diluted in blocking 
buffer and applied to glass slide, 15 µl per coverslip.  The glass coverslip was 
applied onto this with cells facing down and cemented down using Fixogum.  This 
was stored in a humidified chamber overnight at 4°C.  The coverslips were then 
placed back into a 24 well plate with cells facing upwards, and washed 5x with 1x 
PBS for 5 minutes. The appropriate targeting secondary Alexa Fluor antibody (Table 
2.1-d) was applied for 1 hr at 37 °C; the plate was covered in tin foil to protect the 
secondary antibody from light.  The cells were washed 5x with 1x PBS for 5 minutes.  
The coverslips were allowed to dry on Whatman paper.  To visualize the nuclei a 
counterstaine was applied, either DAPI, or Vectashield, or Hoechst (Table 2.1-b).  
The coverslips were sealed using clear nail polish and stored at 4°C.  The cells were 
viewed microscopically using Nikon E800 microscope with DN100 imaging camera 
and imaging software, 100x objective, using FITC and DAPI filters, or using Leica 
SP8 Laser Scanning Confocal Microscope equipped with a 63x objective. Analysis 
was performed using CellProfiler software, minimum 100 cells viewed per control/ 
treatment.  
For the analysis of signal from fluorescent proteins from either transient transfection 
or inducible expression, cells were seeded and transfected as described in section 
2.2.10.3, or seeded and induced as described in section 2.2.11. Following the 
required incubation, the medium was removed and the cells were washed x2 with 
PBS and fixed using 4% fixing (Table 2.1-aError! Reference source not found.) s
olution for 10 minutes at 4℃.  The fixing solution was then removed and 1x PBS 
washes performed 2 times.  The cells were stained with 20000x Dapi and viewed 
microscopically using Nikon E800 microscope with DN100 imaging camera and 
imaging software, 100x objective, using FITC and DAPI filters. 
2.5 Analysis of mitochondrial membrane potential  
ASC52telo cells were seeded at 5000 cells per cm2 in two 96 well plates, with blank 
wells either side; both plates were kept under the same conditions. PHA-767491 
treatment was applied following the PHA model. The cells were incubated for 72 
hours.  One plate was analysed with the MTS viability assay (Section 2.2.7.2). The 
other plate was analysed using TMRE (tetramethylrhodamine, ethyl ester) assay 
(abcam 113852), for this, FCCP (20µm) (carbonyl cyaninde 4-(trifluoromethoxy) 
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phenylhydrazone) was added in FCCP control wells at 1000x dilution in culture 
media, cells incubated for 3 hours.  TMRE at 400µm in culture media was added to 
each well and incubated for 30 minutes, plate wrapped in foil to protect from light.  
All wells were washed x2 with 0.2% BSA.  TMRE was read at Ex/Em 549/575nm, 
Infinite® M200 from Tecan.   
2.6 Molecular cloning 
2.6.1 RECQL4-Emerald tagged construct 
The Emerald-GFP tagged expression construct, pXPfrtto-RECQL4-Emerald, was 
generated with the Gateway® site-specific recombination cloning system by 
recombining the pENTR-RECQL4(F0) entry clone with the pDESTfrtto-Emerald-N0 
expression vector, and was performed by Dr Csanad Bachrati. The recombinant 
constructs were verified with restriction fragment mapping.  
2.6.2 Preparation of LB-Agar plates and LB-broth 
1l of LB was prepared by the addition of 25g LB broth (Miller) powder (Sigma-
Aldrich) to 1l distilled water and sterilised by autoclaving. 1l LB-agar was prepared 
by dissolving 25g of LB broth (Miller) powder (Sigma-Aldrich) and 8g of agar powder 
(Sigma-Aldrich) in 1l of deionised water, and sterilised by autoclaving. When the LB-
agar was cooled to ~50°C Ampicillin was added to the final concentration of 100 
µg/ml. 20ml of LB-agar/Amp was poured into 10cm diameter bacterial petri dishes 
and allowed to cool to room temperature. 
2.6.3 Transformation 
Transformation procedure was performed using aseptic technique, over Bunsen 
flame. 
A 25 µl aliquot of bacterial host cells (Escherichia coli NEB5α; fhuA2 Δ[argF-
lacZ]U169 phoA glnV44 Φ80Δ [lacZ]M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17; 
New England Biolabs) was thawed on ice slowly.   1 µl RECQL4 construct was 
added and mixed and was incubated on ice for 30 minutes. The bacterial cells were 
heat shocked at 42℃ for 35 seconds, and were transferred onto ice for 2 minutes. 
75 µl SOC medium was added to top up to 100 µl and the cell suspension was 
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incubated for 1 hour at 37℃ with vigorous shaking.  Aliquots of the recovered culture 
were spread onto previously cooled agar plates, at variable concentrations (Table 
2.1-i).  The plates were then incubated at 37℃  overnight upside down for the 
prevention of condensation formation.  
2.6.4 Small scale purification of plasmid DNA (miniprep) 
Eight single colonies were selected from the 10 µl transformation plate, and 
inoculated into 5 ml LB and ampicillin at 100 µg/ml in separate vented-lid tubes, and 
incubated overnight at 37℃, with shaking at 190 rpm. 
The isolation of high purity plasmid DNA was performed as per Miniprep Qiagen 
protocol (Qiagen, 2012). Bacterial cells following overnight growth in LB were 
harvested by centrifugation at 13,000rpm at room temperature for 3 minutes. The 
cell pellet formed was re-suspended in 250µl P1 buffer followed by lysing with mixing 
250 µl P2 buffer. 350 µl of P3 buffer was added and mixed to precipitate genomic 
DNA. Precipitated genomic DNA and cell debris was sedimented by centrifuging at 
13.000 rpm for 10 minutes at room temperature.  The supernatant was collected 
into a QIAprep spin column.  The column was centrifuged for 1 minute at 13,000 
rpm and the flow through discarded. 500 µl PB buffer was used to wash the columns, 
centrifuged at 13,000 rpm for 1 minute.  750 µl PE buffer was added and again 
centrifuged. The flow-through was discarded and the column was again spun down 
to remove residual wash buffer. Bound plasmid was eluted by the addition of 50 µl 
EB buffer, followed by centrifugation. DNA concentration was determined using 
Nanodrop as per manufacturer’s instructions. 
2.6.5 Medium scale plasmid purification (maxiprep) 
High yield isolation of high purity plasmid DNA was performed as per Maxiprep 
Qiagen protocol (Qiagen, 2012).  200ml of selective LB was inoculated with 1ml of 
starter culture and was incubated overnight in a 500ml conical flask at 37°C with 
shaking at 250rpm. Bacterial cells were harvested by centrifugation at 6000g for 15 
minutes at 4°C, and the pellet was re-suspended in 10ml P1 buffer. 10ml P2 buffer 
was added to this suspension to lyse the cells, mixed and incubated at room 
temperature for 5 minutes. 10ml of 4°C P3 buffer was added with mixing and 
incubated on ice for 20 minutes. This was centrifuged at 20000g at 4°C for 30 
minutes to remove precipitated material. The Qiagen-tip 500 column was 
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equilibrated with QBT buffer.  The supernatant of centrifuged sample was then 
applied to the Qiagen-tip 500 column and washed 2x with 30 ml QC buffer and 
eluted with 15ml QF buffer.  Precipitation followed using isopropanol, the sample 
was centrifuged at 15000g for 20minutes at 4°C and washed with 70% ethanol.  
Once dried the pellet was re-suspended in 1ml nuclease-free water and stored at -
20 °C. DNA concentration was determined using Nanodrop as per manufacturer’s 
instructions. 
2.6.6 Analysis of plasmids via restriction digestion and gel electrophoresis 
Plasmid DNA was purified using the Miniprep protocol (Section 2.6.4).  The 
recombinant constructs were verified with restriction fragment mapping.  A digest 
mix (Table 2.1-j) was incubated at 37℃.  An agarose gel was prepared (Table 2.1-a), 
with the addition of 4 µl Safeview and was poured into Biolab mini-sub cell GT tray 
with combe and allowed to cool and set.  Samples were centrifuged briefly at 
13000rpm, followed by the addition of 1/5th volume of 6x loading dye (New England 
Biolabs, B7024S). Undigested controls were made using plasmid, water and loading 
dye.  Samples were run alongside a 2 log DNA ladder (New England Biolabs) at 80 
V for 60 minutes.  Gel images were captured using Bio-Rad ChemiDoc™ MP 
imaging system (Bio-Rad), with Image lab 4.1 software.   
2.6.7 Generation of shRNA constructs 
Two pairs of oligonucleotides coding for the stem-loop structure of an shRNA that 
target the 3’ untranslated region of RECQL4 were custom synthesised (Table 2.1-k).  
The annealing reaction mix was set up as shown in (Table 2.1-l) and a PCR machine 
was programmed to anneal the top and bottom oligonucleotides (Table 2.6-a).   The 
pLKO.1 vector was digested with EcoRI, heat inactivated, purified (Qiagen PCR 
purification kit), further Agel digested and the digested pLKO.1 plasmid was purified 
following agarose gel electrophoresis (Qiagen gel extraction kit) (Addgene). A 
ligation reaction (Table 2.1-m) was set up and the ligated constructs were 
transformed into STABL-1 (Invitrogen, Thermo Fisher Scientific) competent cells 
using the protocol described in section 2.6.3.   
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Table 2.6-a PCR set up in (PCR-C100 Touch thermal cycler, BioRad).  
Temperature (℃) Time (minutes) 
 
95 
 
10 
94 2.5 
93 2.5 
92 2.5 
91 2.5 
90 2.5 
89 2.5 
88 2.5 
87 2.5 
86 2.5 
85 2.5 
84 2.5 
83 2.5 
82 2.5 
81 2.5 
80 2.5 
79 2.5 
78 2.5 
77 2.5 
76 2.5 
75 2.5 
74 ∞ 
 
2.6.8 Generation of lentiviral vector and transduction of ASC52telo cells 
Generation of 4th generation lentiviral particles was performed by Dr Timea Palmai-
Pallag following the well established protocol of Addgene (Adggene). The shRNA 
constructs were co-transfected with pRSV/REV, pMDLg/pRRE, pMD2G plasmids 
into 293T cells. The resulting supernatant, containing the infectious lentiviral 
particles was used to transduce ASC52telo cells. 
2.7 DNA fingerprinting  
2.7.1 Preparation of genomic DNA with phenol-chloroform extraction 
Cells were cultured in T25 flask until around 90% confluency. Cells were harvested 
following trypsin-EDTA treatment (Section 2.2.1), centrifuged at 1000rpm for 5 
minutes, and the supernatant was removed to establish a cell pellet. The cell pellet 
was washed by re-suspending in PBS and centrifuging at 1000rpm for 5 mins.  The 
wash step was repeated 3x and cell pellet was stored at -20℃. The pellet was re-
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suspended in 300µl DNA lysis buffer (100mM Tris Hcl and 5mM EDTA in H2O) and 
mixed well by vortex for 1 minute.  15µl of 20% SDS and 6 µl of 10mg/ml Proteinase 
K (Thermo Fisher Scientific) was added, mixed and incubated at 55°C overnight. 1 
volume of Phenol:Chloroform:Isoamyl alcohol 25:24:1 (Thermo Fisher Scientific) 
was added and mixed well by inverting for 3 minutes,+ and centrifuged at 13200rpm 
for 5 minutes.  The supernatant was carefully removed into a new 1.5ml 
microcentrifuge tube and the precipitate discarded.  The extraction step was 
repeated with an equal volume of chlorophorm. 0.1 volumes of 3M sodium-acetate 
pH 5.2 and 2.5 volumes of 100% ethanol was added to the DNA solution mixed and 
incubated at -20°C overnight. The precipitated DNA was centrifuged at 4℃ for 30 
minutes at 13000rpm. The supernatant was discarded and to wash the DNA 500µl 
of 70% ethanol was added, the pellet was mixed with vortexing for 20 seconds, and 
centrifuged again at 4℃ for 30 minutes at 13000rpm. The supernatant was carefully 
removed and DNA pellet was air dried, and resuspended in nuclease free H2O. 
2.7.2 DNA fingerprinting with the GenePrint 10 kit 
For amplification, the extracted DNA concentration was determined using 
NanoDrop. The GenePrint® 10 5X Master Mix and GenePrint® 10 5X Primer Pair 
Mix were completely thawed and centrifuged briefly to bring the contents to the 
bottom, and vortexed to mix well.  Samples were prepared in the order as listed in 
Table 2.1-n.  For the positive control 2800M DNA (part of the kit) was added (1µl), 
and amplification grade water was used as negative control, in place of DNA 
template.  The reaction mixture was then run in Thermal cycle (PCR-C100 touch 
thermal cycler BioRad) as shown in Table 2.7-a .  
 
Table 2.7-a Thermal cycling settings 
Temperature (℃) Time 
(seconds) 
 
96 
 
60 
94 10 
59 60 
72 30 
For 30 cycles then; 
 
 
60 600 
4 soak 
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2.7.3 The detection of amplified fragments 
A loading cocktail was prepared by combining the internal lane standard 600 (0.5μl) and Hi-
Di™ formamide (9.5μl) per sample.  This was mixed and added to tubes before the addition 
of 1μl of amplified sample, or 1μl of GenePrint® 10 Allelic Ladder Mix; used to provide sizing 
and genotyping of the amplified fragments. The samples were centrifuged briefly, and 
denatured at 95°C for 3 minutes, before chilling on ice for a further 3 minutes.  The samples 
were loaded into Applied Biosystems ABI Prism 310 genetic analyser and ran with 
parameters set out in Table 2.7-b. 
 
Table 2.7-b Applied ABI prism 310 genetic analyser parameters 
Parameter  
Amplification type HID 
Capillary length 36cm 
Polymer POP-4® (ThermoFisher Scientific P/N 402838) 
Running Buffer 10x with EDTA (ThermoFisher Scientific P/N 402824) 
Dye set 
Internal colour 
Temperature 
Promega 4Dye 
60 
Red 
Pre-Injection EP time 
Syringe pump time 
Injection time 
EP voltage 
Laser 
Run time 
 
120 seconds 
150 seconds 
24 seconds 
15kV 
9.8mW 
1440 seconds 
 
 
2.7.4 Statistical analysis 
Statistical significance was calculated by the Tukey post hoc test following one-way ANOVA 
analysis.  Significant P-value determined as >0.05. 
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3 Chapter 1 Interfering with DNA replication initiation 
 
Results 
Literature data supports that replication initiation is impaired in cells that contain 
either mutated or no RECQL4 protein (Matsuno et al., 2006).  Establishing our 
model system in mesenchymal stem cells was hindered by the lack of availability of 
mutated MSCs. To determine a potential link between interference of DNA 
replication initiation and tumourigenesis, we employed the dual Cdc7/Cdk9 inhibitor, 
(PHA-767491) to establish a model of mild replication initiation inhibition in 
ASC52telo cells, which was expected to reduce proliferation.   
ASC52telo cells can differentiate into three lineages, adipocytes, chondrocytes, and 
osteocytes. It was important to determine if this capability was maintained in cells 
under PHA-767491 treated model.   
Several studies have suggested that RECQL4 may have a role in mitochondrial 
DNA maintenance (Croteau et al., 2012; Chi et al., 2012; Gupta et al., 2014), which 
in turn can lead to mitochondrial dysfunction.  To determine if the PHA-model 
generates changes in mitochondrial function, mitochondrial membrane potential 
was measured, which closely relates to mitochondrial membrane permeability (Dai 
et al., 2015).  
3.1 Establishing the model system for inhibition of DNA replication initiation  
The first step for mild proliferation inhibition through the interference of DNA 
replication initiation was the identification of a suitable PHA-767491 concentration.  
A suitable seeding density in 96 well plate was determined in a preliminary 
experiment first using the MRC5 normal fibroblast cell line. The seeding density of 
2000 cells per well over 8 days showed steady cell proliferation while maintaining 
cell viability (Figure 3.1-a), PHA-767491 was found to inhibit cellular growth 
following the treatment in MRC5 using a range of concentrations.  A reduced but 
steady proliferation rate was shown with around 1.5µM PHA-767491 (Figure 3.1-b).  
A range of other cell lines: MRC5, AG05013tert, and HS68tert, showed a similar 
sensitivity profile (Figure 3.1-c), however with very wide variability.  We concluded 
that the large observed variability seen in (Figure 3.1-c) could be due to the 
instability of PHA-767491 and repeated the experiment with media changes every 
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3 days. Under these conditions, PHA-767491 treated HS68tert cells showed a more 
stable inhibition of proliferation, confirming the degradation of the PHA-767491 over 
time (Figure 3.1-d).   
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Figure 3.1-a Establishment of a suitable seeding density. MRC5 cells were seeded at the indicated densities in a 96 well 
plate, and cell number was established using a BioRad TC20 cell counter daily for 8 days. The seeding density of 2000 cells 
per well was found to be appropriate, showing steady proliferation rate while maintaining cell viability. Graph shows results of 
one experiment (n=1).   
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Figure 3.1-b Sensitivity of MRC5 cells to PHA-767491. MRC5 cells were seeded at 2000 cells per well in 96 well plate, and 
incubated overnight.  The cells were then treated with the indicated concentrations of PHA-767491. (a) Cell proliferation was 
established using the MTS assay daily for 10 days, read at 490nm, (b)192 hours IC50 1.58µM. Data represents SD of 
triplicates, from one experiment (n=1).  
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Figure 3.1-c Sensitivity of MRC5, AG05013tert, and HS68tert cells to PHA-767491. Each cell line was seeded at 2000 
cells per well as triplicates and incubated overnight.  The cells were then treated with the indicated concentration of PHA-
767491. Cell proliferation was established using the MTS assay 7 days post PHA treatment.  Data represents SEM of 
triplicates, from one experiment (n=1). Proliferation of cells showed a decrease in response to increased PHA-767491 
concentration; however, was highly variable most likely due to instability of the drug. 
 
PHA-767491 concentration M
M
e
a
n
 A
b
s
o
rb
a
n
c
e
 a
t 
4
9
0
n
m
0 2 4 6 8
0.0
0.1
0.2
0.3
0.4
0.5
With Media changes
Without media changes
 
Figure 3.1-d Sensitivity of HS68tert cells to PHA-767491 with or without media changes. Cells were seeded at 2000 
cells per well in 96 well plate in triplicates, and were treated with the indicated concentrations of PHA-767491, alongside 
controls.  On one plate the medium was changed every three days.  Cell viability was established after 7 days of incubation 
following PHA-767491 treatment using the MTS assay. Averages were taken of the absorbance readings. The graphs 
indicated that medium changes are required to produce steady and reproducible response. Data represents means ± SEM of 
triplicates from one experiment (n=1). With media changes the IC50 of PHA-767491 was calculated to be 1.7µM. 
 
To determine sensitivity of mesenchymal stem cells to inhibition of replication 
initiation, ASC52telo cells (hTERT immortalized adipose derived mesenchymal 
stem cells) were treated with PHA-767491.  A reduction in cell viability was 
demonstrated with the increase of PHA-767491 concentration, suitable viability 
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seen with 2500 cells seeded per well and so 5000 cells per well seeding was not 
repeated (Figure 3.1-e).  Low passage ASC52telo cells appeared to be more 
sensitive to low concentrations of PHA (Figure 3.1-f), with increase in cell viability at 
higher PHA concentrations.  This is not expected or explicable, and although was 
seen twice, would need repeating to verify.   PHA-767491 at around 1.5 µM 
demonstrated a reduction in cell proliferation while maintaining cell viability.   
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Figure 3.1-e PHA-767491 sensitivity in ASC52telo cells. 5000 (a) and 2500 (b) ASC52telo cells (p+6) were seeded per 
well in a 96 well plate, in triplicates. 18 hours post seeding medium was changed with the addition of PHA-767491 at the 
indicated concentrations, with media changes with PHA-767491 at appropriate concentrations every 3 days.  MTS absorbance 
was read at 490nm 10 days post initial PHA767491 treatment. Error bars represent the standard error of means (SEM) of 
triplicates combined from one (a) or two (b) independent experiments. Sensitivity to PHA-767491 was observed with 
increasing concentrations, with more steady reduction of cell viability observed with 2500 cells per well. (a) IC50 = 0.48 µM, 
(b) IC50 = 2.5 µM.  
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Figure 3.1-f PHA-767491 sensitivity of high and low passage ASC52telo cells. 2500 ASC52telo hTERT immortalized 
adipose derived mesenchymal stem cells were seeded per well in a 96 well plate, in triplicates. 18 hours post seeding medium 
was changed with the addition of PHA-767491 treatment at variable concentrations, and then again every 3 days.  MTS 
absorbance was read at 490nm 10 days post PHA-767491 initial treatment.  Low; P+13, P+14, High: P+66, P+67, Error bars 
represent the standard error of means (SEM) of combined data from two independent experiments (n=2), Mann-Whitney test 
was applied to test statistical significance *** P≤0.001. Low passage ASC62telo appeared more sensitive to PHA-767491. 
 
These preliminary experiments determined a PHA-767491 concentration 
appropriate for mild interference with DNA replication initiation at 1.5 µM.  Using this 
concentration, a PHA-767491 model (PHA model) was set up to establish 
ASC52telo cell lines under acute treatment (low passages +6 to +38, high passages 
+43 to +96), chronic PHA-767491 treatment (low passages +18 to +41, high 
passages +53 to +90) and recovery in low and high passage cells.   
Using this model, we first determined how chronic PHA-767491 treatment affects 
the viability and proliferative capacity of cells, and further verified the suitability of 
the selected PHA-767491 concentration. As cells were routinely cultured, at each 
passage, cell numbers (haemocytometer) and viability (trypan blue) was determined 
before the same number of cells were re-seeded. Cells under continuous PHA 
treatment showed a significant reduction in proliferation rate compared to untreated 
cells under the same conditions, verifying the effect of interference in DNA 
replication.  A decrease of viability was also seen; however, this was not significant 
(Figure 3.1-g).  Changes in cell morphology were also observed, cells appeared 
larger with chronic PHA treatment (Figure 3.1-h).  
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Figure 3.1-g Cell count and viability following chronic PHA-767491 treatment of ASC52telo cells. High and low passage 
ASC52telo cells were seeded at 5000 cells per cm2 in T25 flasks, with or without chronic PHA-767491 treatment.  At each 
passaging (every 3 days) cell count and viability was measured before cells were reseeded.  Measurements were taken over 
several passages. Low – P+12 to 18, P+26-29, Low Chronic PHA – P+12 to 18, P+29 to 32, High – P+63 to 65, P+68 to 71, 
P+79 to 82. High Chronic PHA- P+53 to 57, P+67 to 73.  Error bar represents SEM, statistical significance was calculated by 
the Tukey post hoc test following one-way ANOVA analysis.  ** P≤0.01,  ****P<0.0001, graph shows data from two 
independent experiments combined (n=2).  Chronic PHA treatment leads to decrease in proliferative rate while maintaining 
cell viability.  
 
 
 
  
  
Page | 85  
 
 
Figure 3.1-h Cell morphology of ASC52telo cells following acute and chronic PHA-767491 treatment. High and low passage ASC52telo cells were seeded at 5000 cells per cm2 in T25 flasks, with or without 
PHA-767491 treatment. Low passage cells; PHA started at p+6.  High passage chronic PHA; PHA started p+13 meaning that these cells have been cultured with PHA over 43 passages.  Phase contrast images were 
taken during cell culture using a Nikon Eclipse TE2000 inverted microscope with x10 and x40 objective.  Black arrows: reduced cell numbers are observed in cells treated with PHA-767491, and cells appeared larger.  
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Ki67 is a marker of proliferation; actively cycling cells stain strongly with Ki67, while 
resting G0 cells show low expression. In order to test how acute and chronic PHA 
treatment influences the proliferation capacity of ASC52telo cells low and high 
passage cells were fixed and stained with Ki67 and the signal intensity of the 
population was quantified. Interestingly, acute PHA treatment in ASC52telo cells 
appeared to have a level of Ki67 expression generally similar to non-treated cells, 
with a general increase seen compared to DMSO control cells.  A decrease of Ki67 
signal intensity was seen in cells treated with PHA for an extended period (chronic 
treatment).  Cells were also treated with Camptothecin (CPT) as a control to 
demonstrate that while cells undergo DNA damage response a reduction of Ki67 
expression is seen (Figure 3.1-i).   
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Figure 3.1-i proliferative state of ACS2telo cells following mild inhibition of replication initiation. High and low passage 
ASC52telo cells were seeded at 5000 cells per cm2 in 24 well plate on glass coverslips, with or without acute or chronic PHA-
767491 treatment. Camptothecin (CPT) was added for 24 hours. The cells were incubated for 72 hours before fixing in 4% 
paraformaldehyde and stained for Ki67 and DAPI. Images were collected using a Leica SP8 confocal microscope and 
analysed and quantified using CellProfiler.  Statistical significance of difference was calculated by the Tukey post hoc test 
following one-way ANOVA analysis, *P≤ 0.05, ****P≤0.0001. Low passage cells: P+11, P+20, P+22, High Passage cells: 
P+62, P+90, P+88, High DMSO: P+62, P+90, P+88, Chronic PHA: P+62, P+90, P+88. Error bars represent the standard error 
of means (SEM) of combined data from three independent experiments (n=3). Reduced Ki67 expression observed in cells 
with CPT, and return to basal levels seen in chronic PHA-767491 cells.  
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3.1.1 PHA-767491 effect on osteocyte differentiation 
ASC52telo cells undergoing acute and chronic PHA treatment, and without PHA 
treatment were successfully differentiated into osteoblasts. Cell morphology 
changes were seen (Figure 3.1-j), and osteoblast differentiation was verified by 
staining mineralised calcium deposits using Alizarin Red S stain (Figure 3.1-k, 
Figure 3.1-l, and Figure 3.1-n ), and following chronic PHA-767491 (Figure 3.1-m).  
Differentiation capability was also followed and verified over time at 7, 14 and 21 
days in low and high passage cells (Figure 3.1-n, and Figure 3.1-o). Generally, 
higher levels of calcified extracellular matrix was observed following PHA-767491 
treatment (Figure 3.1-l, and Figure 3.1-o).  
ASC52telo cells were successfully differentiated into adipocytes, as demonstrated 
with the appearance of lipid droplets stained red with Oil Red O (Figure 3.1-l), with 
and without acute PHA treatment over 7, 14, and 21 days (Figure 3.1-n and Figure 
3.1-o).  High passage acute PHA treated cells seem to have a reduced amount of 
lipid droplets.  
Osteoblast, adipocyte, and chondrocyte differentiation was also verified in high 
passage ASC52telo cells, following Alizarin Red S, Oil Red O, and Alcian Blue 
staining, respectively (Figure 3.1-p).   
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Figure 3.1-j Morphology changes of ASC52telo cells under osteoblast differentiation and acute PHA treatment. Low 
passage ASC52telo cells (p+13) were seeded at 5000 cells per cm2 on 24 well plate and allowed to differentiate for 22 days. 
UD- undifferentiated cells, UD PHA- un-differentiated cells, acute PHA treatment. OD- Osteoid differentiation, OD PHA- acute 
PHA treatment and osteoid differentiation. Phase contrast images were taken on a Nikon Eclipse TE2000-s inverted 
microscope and Nikon DN100 camera with x4 and x10 objective.   Changes in cell morphology were observed following 
differentiation, as expected, and confirm the differentiation capabilities of ASC52telo cells. PHA-767491 treated cells appeared 
larger (red arrows) and show signs of increased mineralisation (white arrows).  
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Figure 3.1-k Differentiation of ASC52telo cells to osteoblasts under acute treatment with PHA-767491.  ASC52telo 
cells p+13 were seeded at 5000 cells per cm2 on 24 well plate, and allowed to differentiate for 22 days with or without acute 
PHA treatment. Medium was changed every 3 days.  Cells were fixed in 4 % formaldehyde in PBS and stained with Alizarin 
Red S (as per protocol).  UD- undifferentiated cells, UD PHA- acute PHA treatment, un-differentiated cells. OD- Osteoid 
differentiation, OD PHA- acute PHA treatment, osteoid differentiation. Images were taken on a Nikon eclipse TE2000-s 
inverted microscope with a Nikon DN100 camera and x4, x10 objectives.  Bright orange-red staining shows calcified deposits 
synthesised by MSC-derived osteoblasts.  
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Figure 3.1-l Differentiation of low passage ASC52telo cells under acute PHA treatment.  Low passage (P+17) ASC52telo 
cells were seeded at 5000 cells per cm2 in 24 well plate and allowed to differentiate for 21 days in the presence or absence 
of PHA. Cells were fixed in 4 % paraformaldehyde in PBS and stained with Alizarin Red S. Bright orange-red staining 
demonstrates calcified deposits synthesised by differentiated osteoblasts. Oil Red O highlights lipid droplets in adipocyte 
differentiated cells. OD- Osteoid differentiation, OD PHA- acute PHA treatment, osteoid differentiation AD: Adipocyte 
differentiation. Images were taken on a Nikon Eclipse TE2000-s inverted microscope and a Nikon DN100 camera and x4, x10 
objectives.  Increased alizarin Red S staining seen between OD and OD acute PHA-767491 treated cells.   
 
 
Figure 3.1-m Osteoblast differentiation in ASC52telo under Chronic PHA-767491 treatment.  ASC52telo cells P+22 were 
seeded at 5000 cells per cm2 and chronic PHA cells continued with PHA treatment (commenced P+13).  Cells were allowed 
to differentiate for 21 days, with media changes every 3 days, were fixed with 4% formaldehyde in PBS and stained with 
Alizarin Red S. Images were taken on a Nikon Eclipse TE2000-s inverted microscope and a Nikon DN100 camera and x4, 
x10 objectives. Bright orange-red staining demonstrates calcified deposits synthesised by differentiated osteoblasts. OD: 
osteoid differentiation, OD Chronic PHA: osteoid differentiation with continual PHA-767491 treatment.  
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Figure 3.1-n Monitoring of osteocyte and adipocyte differentiation capability over 7, 14, and 21 days in acute PHA-767491 treated low passage ASC52telo cells.  Low passage (P+28) ASC52telo cells were 
seeded at 5000 cells per cm2 in 24 well plate and allowed to differentiate for 7, 14, and 21 days before being fixed in 4 % formaldehyde in PBS and stained with Alizarin Red S. Bright orange-red cells demonstrate 
calcified deposits, synthesised by osteoblasts. Oil Red O highlights lipid droplets in adipocyte differentiated cells. UD: un-differentiated, UD PHA: acute PHA treated, un-differentiated cells, OD: osteoid differentiation, 
OD PHA- acute PHA treated cells, osteoid differentiation, AD: Adipocyte differentiation, AD PHA: acute PHA treated cells, adipocyte differentiation. Images were taken on a Nikon Eclipse TE2000-s inverted microscope 
and Nikon DN100 camera, with x4, x10 objective.  
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Figure 3.1-o Monitoring of osteocyte and adipocyte differentiation ability over 7, 14, and 21 days with acute PHA-767491 in high passage ASC52telo cells.  High passage (P+81) ASC52telo cells were 
seeded at 5000 cells per cm2 in 24 well plate, and allowed to differentiate for 7, 14, and 21 days before fixing in 4 % formaldehyde in PBS and stained with Alizarin Red S. Bright orange-red cells demonstrate calcified 
deposits synthesised by osteoblasts. Oil Red O highlights lipid droplets in adipocyte differentiated cells. OD: osteoid differentiation, OD PHA: osteoid differentiation with acute PHA-767491 treatment, AD: Adipocyte 
differentiation, AD PHA: adipocyte differentiation with acute PHA treatment. Images were taken on a Nikon Eclipse TE2000-s inverted microscope with Nikon DN100 camera and x4, x10 objectives 
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Figure 3.1-p Osteocyte, adipocyte, and chondrocyte differentiation in high passage ASC52telo cells. High passage 
(P+43 and P+95) ASC52telo cells were seeded at 5000 cells per cm2 on 24 well plate, and allowed to differentiate for 21 days 
before fixing in 4 % formaldehyde in PBS and staining. Alizarin Red S staining highlights calcified deposits synthesised by 
osteoblasts, Oil Red O highlights lipid droplets in adipocyte differentiated cells, and Alcian Blue demonstrates the presence 
of proteoglycans synthesised by chondrocytes. UD: un-differentiated, OD: osteoid differentiation, AD: Adipocyte 
differentiation, CD: Chondrocyte differentiation. Images were taken on a Nikon Eclipse TE2000-s inverted microscope with 
Nikon DN100 camera and x4, x10. objectives.  
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In addition to using histological stains as described above, differentiating cells were 
stained for the expression of differentiation and proliferation markers. RUNX2 is a 
marker of osteoblast differentiation, with the most abundant expression seen in early 
differentiation, which reduces upon maturation. RUNX2 showed reduced expression 
upon osteoblast differentiation (Figure 3.1-q and Figure 3.1-r).  Interestingly, RUNX2 
expression appeared to increase in low passage ASC52telo cells with acute PHA-
767491 treatment during osteoblast differentiation (Figure 3.1-q). A trend of this 
increase was also seen in subsequent experiments under chronic PHA-767491 
(Figure 3.1-r and Figure 3.1-s) however, it was not always consistent, or proved 
statistically significant.   
Ki67, as discussed above, is a marker of proliferation. Interestingly, cells kept in 
culture for long term (21 days) undisturbed, demonstrated an increase in Ki67 
positive cells under acute PHA treatment. Although we have not formally verified 
this finding, it is likely that due to their slower proliferation rate under interference 
with replication initiation they reach confluency and exit the cell cycle later then the 
untreated culture, therefore contain more cycling cells at the day 21 timepoint 
(Figure 3.1-t).    
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Figure 3.1-q RUNX2 expression in ASC52telo cells with acute PHA-767491 treatment and osteoid differentiation.  Low 
passage (P+13) ASC52telo cells were seeded at 5000 cells per cm2 onto glass coverslips in 24 well plate, with or without 
PHA-767491.  Cells were differentiated for 22 days with media changes every 3 days; control cultures were kept in normal 
MSC medium but otherwise were treated similarly. Cells were fixed with 4% formaldehyde and stained for RUNX2 and DAPI. 
Images were collected using a Leica SP8 confocal microscope and quantified using CellProfiler.  Error bars represent SEM 
from one experiment. Statistical significance was calculated by the Tukey post hoc test following one-way ANOVA analysis, 
****P<0.0001. UD: un-differentiated, UD acute PHA: un-differentiated with PHA treatment, OD: osteoid differentiation, OD 
acute PHA: osteoid differentiation with PHA-767491 treatment. Reduced levels of RUNX2 expression following mature 
osteoblast differentiation, with an increase seen in PHA-767491 acute treated cells.  
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Figure 3.1-r RUNX2 expression in ASC52telo cells under chronic PHA-767491 treatment and osteocyte differentiation.  
ASC52telo cells p+22 were seeded at 5000 cells per cm2 and kept treated with PHA (Chronic PHA started at p+13).  Cells 
were allowed to differentiate for 21 days, with media changes every 3 days; parallel control cultures were kept in normal MSC 
media but otherwise were treated similarly. Cells were fixed with 4% formaldehyde and stained for RUNX2 and DAPI. Images 
were collected with a Leica SP8 confocal microscope and quantified using CellProfiler.  Error bars represent SEM from one 
experiment. Statistical significance was calculated by the Tukey post hoc test following one-way ANOVA analysis. UD: un-
differentiated, UD acute PHA: un-differentiated with PHA treatment, OD: osteoid differentiation, OD chronic PHA: osteoid 
differentiation with continual PHA-767491 treatment. Reduced levels of RUNX2 expression following mature osteoblast 
differentiation, ****P≤0.0001. 
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Figure 3.1-s RUNX2 expression in ASC52telo under Chronic PHA-767491 treatment and Osteoid differentiation.  Low 
passage (P+17) ASC52telo cells were seeded at 5000 cells per cm2 and continued with PHA treatment (commenced at P+13). 
Cells were allowed to differentiate for 21 days, with media changes every 3 days, were fixed with 4% formaldehyde and 
stained for RUNX2 and DAPI. Images were collected on a Leica SP8 confocal microscope and quantified using CellProfiler.  
Error bars represent SEM from one independent experiment. Statistical significance was calculated by the Tukey post hoc 
test following one-way ANOVA analysis. OD: osteoid differentiation, OD PHA: osteoid differentiation with PHA-767491 
treatment. Although RUNX2 expression intensity appears higher in PHA-767491 treated differentiated cells, this increase is 
not statistically significant.  
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Figure 3.1-t Ki67 expression in chronic PHA -767491 treated ASC52telo cells.  ASC52telo cells p+22 were seeded at 
5000 cells per cm2.  Media was changed to Osteoid differentiating media or maintained in Mesenpro media with or without 
PHA (Chronic PHA started p+13).  The cells were incubated for 21 days. Media was changed every 3 days.  The cells were 
fixed with 4% formaldehyde and stained for Ki67 and DAPI.  Images were collected on a Leica SP8 confocal microscope and 
quantified using CellProfiler.  Error bars represent SEM from one independent experiment.  Statistical significance was 
calculated by the Tukey post hoc test following one-way ANOVA analysis. ****P≤0.0001. An increase of Ki67 observed in UD 
PHA cells. UD: un-differentiated, UD PHA: un-differentiated with PHA treatment, OD: osteoid differentiation, OD PHA: osteoid 
differentiation with PHA-767491 treatment.  
 
3.1.2 Relationship of DNA replication initiation and cellular transformation 
Mesenchymal stem cell differentiation into osteoblasts, chondrocytes, and 
adipocytes (Pittenger et al., 1999)  was previously verified in ASC52telo cells using 
differentiation inducing media. RUNX2 staining in previous experiments raised the 
possibility of spontaneous differentiation, which was investigated in more detail. 
Spontaneous differentiation is the occurrence of differentiated cells during culturing 
in non-inducing media. Appearance of such cells was investigated following chronic 
PHA treatment kept in normal MSC media and analysed by histochemical and 
immunohistochemical staining for differentiation markers.   
Differentiation of ASC52telo cells into osteoblasts is shown in high passage cultures 
under continuous (chronic) mild proliferation inhibition, shown by red staining of 
calcium deposits, which persists after withdrawal of chronic PHA treatment 
(recovery) (Figure 3.1-u).  Low and high passage cells show an increase of RUNX2 
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expression in response to acute PHA treatment. High passage cells under chronic 
treatment have high RUNX2 expression, which falls to normal levels following 
cessation of PHA treatment (Figure 3.1-v).   
 
 
Figure 3.1-u Production of calcified matrix by ASC52telo cells following chronic PHA-767491 treatment in normal 
Mesenpro media. ASC52telo cells were cultured as per PHA model and seeded at 5000 cells per cm2 on 24 well plate, and 
incubated for 3 days, Cells were fixed in 4 % paraformaldehyde in PBS and stained with Alizarin Red S. Bright orange-red 
staining demonstrated calcium deposits. Images were taken on a Nikon Eclipse TE2000-s inverted microscope with Nikon 
DN100 camera and x10 objectives. P+: cell passage. 
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Figure 3.1-v RUNX2 levels in undifferentiated ASC52telo cells cultured under replication stress.  ASC52telo cells 
precultured according to the PHA model were seeded at 5000 cells per cm2 and kept treated as before or released (recovery).  
Cells were incubated for 3 days, were fixed with 4% formaldehyde and stained for RUNX2 and DAPI. Images were collected 
using a Leica SP8 and quantified using CellProfiler.  Error represents SEM. Statistical significance was calculated by the 
Tukey post hoc test following one-way ANOVA analysis.  Low – P+35, P+37, P+38, High – P+88, P+90, P+91, High chronic- 
P+83, P+85, P+86, Low chronic – P+37, P+40 P+41. *** P≤0.001, ****P≤0.0001. Graph represents combined data from three 
independent experiments.  
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3.1.3 Relationship of DNA replication initiation and Membrane potential 
Membrane potential appeared to remain unchanged following mild proliferation 
inhibition in ASC52telo cells (Figure 3.1-w).  In parallel wells MTS reading was also 
taken to reflect cell viability, and the readings taken from TMRE were divided by 
MTS reading to give a representative effect to cell viability.   The protonophore p-
trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP), a mitochondrial 
uncoupler, induces mitochondrial depolarization leading to a rapid release from 
quenched matrix into the cytoplasm, abolishes ATP synthesis, and can deplete the 
cytoplasmic pool of ATP. FCCP was used as a control to induce mitochondrial 
membrane depolarization generating the loss of fluorescent intensity  (Perry et al., 
2011; Wang et al., 2017b; Nicholls, 2018) a significant reduction was seen. 
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Figure 3.1-w Mitochondrial activity in acute and chronic PHA-767491 ASC52telo cells.  ASC52telo cells were seeded at 
5000 cells per cm2 in two 96 well plates in triplicates, and kept under the same conditions except PHA treatment was applied 
as per the representative PHA model. The cells were incubated for 72 hours.  One plate was analysed using MTS and the 
other using the TMRE assay, TMRE readings were averaged against MTS reading. Error bars represent SEM; graphs 
represent combined data from three independent experiments (n=3), Low: p+23, P+26, P+27, Low Chronic PHA/recovery: 
P+26, P+29, P+30, High: P+78. P+79, P+80 High Chronic PHA/recovery: P+68, P+69 P+70 Statistical significance was 
calculated by the Tukey post hoc test following one-way ANOVA analysis, * P≤0.05, *** P≤0.001.  No significant differences 
in mitochondrial activity have been demonstrated in ASC52telo cells under PHA-model. White arrow; slow proliferation.   
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3.1.4  Summary 
 
To establish a model of mild replication initiation inhibition in mesenchymal stem 
cells, ASC52telo cells were treated with PHA.  This was to enable further 
investigations on the effects of this treatment on cell morphology, physiology, and 
differentiation into osteoblasts.  ASC52telo cells have been employed in many 
studies (Wolbank et al., 2009; Hasebe-Takada et al., 2016; Nardone et al., 2017; 
Pitrone et al., 2017).  We surprisingly demonstrated more pronounced PHA 
sensitivity at low concentrations in low passage cells, with an unexpected increase 
in cell viability at higher PHA concentrations.  This is not expected or explicable, and 
although was seen twice, would need repeating to verify.  
We wanted to put a continuous pressure on replication initiation without affecting 
viability in ASC52telo cells, therefore we selected 1.5 µM, the highest concentration 
that showed the minimal effect on cell survival (Figure 3.1-b and Figure 3.1-e).  A 
model of PHA-767491 was established in low and high passage ASC52telo cells 
with acute and chronic PHA treatment, and withdrawal of treatment in either case 
(‘recovery’).  This enabled us to further understand the effects of reduced replication 
over time and the potential cellular stress this generates, similar to the effect of 
RECQL4 mutations, and if and how the cells may recover following the cessation of 
treatment with PHA-767491. Reduced proliferative rate was verified using cell count 
(haemocytometer), and maintained viability was measured using trypan blue. 
Interestingly, PHA-767491 treated cells appeared to lead to cell morphology 
changes, as the cells appeared larger, which is an indication of cellular 
morphological modifications that have been further explored in this study.   
Successful adipocyte, chondrocyte, and osteoblast differentiation was achieved in 
the ASC52telo cells, under PHA-767491 treatment, and cells under long term 
culture.  PHA-767491 treated ASC52telo cells were further analysed for induced 
and spontaneous differentiation. RUNX2 expression suggests the commitment of 
the MSCs towards osteoblast differentiation (Ducy et al., 1997; Komori et al., 1997), 
which was evaluated to determine if the cells showed signs of this commitment 
under normal media.  An increase in RUNX2 expression was demonstrated 
following acute PHA-767491 treatment in low passage cells and following chronic 
PHA-767491 treatment in high passage cells, while reduced levels were seen 
following recovery.  The difference between passages suggests that low passage 
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cells may be more sensitive to the initial treatment, and chronic treatment also leads 
to sensitivity over long term culture.  Further studies are needed to identify if the 
association of the cell cycle is the link to the data obtained. However, these results 
taken together with the mineralised calcium levels also observed within these 
treated cells, suggest differentiation into osteoblasts, or disruption of the regulation 
of these markers.  The ASC52telo cells were not investigated for spontaneous 
differentiation into the other forms of cell lineages.  This would be useful to further 
our understanding of the transformation mechanisms that appeared to establish 
following chronic replicative stress in these cells. 
The mitochondrial membrane appeared stable following PHA treatment, no 
significant changes of membrane potential was seen.   
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4 Chapter 2 The interference with DNA replication 
initiation generates genomic instability 
 
Results 
We established that ASC52telo cells under acute and chronic mild replication 
interference using PHA-767491 held the ability for osteoblast differentiation.  In 
addition, dysregulation of differentiation markers, suggestive of transformation may 
follow chronic treatment.  We hypothesis these cells established genomic instability, 
promoting transformation. A characteristic of OS is chromosomal instabilities; 
markers of this were investigated as the next step using the established model.   
4.1 PHA-767491 induces chromosomal instabilities in ASC52telo cells 
 
To establish if continuous interference with replication initiation influences the DNA 
damage response, ASC52telo cells under the PHA-767491 model were treated with 
Camptothecin and cell viability was analysed. The sensitivity of acute and chronic 
PHA-767491 cells to Camptothecin induced DNA damage did not appear to be 
significantly different (Figure 4.1-a).   
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Figure 4.1-a Camptothecin sensitivity of ASC52telo cells under acute and chronic PHA-767491 treatment. 2500 high 
and low passage ASC52telo cells treated according to the PHA model were seeded per well in a 96 well plate. Treatment was 
administered in triplicates.  18 hours post seeding medium was changed with the addition of Camptothecin at variable 
concentrations with or without PHA-767491.  MTS assay was performed 24 hours post Camptothecin treatment.  Data 
represent means ± SD of triplicates; representative graph from two independent experiments. A decline of cell viability was 
observed on increasing CPT concentrations. Data was normalised to media and CPT alone.  P+19 IC50 = 0.3890, p+83 IC50 
= 0.5485, p+19 Acute PHA IC50 = 0.6926, p+34 Chronic PHA IC50 = 0.6535; calculated from one repeat shown above.  
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Chromosomal instabilities can be demonstrated in cells following DNA damage 
through observing cell morphology changes and known markers including 
micronuclei, budding, chromatin bridges etc. (Wilkens et al., 2004; Verma and Dey, 
2014; Tyagi et al., 2015).  These markers were found in ASC52telo cells under the 
PHA model (Figure 4.1-b).  To establish a baseline of potential DNA damage in low 
and high passage untreated ASC52telo cells, these changes in nuclear morphology 
were observed and quantified in control untreated cells and cells treated according 
to the PHA model.   High passage cells appeared to demonstrate a higher 
percentage of chromosomal instability markers in comparison to lower passage 
cells (Figure 4.1-c and Figure 4.1-d).  Although not always significant, a further 
increase was observed in acute and chronic PHA-767491 treated cells (Figure 
4.1-c).  Ki67 and γH2AX staining was also observed in the micronuclei (Figure 
4.1-e).   
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Figure 4.1-b Chromosomal instability markers observed in acute and chronic PHA-767491 treated ASC52telo cells.  
ASC52telo cells were seeded onto coverslips at 5000 cells per cm2.  The cells were treated with PHA-767491 as per the PHA 
model. The cells were fixed in 4% paraformaldehyde and stained with DAPI. Images were collected with a Leica SP8 confocal 
microscope x63 objective. Morphology changes observed:  White arrow head: Bridge, white open arrow head: micronuclei, 
red arrow head: bleb, yellow arrow head: multi-lobed, white oval arrow: doughnut -shaped, white diamond arrow head: 
enlarged nuclei.  
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Figure 4.1-c Chromosomal instability markers in untreated ASC52telo cells.  ASC52telo cells were seeded onto 
coverslips at 5000 cells per cm2 and allowed to reach around 80% confluence..   The cells were fixed in 4% paraformaldehyde 
and stained with DAPI. Images were collected with a Leica SP8 confocal microscope, graph represents combined data from 
three independent experiments (n=3).  Changes in nuclear morphology were observed and quantified. Low:  P+ 20, 14, 22, 
High: P+ 67, 88, 90,  
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Figure 4.1-d Chromosomal instability markers in ASC52telo under acute and chronic PHA-767491 treatment.  
ASC52telo cells were seeded onto glass coverslips at 5000 cells per cm2.  The cells were treated with PHA in acute or chronic 
way as indicated.  Camptothecin (CPT) was used to generate DNA damage as control; cells were treated at 0.8µM for 24 
hours.  The cells were fixed in 4% paraformaldehyde and stained with DAPI. Images were collected with a Leica SP8 confocal 
microscope.   Low and Low acute PHA: p+20, 22, 11, and 13, Low chronic PHA: p+11,13, 20, 22.  High and High acute PHA: 
p+62, 65, 88, and 90, High chronic PHA: p+47, 49, 53, and 55. Graphs represent data combined from four independent 
experiments (n=4).   Statistical significance was calculated by the Tukey post hoc test following one-way ANOVA analysis, * 
P≤0.05, ** P≤0.01. Chromosomal instability markers were detected at high rate following CPT treatment in high and low 
passage cells, and also present in PHA-747691 treated cells.  
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Figure 4.1-e ASC52telo cells form micronuclei staining positive for Ki67 and H2AX, following mild inhibition of 
replication initiation. High and low passage ASC52telo cells were seeded at 5000 cells per cm2 in 24 well plate on glass 
coverslips, with acute or chronic PHA-767491 treatment. The cells were incubated for 72 hours before fixing in 4% 
paraformaldehyde and stained for Ki67 and DAPI and γH2AX. Images were collected using a Leica SP8 confocal microscope, 
x63 objective.  Intense staining observed in some micronuclei; representative images are shown.   
 
4.1.1 DNA damage marker and mild proliferation inhibition 
To further characterize the origin of observed signs of chromosomal instabilities, the 
existence of spontaneous DNA damage was examined in our model of cells 
exposed to mild proliferation inhibition by assessing γH2AX expression, which is a 
marker of DNA double strand breaks.  We demonstrated that Camptothecin (CPT) 
treatment induces γH2AX foci formation with strong intensity of expression (Figure 
4.1-f) as expected.  
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A significant increase in the number of spontaneous γH2AX foci was shown in high 
and low passage ASC52telo cells under acute and chronic PHA-767491 treatment 
(Figure 4.1-f).  Importantly, the number of γH2AX foci was decreased to basal level 
in low passage cells under recovery, however, the same was not observed in high 
passage cells indicating persistent DNA damage.  Quantifying the intensity of 
γH2AX signal in the nuclei is another method of assessing DNA damage, albeit not 
as sensitive as foci count. Acute and chronic PHA-767491 in low passage cells led 
to an increase in γH2AX intensity, with recovery again seen.  In high passage cells 
chronic PHA treatment did not significantly cause an increase in expression 
compared to acute treatment, but a reduction was also seen in recovering cells 
(Figure 4.1-f). The discrepancy between the two measurements is interesting and 
probably reflects the overall size of the individual foci: high number of small foci are 
still detectable with counting but cause a lower signal intensity.   
Unrepaired double-stranded breaks can be a source of chromosomal instabilities 
resulting in chromosome fusions and breaks, changing the number of telomeres 
directly, or can influence telomere maintenance via other mechanisms indirectly. To 
assess telomere numbers in our PHA model, the expression of TRF2, a member of 
the telomeric shelterin complex was quantified. TRF2 foci count and intensity 
(Figure 4.1-g) increased following PHA treatment in low passage cells, with recovery 
as the PHA treatment was withdrawn in the released population, as observed with 
γH2AX expression previously.  High passage cells showed an increase in TRF2 foci 
count following acute treatment, however this was not seen in chronic PHA-767491, 
interestingly, the cells under recovery demonstrated an increase in TRF2 foci count.  
TRF2 intensity was only increased in acute PHA-767491 cells (Figure 4.1-g).  
We also tested if the increased occurrence of γH2AX foci observed previously is 
concentrated specifically to the telomeres, which would indicate telomere erosion or 
specific telomeric damage. We co-stained ASC52telo cells with γH2AX and TRF2, 
and quantified their co-localization (Saha et al., 2013). Significant telomeric damage 
was only demonstrated in low passage cells with acute and chronic PHA-767491, 
with recovery seen (Figure 4.1-h), following analysis of γH2AX foci co-localized with 
TRF2. 
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Figure 4.1-f γH2AX foci and intensity following mild inhibition of replication initiation, in high and low passage 
ASC52telo cells.  ASC52telo cells were seeded at 5000 cells per cm2 onto glass coverslips.  The cells were incubated until 
the untreated cells reached around 80% confluency.  PHA was added to short term treated cells throughout this incubation 
(acute treatment; 3 days), while long term (chronic) treatment was maintained continuously.  The cells were fixed in 4% 
paraformaldehyde and and probed for γH2AX. Low: P+16, 11, 17, 13, 9, 14, Low DMSO: P+ 16, 17, 14, Low CPT: P+11, 18, 
13 , Low acute PHA-767491: P+16, 17, 11, 9, 14, Low chronic PHA-767491: P+17, 18, 13, 11, 12, Low chronic PHA-767491 
recovery: P=16,P+17, 18, High: P+69, 70 62, 65, 67, High DMSO: P+69, 70, 67, DMSO, High CPT: P+62, 65, 67, High acute 
PHA-767491: P+69, 62, 65, 67, High chronic PHA-767491: P+68,  69, 55, 67, High chronic PHA-767491 recovery: P+68, 69, 
67. Images were collected with a Leica SP8 confocal microscope and quantified using CellProfiler.  Error bars represent SEM 
of combined data from three independent experiments (n=3), statistical significance was calculated by the Tukey post hoc 
test following one-way ANOVA analysis. ***P≤0.001, ****P≤0.0001. An increase of γH2AX foci was shown in high and low 
passage ASC52telo cells under acute and chronic PHA-767491 treatment,  
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Figure 4.1-g Quantification of TRF2 foci and intensity following mild inhibition of replication initiation, in high and 
low passage ASC52telo cells.  ASC52telo cells were seeded at 5000 cells per cm2 onto glass coverslips.  The cells were 
incubated until the untreated cells reached around 80% confluency.  PHA was added to short term treated cells throughout 
this incubation (acute treatment; 3 days), while long term, chronic, treatment was maintained continuously. The cells were 
fixed in 4% paraformaldehyde and stained for TRF2. Images were collected with a Leica SP8 confocal microscope and 
quantified using CellProfiler. Passage numbers; Low: p+16, 11, 17, 13, 9, 14, Low DMSO: p+16, 17, 14, Low acute PHA: 
p+16, 17, 11, 9, 14, Low Chronic PHA: p+17, 18, 13, 11, 12 (n=5), Low chronic PHA Recovery: P+16, p+17, 18, High: p+ 69, 
70 62, 65, 67, High DMSO: p+69, 70, 67, High acute PHA: p+69, 62, 65, 67, High chronic PHA: p+68,  69, 55, 67, High chronic 
PHA recovery:  p+68, 69, 67. Error bars represent SEM of combined data from three independent experiments (n=3), 
statistical significance was calculated by the Tukey post hoc test following one-way ANOVA analysis. * P≤0.05, ** P≤0.01, 
****P≤0.0001. TRF2 foci count and intensity increased in Low acute and chronic PHA treated cells.  
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Figure 4.1-h Co-localisation of TRF2 with γH2AX following mild inhibition of replication initiation in high and low 
passage ASC52telo cells. ASC52telo cells were seeded at 5000 cells per cm2 onto glass coverslips.  The cells were 
incubated until the untreated cells reached around 80% confluency.  PHA was added to short term treated cells throughout 
this incubation (acute treatment, 3 days), while long term (chronic) treatment was maintained continuously.  The cells were 
fixed in 4% paraformaldehyde and co-stained for TRF2 and γH2AX. Images were collected with a Leica SP8 confocal 
microscope and quantified using CellProfiler. Passage numbers; Low: P+16, 11, 17, 13, 9, 14, Low DMSO- p+16, 17, 14, Low 
acute PHA: p+16, 17, 11, 9, 14 , Low chronic PHA: p+17, 18, 13, 11, 12, Low chronic PHA recovery: P=16, p+17, 18, High: 
P+ 69, 70 62, 65, 67, High DMSO: p+69, 70, 67, High acute PHA: p+69, 62, 65, 67, High Chronic  PHA: p+ 68,  69, 55, 67, 
High chronic PHA recovery: p+68,69, 67. Error bars represent SEM of combined data from three independent experiments 
(n=3). Statistical values were calculated by the Tukey post hoc test following one-way ANOVA analysis. * P≤0.05. Percentage 
of co-localisation represents TRF2 foci also positive for γH2AX foci (white arrows).  Significant co-localisation seen in low 
passage PHA treated cells.   
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Resolving and regulating a response following DNA damage is maintained by a 
number of pathways;  ATM and ATR initiating a DNA response via phosphorylation 
of mediator proteins, including 53BP1, and effector protein CHK1 (Friedel et al., 
2009; Dai and Grant, 2010).  Low passage ASC52telo under acute PHA-767491 
showed a significant decrease in 53BP1 (DSB interacting protein); although not 
significant a similar finding appeared in the high passage cells under the same 
conditions. 53BP1 expression significantly increased in the low passage acute PHA-
767491 cells with suggested rise in phosphorylated-CHK1 (Phospho-CHK1, the 
activated form) (Figure 4.1-i).  However, further repeats are necessary to verify 
these findings.   
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Figure 4.1-i Expression of markers of the DBS damage response pathway in ASC52telo cells following acute and chronic PHA-767491 treatment.  ASC52telo cells were seeded at 5000 
cells per cm2 in 24 well plate, and incubated until the untreated cells reached around 80% confluency (4 days).  Cells were treated as per PHA model with media changes at day 3.  Cell lysate was 
collected and SDS PAGE and western blot was performed.  The membrane was probed with antibodies detecting 53BP1, Phospho-Chk1, Chk1, and tubulin, and quantified using ImageJ. Intensity 
values are presented as relative intensity. Statistical significance of difference was calculated by the Tukey post hoc test following two-way ANOVA analysis * P≤0.05, ** P≤0.01, graphs and error 
bars SEM represent data combined of number of independent experiments as indicated in brackets.  53BP1: Low/High, Low/High Acute PHA, High Chronic PHA (n=3), Low Chronic PHA (n=2). 
Low/High DMSO, High Chronic PHA recovery (n=1).  Chk1: Low/High, Low/High Acute PHA, Low/High Chronic PHA (n=2), Low/High DMSO, High Chronic PHA recovery (n=1), Phospho-Chk1: 
Low, Low/High DMSO, High Chronic PHA recovery (n=1), High, Low/High Acute PHA, High Chronic PHA (n=2). DNA damage response markers were present, with some correlation in PHA-
767491 treated cells.  
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4.2 Markers of cellular transformation in ASC52telo cells following chronic 
inhibition of replication initiation 
The model of cancer proposed by Vogelstein and Kinzler suggests that cancer is a 
disease of damaged DNA, accumulating a range of genetic mutations capable of 
transforming normal cells into cancer cells (Kinzler and Vogelstein et al., 1996; 
Hanahan and Weinberg, 2000).  Cancer is generated in response to exposure to 
external sources of damage, and genetic predisposition (Sonnenschein and Soto, 
2008).  Malignant cellular transformation refers to the process of cells acquiring 
properties and hallmarks of cancer (Parsa, 2012).  We showed previously that the 
ASC52telo cells under chronic PHA-767491 treatment have established persistent 
DNA damage.  To establish if mild proliferation inhibition leads to cellular 
transformation in vitro, some further hallmarks or properties of cancer cells were 
investigated. A fundamental feature of cancer biology is the ability of the cell to 
exhibit anchorage-independent cell growth, which is the capability of colony forming 
in semisolid media.  This feature is associated with tumour cell aggressiveness in 
vivo, including tumour cell metastasis, and a marker of transformation in vitro (Mori 
et al., 2009).   
The ASC52telo cells were to be cultured for an extended period of time and a 
suitable density, while maintaining viability was to be established. ASC52telo cells 
were seeded at a range of densities and viability was measured by morphology 
appearance, cell count, and percentage of viability during cell culture over 5 days. 
These parameters were maintained over the culture time in ASC52telo cells seeded 
at 2000 cells per 96 well, which was deemed a suitable seeding density for both 
high and low passages (Figure 4.2-a).  To establish if ASC52telo cells under the 
PHA-model acquired anchorage independent growth, the cells were seeded onto 
ultra-low attachment 96 well plates, alongside adherent plates. Cell morphology 
changes were shown with viable cells forming clumps while cultured under 
anchorage-independent conditions, with large clumps were seen (Figure 4.2-b). Cell 
viability of these cells was measured using MTS assay with a significant difference 
seen in High passage chronic PHA-767491 ASC52telo cells. This measurement 
was normalised against ASC52telo cells treated under the same conditions except 
seeded onto the adherent (standard) plate, representing an appropriate baseline of 
cell viability (Figure 4.2-c).   When the cells were collected following anchorage-
independent growth and reseeded onto adherent plates, continued cell growth was 
observed (Figure 4.2-d)  
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Figure 4.2-a Cell viability with varied seeding density in ASC52telo cells. ASC52telo low (p+12) and high (p+65) passage 
cells were seeded at a range of seeding densities (as indicated in the legend) in a 96 well plate and incubated for 5 days.  
Each day the cells were detached using trypsin and counted using haemocytometer in trypan blue to measure cell viability.  
Seeding at 2000 cells per well showed steady increase in cell count while maintaining cell viability in both high and low 
passages, graphs represent one independent preliminary experiment (n=1). Phase contrast images were collected using a 
Nikon Eclipse T5100 inverted microscope and DN100 camera with x10 objective. Cell growth and confluence were observed 
while maintaining normal morphological appearance, over the culture period, white arrows-normal elongated cells. 
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Figure 4.2-b Cell morphology and anchorage-independent growth in ASC52telo cells treated according to the PHA 
model. ASC52telo cells were seeded at 2000 cells per well in Costar flat bottom ultra-low attachment surface non-pyrogenic 
(3474) 96 well plate. PHA-767491 was added to short term treated cells throughout this incubation (15 days), while long term 
treatment was maintained continuously. Phase contrast images were taken using a Nikon Eclipse T5100 inverted microscope 
and DN100 camera, with x10 objectives. Cell clump formation was observed (white arrows) to a different degree in correlation 
with treatment.  
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Figure 4.2-c Anchorage-independent growth in ASC52telo cells under PHA-model. ASC52telo cells were seeded at 
2000 cells per well in triplicates in Costar flat bottom ultra-low attachment surface non pyrogenic (3474) 96 well plate, and 
control standard 96 well plate. The cells were incubated and the media was changed carefully every 3 days.  MTS assay was 
performed at day 15.  Low/Low DMSO/Low Acute PHA: P+15, 17, and 23, Low Chronic/Recovery: P+18, 19, 24. High/High 
DMSO/ High Acute PHA: P+68,70, 76,  High Chronic/Recover: P+68, 69, 75. Error bars represents SEM, statistical values 
were calculated by the Tukey post hoc test following one-way ANOVA analysis * P≤0.05, Graphs represent combined data 
of three independent experiments (n=3). Cell viability was maintained over the culture time on standard plate, significant 
reduced proliferative rate was not seen in PHA-767491 treated cells over long-term culture (standard plate).  Following growth 
on ultra-low attachment plate high passage chronic PHA-767491 cells demonstrated an increase in MTS signal, suggesting 
growth under anchorage independent conditions.  
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Figure 4.2-d Recovery of ASC52telo cells cultured according to the PHA model, following anchorage-independent 
growth. ASC52telo cells P+68 were seeded at 2000 cells per well in Costar flat bottom ultra-low attachment surface non-
pyrogenic (3474) 96 well plate for 15 days, with careful media changes, under PHA-model.  After culturing under anchorage 
independent conditions, the cells were trypsinised and re-seeded onto standard adherent plate for 10 days. Phase contrast 
images were taken using a Nikon Eclipse T5100 inverted microscope and DN100 camera, with x4, x10 objectives. Cell 
recovery was seen with adherent growth observed (white arrow), cell clump adhering to plate surface (black arrow),  
 
4.2.1 Contact inhibition 
A hallmark of cell transformation is impaired contact inhibition (Abercrombie, 1979).  
To determine if ASC52telo treated with PHA-767491 for an extended period have 
acquired this characteristic, analysis of contact inhibition was performed using a 
range of methods.   
ASC52telo cells were cultured as per the PHA-767491 model for 18 days with cell 
count and cell viability analysed.  As expected, untreated ASC52telo cells under 
normal growth conditions (high and low passage) demonstrated a steady increase 
of cell numbers, which reached a plateau during long term culture to 18 days.  Acute 
PHA-767491 treated cells demonstrated a steady reduced proliferative rate up to 
day 4 as found previously, however an increase similar to untreated cells was seen 
following extended culture time.  Chronic PHA-767491 cells appeared to increase 
in cell number further, suggesting reduced contact inhibition as a possibility.  Cell 
viability was also analysed and verified to be >95% in all cell treatments.  Although 
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increased cell growth may have been seen, the PHA treated cells appeared to form 
clumps which would result in discrepancies in cells count, resulting in inaccurate 
representation (Figure 4.2-e).   
Therefore, the cells were lysed and protein concentration was analysed as a 
measure of growth. Low passage acute culture showed an increase which then fell 
again. Continual cell growth was further demonstrated in high passage chronic 
PHA-767491 treated cells following recovery (Figure 4.2-f), while MTS assay 
suggested continued cell proliferation (Figure 4.2-g), however, this finding needs to 
be verified.  The cells were also assayed with the Promega Real-time Glo MT assay 
using luminescence, which allows non-endpoint measurements, unlike the MTS 
assay.  It showed steady cell growth at day 21. We hoped to analyse these cells 
using the same method at day 24, but luminescence was lost, therefore an MTS 
assay was performed on these cells at day 28. It suggested continual growth in high 
passage chronic PHA-767491 cells compared to same passage cells with no 
treatment (Figure 4.2-h).  
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Figure 4.2-e Analysis of contact inhibition using cell count and viability following long term culture of ASC52telo 
cells treated with PHA-767491. ASC52telo cells were seeded at 2000 cells per well in 96 well plate in various conditions as 
per the PHA model, and incubated for the indicated number of days.  At those points the cells were counted using 
haemocytometer and cell viability was measured using trypan blue. Graphs and error bars represent SEM of combined data 
from independent experiments as indicated in brackets, Low, Low DMSO, Low acute PHA-767491:P+14, P+16, P+17 (n=3), 
Low chronic PHA-867491, Low chronic PHA-767491 recovery: P+19, +20 (n=2). High, High DMSO, High acute PHA-767491, 
High chronic PHA-867491, High chronic PHA-767491 recovery:P+67, 69, P+70 (n=3).  Morphology was observed and phase 
contrast images were taken using a Nikon Eclipse T5100 inverted microscope and DN100 camera with x4 and x10 objectives. 
Cell clumping was observed with high cell density during culture. White arrow – Normal cell elongation, Red arrow- cell debris, 
Black arrow – cell clumps.  Cell viability across treatments was maintained <95%,    
 
 
 
Page | 126  
 
D a y s  o f c u ltu re
T
o
ta
l 
p
ro
te
in
 c
o
n
c
e
n
tr
a
ti
o
n
 m
g
/m
l
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
0
1
2
3
L o w
L o w  D M S O
L o w  A c u te  P H A
L o w  C h ro n ic  P H A
L o w  C h ro n ic  R e c o v e ry*
 
D a y s  o f c u ltu re
T
o
ta
l 
p
r
o
te
in
 c
o
n
c
e
n
tr
a
ti
o
n
 m
g
/m
l
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
D
a
y
 7
D
a
y
 1
1
D
a
y
 1
8
D
a
y
 2
1
0
1
2
3
H ig h
H ig h  D M S O
H ig h  A c u te  P H A
H ig h  C h ro n ic  P H A
H ig h  C h ro n ic  R e c o v e ry
****
 
Figure 4.2-f Contact inhibition in ASC52telo cells treated long term with PHA-767491 analysed based on protein 
concentration.  ASC52telo cells were seeded at 5000 cells per cm2 on a 96 well plate in triplicates, under the various PHA 
conditions, as per the PHA model. Cells were incubated for the indicated number of days with media changes every 3 days. 
At the indicated days cell lysates were collected and protein concentrations were measured with Bradford assay. Day 7 and 
11- Low: P+28,29,32 Low Chronic PHA/Recovery: P+31,32,35. High: P+81,82,85, High Chronic PHA/Recovery: P+72, 73,81 
(n=3), Day 18 Low: P+28, 32, Low Chronic PHA/Recovery: P+31, 35. High: P+81, 85, High Chronic PHA/Recovery: P+72, 
80, (n=2), Day 21- Low: P+29, Low Chronic PHA/Recovery: P+32. High: P+82, High Chronic PHA/Recovery: P+73 (n =1). 
Error bars represent SEM, statistical values were calculated by the Tukey post hoc test following two-way ANOVA analysis, 
* P≤0.05, Graphs represent combined data from independent experiments as indicated in brackets.  Overall significant 
increase in continual growth in High passage chronic PHA-767491 treated cells under recovery.   
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Figure 4.2-g Cell viability of ASC52telo cells following long term culture with PHA-767491 treatment, measured by 
MTS assay.  ASC52telo cells were seeded at 5000 cells per cm2 on a 96 well plate in triplicates, under conditions set out by 
the PHA model. Cells were incubated for the indicated number of days and the media was changed every 3 days. At the 
indicated days MTS assay was performed. Error represents SEM of triplicates; statistical values were calculated by the Tukey 
post hoc test following one-way ANOVA analysis, * P≤0.05, ** P≤0.01, ***P≤0.001, ****P≤0.0001. Graphs represent 
combined data from independent experiments as indicated in brackets.  . Day 21- Low/Low DMSO/Low Acute PHA: P+29, 
31, Low Chronic PHA/Recovery: P+32,34. High/ High DMSO/High Acute PHA: P+82, 84,(n=2). Day 28 - Low/Low DMSO/Low 
Acute PHA: P+34, Low Chronic PHA/Recovery: P+37. High/ High DMSO/High Acute PHA: P+87, High Chronic 
PHA/Recovery: P+82, (n=1). A higher increase in cell numbers was indicated by the MTS assay in high passage PHA-767491 
treated cells under recovery, compared with controls, which increased further following longer culture time.   
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Figure 4.2-h Continual cell viability following long term culture and PHA-767491 in ASC52telo, measured using real-
time-Glo MT assay followed by MTS assay.  ASC52telo cells were seeded at 5000 cells per cm2 on a 96 well plate in 
triplicates, under conditions defined by the PHA model. Cells were incubated for 21 days with media changes every 3 days. 
On day 21 the real-time-Glo MT assay was performed with luminescence reading. The media was changed and the cells 
maintained under the same conditions of PHA model; media was further changed every 3 days. At day 28 an MTS assay was 
performed. Error represents SEM of triplicates, statistical values were calculated by the Tukey post hoc test following one-
way ANOVA analysis. Low DMSO/Acute PHA: P+32,33, Low Chronic PHA/Recovery: P+35, 36. High DMSO/Acute PHA: 
P+85,86, High Chronic PHA/Recovery: P+80,81, Graphs represent combined data from two independent experiments (n=2). 
A higher increase of cell numbers was indicated by the analysis over long term culture in high passage chronic PHA-767491 
cells under recovery compared to untreated cells, although not significant, suggests continual growth.  
 
4.3 Verification of STR genotypes 
Following long term culture of ASC52telo cells in our study, it was important to verify 
the genotype of ASC52telo cell line, and rule out contamination. We originally 
obtained the ASC52telo cells from ATCC® hTERT immortalized adipose derived 
Mesenchymal stem cells (ATCC® SCRC 4000™), and cultured over long term, and 
under acute and chronic PHA-767491 treatment. The genotype of the cells was 
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analysed with DNA fingerprinting of polymorphism by profiling short tandem repeats 
by PCR amplification followed by capillary gel electrophoresis.  For genotyping we 
used the Promega GenePrint 10 kit, which types the cell lines using 10 loci. In our 
analysis CSCF1PO was not seen which is likely due to not running the PCR 
products on the capillary electrophoresis equipment long enough.  We are confident 
that the cell lines were not contaminated as matched genotype without overlapping 
signal was demonstrated (Figure 4.3-a).    
  
ASC52telo p+6  
Page | 130  
 
 
ASC52telo P+96 
 
ASC52telo P+96 Chronic PHA 
Figure 4.3-a STR profile of ASC52telo cell line with and without chronic PHA-767491 treatment.  Amplicons were 
generated by PCR and separated by capillary gel electrophoresis on an Applied Biosystems ABI Prism 310 Genetic Analyser, 
and analysed using GeneMarker HID.  Expected DNA profile (red arrows at peaks): Amelogenin: X, D13S317: 8, 12, 
D16S539: 10, 13, D5S818: 11, 13, D7S820: 8, 11, THO1: 7, TPOX: 8, vWA: 16, which match the genotype of our ASC52telo 
cell lines, high and low passage, and chronic PHA-767491 treated cells.   
 
4.4 Summary 
Overall, our data suggests that chronic interference with DNA replication initiation 
induced with PHA-767491 treatment leads to chromosomal instabilities.  Inefficient 
DNA repair or avoiding apoptosis may result in the acquiring of sustained DNA 
damage and cell transformation. The genotype of long term culture of ASC52telo 
cells was maintained.   
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5 Chapter 3 RECQL4 dynamics and interacting partners 
  
Results  
We established that prolonged, mild interference with DNA replication initiation by 
inhibiting DDK can result in genomic instabilities and can contribute to the 
transformation of mesenchymal stem cells. DDK acts upstream of RECQL4 in the 
process of replication initiation (Labib, 2010; Im et al., 2015), which suggests that 
the changes we observed parallel to long-term inhibition of DDK could recapitulate 
changes shown by RTS patients who carry mutations that disable RECQL4 
functions. RECQL4 mutations lead to a significant predisposition to OS 
development in RTS type II patients. The second aim of our work was to establish 
a system that models the effect of impaired / complete lack of RECQL4 in 
proliferating and differentiating mesenchymal stem cells.   
We set out to identify if RTS cells lines show cellular changes similar to our previous 
findings using the PHA-767491 model, which may sensitize the cells to OS.   
The results of RECQL4 mutations could also originate from disrupting protein-
protein interactions and protein complexes, and as such could be secondary 
consequences of disrupted RECQL4 function. A number of RECQL4 interacting 
proteins have been described in the literature (Croteau et al., 2012b), and we aim 
to verify some of these to serve as controls in our search for novel interactions 
following posttranslational modifications.  To enable further investigations relating 
to the knockdown and overexpression of RECQL4, and to further identify interacting 
RECQL4 proteins, Emerald-GFP tagged RECQL4 cell lines were established.    
5.1 Establishing of expression characteristics of RECQL4 
In our experiments, we interfere with RECQL4 expression in various ways, therefore 
it was important to establish the natural expression dynamics as well as expression 
characteristics following siRNA mediated knockdown.  
To establish the influence of proliferation and RECQL4 expression, RECQL4 
expression was monitored in U2OS-FLIPINTREX and HeLa LacZeo cells over 9 
days without passaging. RECQL4 expression appears to vary over the 9 days; 
expression increases as cells proliferate, and generally decreases when cells 
appear to reach confluency, HeLa cells showed more variable expression levels 
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(Figure 5.1-a and Figure 5.1-b). Unfortunately, we were not able to show RECQL4 
expression with immunofluorescence, the antibody turned out to be unsuitable for 
immunofluorescent staining (Figure 5.1-c). 
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Figure 5.1-a RECQL4 expression in relation to cell confluence in U2OS-FLIPINTREX cells. 12,000 U2OS FLIPINTREX 
cells were seeded per well in a 96 well plate and incubated for 9 days.  Each day cell lysate was collected.  Western blot was 
performed and probed with Tubulin and RECQL4 antibodies.  Tubulin verified uniformity of loading.  Graph represents data 
combined from two independent experiments (n=2), error bars represent SEM, one representative western blot is shown. 
RECQL4 expression was shown to increase with cell proliferation and decrease as cells became confluent,  
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Figure 5.1-b RECQL4 expression in relation to cell confluence in HeLa cells over 9 days.  12,000 HeLa LacZeo cells 
were seeded per well in a 96 well plate and incubated for 9 days.  Each day cell lysate was collected.  Western blot was 
performed and probed with Tubulin and RECQL4 antibodies.  Tubulin verified loading efficiency. Graph represents data 
combined from two independent experiments (n=2), error bars represent SEM, one representative western blot is shown.  
RECQL4 expression was variable but appeared to increase with cell proliferation and decrease as cells become confluent. 
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Figure 5.1-c Analysis of RECQL4 antibody in HeLa and U2OS cells. 72000 HeLa LacZeo and U2OS FLIPINTREX cells 
were seeded per well, in a 24 well plate on sterile glass coverslips and incubated for 4 and 5 days, with medium change on 
day 3.  The cells were fixed with 4% paraformaldehyde and probed for RECQL4 expression.  HeLa day 4 1:100 antibody 
dilution, HeLa day 5 1:75 antibody dilution, U2OS day 5 1:50 antibody dilution, U2OS day 4 1:30 antibody dilution.  The cells 
were analysed by immunofluorescence. Green signal is due to auto-fluorescence detected in high gain setting; no RECQL4 
expression was detected (Nikon gain 400); x100 objective.  
 
RECQL4 expression and cellular proliferation was further invesitigated over 10 
days.  Cell count and viabilty was recorded daily.  Cell viability was maintained over 
the culture time with a steady increase as cell proliferation occurred, and reduction 
with high cell density (Figure 5.1-d).  U2OS cells overall, maintained cell viability 
and increased in cell count over the 10 day period (Figure 5.1-d).  HeLa cells 
appeared to pick up following a reduction in cell viability and count before a 
decrease is observed again (Figure 5.1-d).  The increase in cell count in HeLa and 
U2OS cells appears around day 4 or 5, similar to the RECQL4 expression levels 
previously shown (Figure 5.1-a and Figure 5.1-b).  The expression of the Ki67 
antigen in cells correlated with cell proliferation: lack of expression represents 
resting cells with reduced expression following extended culturing in U2OS and 
HeLa cells (Figure 5.1-e and Figure 5.1-f) as cells stopped cycling.  The percentage 
of Ki67 ‘dim’ cells defined at a threshold set at the lowest 10% of expression level 
at day 1 post seeding, was analysed and verified decrease in Ki67 expression as 
cells became confluent over extended culturing in HeLa and U2OS cells, which 
appeared to correlate with reduced RECQL4 expression in U2OS cells, however, 
this appeared more variable in HeLa cells (Figure 5.1-e and Figure 5.1-f).  
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Figure 5.1-d U2OS and HeLa cell proliferation rate and viability over 10 days.  72000 HeLa LacZeo and U2OS 
FLIPINTREX cells were seeded per well in a 24 well plate and incubated for 10 days, with medium changes every 3 days.  
Cell count, using BioRad counter, and viability was recorded daily using trypan blue in (a) U2OS, (b) HeLa cells. Cell 
proliferation was demonstrated with an increase in cell count while maintaining cell viability. Graph represents one preliminary 
experiment (n=1).  Over long-term culture, proliferation rate seems to decrease in HeLa cells,  
 
 
 
  
 
 
(a) 
(b) 
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Figure 5.1-e The percentage of Ki67 'dim' cells in relation to RECQL4 expression in U2OS cells. 72000 U2OS 
FLIPINTREX cells were seeded per well in a 24 well plate in duplicates and incubated for 10 days with medium changes every 
3 days.  Each day cell lysate was collected from the appropriate well.  SDS page and Western blot were performed and the 
membrane was probed for Tubulin and RECQL4. RECQL4 expression represented as relative density compared to Tubulin. 
Cells on a parallel well were also fixed with 4% paraformaldehyde and probed for Ki67 expression. The cells were analysed 
by immunofluorescence. One representative graph and western blot is shown. Red cells show Ki67 expressing cells. Ki67 
expression decreased over 10 days of cell culturing. Representative images are shown from day 5 and 10.   Ki67 signal was 
detected using Nikon E800 microscope with DN100 imaging camera, using DAPI and TRITC filters and imaging software, 40x 
objective. Ki67 expression quantified using CellProfiler. ‘Dim’ cells show low Ki67 signal and are non-proliferating.   
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Figure 5.1-f Percentage of Ki67 'dim' cells in relation to RECQL4 expression in HeLa cells. 72000 HeLa cells were 
seeded per well in a 24 well plate in duplicates and incubated for 10 days with medium changes every 3 days.  Each day cell 
lysate was collected from the appropriate well.  SDS page and western blot were performed and the membrane was probed 
for Tubulin and RECQL4. RECQL4 expression represented as relative density. Cells from parallel wells were also fixed with 
4% paraformaldehyde and probed for Ki67 expression. The cells were analysed by immunofluorescence. One representative 
graph and western blot is shown.  Red cells show Ki67 expressing cells. Ki67 expression decreased over 10 days of cell 
culturing. Representative images from days 5 and 10 are shown. Ki67 signal was detected using Nikon E800 microscope with 
DN100 imaging camera, using DAPI and TRITC filters and imaging software, 40x objective. Ki67 expression was quantified 
using CellProfiler. ‘Dim’ cells show low Ki67 signal and are non-proliferating. 
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To identify if RECQL4 mutations affect proliferation and Ki67 expression levels, the 
proliferative capacity of primary RTS cells was tested.  AG18375 RTS primary cells 
did not demonstrate reduced Ki67 levels, whereas AG03587 cells showed lower 
levels, suggesting reduced proliferative state.  These experiments, however, need 
to be repeated and extended to other primary RTS cell lines; these lines are now 
available in the laboratory (Figure 5.1-g).   
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Figure 5.1-g Proliferation rate in a selection of primary RTS cell lines. AG18375 P+4, 5, AG03587 P+13, 14, HS68tert 
P+30, 31, and MRC5 P+33,34, were seeded onto glass coverslips in a 24 well plate and allowed to reach around 80% 
confluency.  The cells were fixed in 4% paraformaldehyde, and stained for Ki67 and DAPI. Images were collected using a 
Leica SP8 confocal microscope, and analysed and quantified using CellProfiler. Error bar represents SEM, statistical 
significance was calculated by the Tukey post hoc test following one-way ANOVA analysis. ****P≤0.0001, graphs represent 
combined data from two independent experiments (n=2). Reduced Ki67 expression was seen in AG03587 cells.  
 
5.2 Establishing overexpression and depletion of RECQL4 
As discussed previously, it appears that RECQL4 overexpression and under-
expression may contribute to tumourigenesis, suggesting that RECQL4 expression 
may be a double-edged sword (Buffart et al., 2005; Choi et al., 2007; Saglam et al., 
2007; Maire et al., 2009; Sadikovic et al., 2010; Su et al., 2010; Fang et al., 2013; 
Ghosal and Chen, 2013).  As we understand, RTS patients with identified RECQL4 
mutations demonstrate a clear predisposition to OS (Tong, 1995; Lindor et al., 1996; 
Miozzo et al., 1998; Kitao et al., 1999; Lindor et al., 2000; Wang et al., 2001; Balraj 
et al., 2002; Wang et al., 2002b; Siitonen et al., 2003; Wang et al., 2003).   
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In order to study the influence of knockdown and overexpression of RECQL4 on the 
physiology of standard laboratory cell lines and mesenchymal cells, and to identify 
interacting partners of RECQL4 with GFP-pulldown, we established cell lines that 
express Emerald-GFP tagged RECQL4 in a Doxycycline inducible manner, verified 
the effect of commercially available siRNA molecules, and generated lentiviral 
vectors that express these siRNA molecules as short-hairpin RNAs (shRNAs). 
5.2.1 Generation of Emerald–GFP tagged RECQL4 expression construct 
Hitherto, there has been no reliable data available on the effect of overexpression 
of RECQL4 in cell culture. To avoid the potential effect of continuous overexpression 
we opted for a tetracycline inducible expression system. RECQL4 fused with 
Emerald-GFP also allowed for the immunopurification of interacting partners of 
RECQL4, as well as identifying its post-translational modifications. 
5.2.1.1 Establishing a suitable plasmid delivery system 
A suitable delivery system was identified and optimised for our cell lines. 
Lipofectamine 2000 and Fugene 6 transfection reagents were used at varying 
transfection reagent:DNA ratios in HeLa cells. pEYFP -C1 was used for verifying 
the efficiency of delivery. This vector contains a C-terminal enhanced yellow variant 
of green fluorescent protein.  Its fluorescence can be easily analysed with 
fluorescence microscopy (Wilson et al., 2002; Karpova et al., 2003; Fahrner et al., 
2014; Tanida et al., 2015; Uritu et al., 2015).  Based on these experiments 
Lipofectamine 2000 was selected for further work in a ratio of 3:1 (Lipofectamine: 
DNA) (Figure 5.2-a).   
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Figure 5.2-a Determining the optimal transfection ratio in HeLa cells.  HeLa LacZeo cells were seeded at 1x105 onto 
glass coverslips in 24 well plate and incubated overnight.  The cells were transfected with variety of ratios of delivery and 
plasmid (a; lipofectamine, b; Fugene) and pEYFP-C1 plasmid (EYFP). 6 hours after transfection with Lipofectamine, media 
was removed and replaced with fresh media alone; additional media was added to Fugene transfected wells. 72 hours post 
seeding, cells were fixed with 4% paraformaldehyde and stained with DAPI. Cells were photographed using Nikon E800 
microscope with DN100 imaging camera, using DAPI and FITC filters and imaging software, with x40 objective. Successful 
intracellular localisation in the nucleus and cytoplasm of pEYFP-C1 expression is shown in green. pEYFP-C1 was used as 
transfection control in further experiments.  
 
An Emerald-GFP tagged expression construct was generated with the Gateway® 
site-specific recombination cloning system (Peakman et al., 1992; Boyd, 1993; Liu 
et al., 1998), (ThermoFisher Scientific), by recombining pENTR-RECQL4(F0) with 
the expression vector pDESTfrtto-Emerald-N0. This reaction resulted in an 
expression construct with the Emerald tag on the carboxy terminus of RECQL4.  
The entry clone and the destination vector have been available in our plasmid 
collection. Recombinant constructs were verified with restriction fragment mapping 
(Figure 5.2-b). Expression of RECQL4-Emerald from the verified constructs was 
confirmed with fluorescent microscopy following transient transfection of the 
miniprep DNA into U2OS-FLIPINTREX and HeLa-LacZeo cells (Figure 5.2-c). 
Maxiprep plasmid DNA was prepared from the verified clone 3 and was co-
transfected into U2OS-FLIPINTREX cells with pOG44 to generate clones with 
stable chromosomal integration.   
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Figure 5.2-b Verification of recombinant constructs.  NcoI digestion was performed on DNA from minipreps of clones #1-
4 (a). (b) Maxiprep DNA of clone 3.  Control lanes contain undigested plasmid from the same clone. (c) plasmid map.  
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Figure 5.2-c Transiently transfected RECQL4-Emerald localisation in HeLa-LacZeo and U2OS-FLIPINTREX cells.  
HeLa and U2OS cells were seeded at 105 cells per well and incubated overnight on 24 well plate.  Cells were transiently 
transfected with mini-prep DNA of clones #1 and #3 with Lipofectamine (1:3), fixed 48 hours post transfection and stained 
with Hoechst-33258.  Signal was detected using Nikon E800 microscope with DN100 imaging camera, using FITC and DAPI 
filters and imaging software, x100 objective, FITC filter set for GFP and DAPI filter set for detecting Hoechst-33258-stained 
nuclei. Successful intracellular localisation of RECQL4-Emerald expression is shown in green; white arrow-nucleus, white 
oval arrow – cytoplasm and nucleus. pEYFP-C1 was used as transfection control.  
 
The transfected cell population was selected for accurate integration and 
maintained under selection. The Hygromycin B resistance marker carried on the 
expression plasmid is only expressed if it is integrated into the target FLP 
recombination site as desired. The recipient cells are also resistant for Blasticidin-
S; the construct that expresses the tetracycline receptor needed for inducibility 
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carries a Blasticydin S resistance marker.  Optimal concentrations of Hygromycin B 
and Blasticidin-S required for successful selection were determined in cell survival 
experiments. The optimal concentrations for selection in HeLa cells were 4µg/ml 
Blasticidin-S and 225µg/ml Hygromycin B, and 4µg/ml Blasticidin-S and 150µg/ml 
Hygromycin B in U2OS cells. HeLa LacZeo#2 and U2OS FLIPINTREX#15 showed 
stable, inducible expression upon addition of doxycycline (Figure 5.2-d). These 
clones were further analysed, and induced RECQL4 expression was verified (Figure 
5.2-e, Figure 5.2-f Figure 5.2-g).  These clones were used for further work in GFP 
Nanotrap pulldown experiments.   
 
   
 
 
Figure 5.2-d Dual selection Hygromycin B titration with Blasticidin-S®.  HeLa cells were seeded into petri dishes 
containing 10ml DMEM medium with 10% FBS, 4µg/ml Blasticidin-S® and variable Hygromycin B concentrations from 0 µg/ml 
to 250 µg/ml and incubated for 2 weeks and 3 weeks.  The cells were observed microscopically using Nikon Eclipse TE2000 
inverted stage microscope, x10 objective.   250µg/ml Hygromycin showed cell toxicity while 200µg/ml showed slight inhibition 
of cell selection. 4µg/ml Blasticidin-S® with 225µg/ml Hygromycin B was deemed suitable for further work.   
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Figure 5.2-e Inducible expression of Emerald-GFP tagged RECQL4. RECQL4-Emerald HeLa and U2OS clones under 
selection were harvested using trypsin and seeded in a 24 well plate layout with or without 2µg/ml doxycycline. 48 hours 
following induction cells were fixed and nuclei were stained with Hoechst-33258. Images were collected on a Nikon Eclipse 
E800 microscope with DN100 imaging camera and imaging software, at x100 magnification, using FITC and DAPI filters. 
Induced expression seen with doxycycline treatment. Blue – cell nuclei, Green – Emerald tagged expression. HeLa LacZeo 
# 2 and U2OS FLIPINTREX # 15 clones were selected for further analysis. 
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Figure 5.2-f Expression intensity in U2OS cells expressing RECQL4 Emerald.  U2OS FLIPINTREX RECQL4-Emerald 
clone # 15 cells were seeded at 12,000 cells per well on glass coverslips with or without induction using doxycycline (DOX) 
at 2ug/ml, and allowed to reach around 70% confluency (3 days).  The cells were fixed in 4% paraformaldehyde Emerald-
GFP signal was detected using Leica SP8, confocal laser scanning microscope, and images analysed and quantified using 
CellProfiler. U2OS em #15: U2OS FLIPINTREX RECQL4-Emerald clone # 15. Graphs represent data combined from three 
independent experiments (n=3), ****P≤0.0001 unpaired t test. Significantly induced RECQL4 expression demonstrated in 
U2OS FLIPINTREX RECQL4-Emerald # 15 clone.   
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Figure 5.2-g Expression intensity in HeLa cells expressing RECQL4-Emerald.  HeLa LacZeo RECQL4-Emerald clone  
#2, cells were seeded at 12,000 cells per well on glass coverslips with or without induction using doxycycline (DOX) at 2ug/ml, 
and allowed to reach around 70% confluency (3 days).  The cells were fixed in 4% paraformaldehyde. Emerald signal was 
detected using Leica SP8 confocal laser scanning microscope. Images were analysed and quantified using CellProfiler. Hela 
em#2: HeLa LacZeo RECQL4-Emerald clone #2. Graphs represent data combined from three independent experiments (n=3) 
****P≤0.0001 unpaired t test. Significantly induced RECQL4 expression demonstrated in HeLa LacZeo RECQL4-Emerald #2.  
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5.2.2 Establishing conditions for siRNA-mediated depletion of RECQL4 
In order to identify suitable conditions and dynamics of RECQL4 depletion RECQL4 
knockdown was performed in HeLa and U2OS cells transfected with RECQL4 
siRNA molecules. Efficient RECQL4 siRNA knockdown was demonstrated over 7 
and 9 days using siRNA molecules that target the coding region of the mRNA (#1, 
#2, #3 and #4 see table 2.2-b; (Figure 5.2-m), and the 3’ untranslated region (#9 
and #10 see table 2.2-b; Figure 5.2-i) however, intrinsic changes in RECQL4 
expression due to the proliferative state of the cells also has to be considered as 
previously discussed. 
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Figure 5.2-h Dynamics of siRNA mediated knockdown in HeLa LacZeo cells. Reverse transfection was performed using 
2µM RECQL4 siRNA pool (containing siRNAs #1, #2, #3, #4) and Dharmafect only as a control. 12,000 HeLa cells were 
seeded and incubated overnight.  18 hours post transfection the medium was topped up.  42 hours post transfection and each 
day afterwards, cell lysate was collected and analysed with SDS page and western blotting.  One representative graph and 
western blot is shown (n=1). RECQL4 expression was shown to increase indicating cell proliferation, and decrease as cells 
became confluent.  RECQL4 pool siRNA transfection showed little expression indicating successful knockdown. The loading 
was verified with tubulin.   
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Figure 5.2-i RECQL4 knockdown efficiency using RECQL4 siRNA 9 and 10 in HeLa and U2OS cells, western blot.  
12,000 U2OS FLIPINTREX and HeLa LacZeo cells were seeded per well in a 96 well plate and reverse transfected with the 
indicated siRNAs.  The medium was topped up after 18 hrs and the cells were lysed 3 days post transfection.  Western blot 
was performed and probed with Tubulin and RECQL4 antibodies. Loading was normalised and verified with Tubulin. One 
representative graph and western blot is shown (n=1).  In HeLa cells RECQL4 expression appeared to not change and 
expression was low.  In U2OS cell line RECQL4 knockdown was shown to be efficient in both RECQL4 siRNA 9 and 10 with 
little expression seen and high expression in the non-targeting control siRNA and Dharmafect only cells.  
 
5.2.3 Generation of shRNA constructs 
A number of primary cell lines are extremely difficult to transfect with traditional 
methods, and this limitation extends to introduction of siRNA molecules into these 
cell types. Although successful transfection methods have been described in 
mesenchymal stem cells (Jaiswal et al., 2000; Yoshikawa et al., 2004) we sought 
for a more efficient approach that generates stable knockdown.  In order to mediate 
knockdown in ASC52telo cells a fourth-generation lentiviral transduction system 
was employed, and an shRNA expression construct was generated. 
Page | 150  
 
Two oligonucleotides harbouring the siRNA sequences that target the 3’ 
untranslated region of RECQL4, and identical in the core sequence to siRNAs 9 and 
10 described above, were custom synthesised, annealed and cloned into the 
pLKO.1 lentiviral vector. The ligated plasmids were transformed into NEB-Stable 
competent E.coli host cells. Miniprep DNA was purified from emerging colonies and 
mapped with XhoI and HinfI digestions.  RECQL4sh 10A3 and RECQL4 9A1 
showed fragment bands at the expected sizes following restriction digest (Figure 
5.2-j and Figure 5.2-k).  Confirmed clones were further verified by sequencing, and 
selected for maxiprep, lentiviral packaging and downstream applications.   
 
 
 
 
 
 
 
 
 
 
 
Page | 151  
 
     
 
 
 
Figure 5.2-j Verification of recombinant shRNA constructs. Restriction digest was performed on the miniprep plasmid DNA. ladder- 100 bp ladder (NEB). (a) XhoI digested fragments; empty 
vector: 6556, 304, 190;  shRNA clone:  6556, 295, 190, 43.  (b) HinfI digested fragments; empty vector: 1074, 948, 947, 597, 571, 517, 456, 454, 396, 380, 224, 133, 118, 75, 73, 65, 22;  shRNA 
clone:  1074, 947, 724,  597, 571, 517, 456, 454, 396, 380, 253,133, 118, 75, 73, 65, 22, 5.  (c) Plasmid map.  
Page | 152  
 
 
 
Figure 5.2-k Recombinant construct RECQL4 9A verification. Restriction digest was performed on the Mini-prep plasmid 
DNA. ladder- 100 bp.  (a) HinfI digested fragments, (b) XhoI digested fragments. XhoI sizes: empty vector: 6556, 304, 190; 
shRNA clone:  6556, 295, 190, 43.  Hinfl sizes: empty vector: 1074, 948, 947, 597, 571, 517, 456, 454, 396, 380, 224, 133, 
118, 75, 73, 65, 22;  shRNA clone:  1074, 947, 724,  597, 571, 517, 456, 454, 396, 380, 253,133, 118, 75, 73, 65, 22, 5. 2 log 
ladder.  (c) Plasmid map.  
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5.2.4 RTS cell lines and PHA Sensitivity  
RECQL4 holds an important role in DNA replication initiation.  To determine if 
RECQL4 mutation sensitizes cells to interference of DNA replication, RTS cell line 
AG05013 and RECQL4 knockdown U2OS and HeLa cells were treated with PHA-
767491.  We established previously that media changes were required in PHA-
767491 treated cells (see section 3.1).  AG05013tert, HS68tert, and MRC5 cells 
were re-tested with medium changes (Figure 5.2-l), which confirmed that the 
RECQL4 mutated cell line (AG05013tert) is indeed more sensitive to inhibition of 
replication initiation inhibitors than wild-type cells. We suggest that RTS cells are 
more sensitive to this drug, because of their inherent problem with replication 
initiation due to the lack of RECQL4.  Whether this finding represents a general 
feature of RTS cells or specific to AG05013 needs to be verified using other RTS 
cell lines.   
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Figure 5.2-l Sensitivity of AG05013tert, HS68tert, and MRC5 cells to PHA-767491. Cells were seeded at 2000 cells per 
well in 96 well plate, and were treated with the indicated concentration of the drug alongside controls. Medium was changed 
and treatment reapplied to the cells every 3 days. Cell viability was established post 7 days incubation using the MTS assay 
read at 490nm. Error bars represents SEM of triplicates, graph represents one of three independent experiments (n=1). The 
RECQL4 mutated cell line AG05013tert shows a higher sensitivity to replication inhibition than the control cell lines. 
RECQL4 mutated cells (AG05013) appeared to demonstrate sensitivity to PHA-
767491.  To verify a link between RECQL4 expression and sensitivity, RECQL4 was 
depleted using siRNA, as previously verified (Figure 5.2-m), and cells were treated 
with PHA-767491.  U2OS cells showed steadily reduced cell viability with increasing 
concentrations of PHA-767491 after 0.4 µM with Non-targeting siRNA treatment and 
in RECQL4 depleted cells (Figure 5.2-n).  Viability measurement was variable in 
HeLa cells but fell sharply above 2.5 µM (Figure 5.2-o).  Knockdown of RECQL4 in 
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these U2OS and HeLa cells was verified with western blotting; however, increased 
sensitivity to PHA following RECQL4 siRNA knockdown was not seen (Figure 5.2-n 
and Figure 5.2-o).  This data suggests, contradicting to data obtained from primary 
fibroblasts, that siRNA mediated knockdown of RECQL4 in HeLa and U2OS cells 
does not sensitise these cells to inhibition of replication initiation. 
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Figure 5.2-n Sensitivity of cells to PHA-767491 following siRNA mediated knockdown of RECQL4 in U2OS. 4000 U2OS 
cells were seeded per well in a 96 well plate and reverse transfected with RECQL4 siRNA pool (9 + 10) and the control Non-
targeting siRNAs. 18 hours post transfection medium was changed with the addition of PHA-767491 at variable 
concentrations. Medium was replaced every 3 days with fresh medium containing the appropriate concentrations of PHA-
767491.  MTS absorbance was read at 490nm 7 days following initial PHA-767491 treatment.  Data represent means ± SEM 
of triplicates, western blot and graphs is a representative of one of two independent experiments. Cells were lysed 7 days 
following initial PHA-767491 treatment, the lysates were run on SDS PAGE and western blot performed.  Membrane was 
probed for Tubulin and RECQL4.   Loss of both RECQL4 and tubulin signal represents the loss of cells.  a:NT (non-targeting) 
siRNA b:RECQL4 siRNA. RECQL4 knockdown did not demonstrate sensitivity to PHA-767491. 
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Figure 5.2-o– Sensitivity of cells to PHA-767491 following siRNA mediated knockdown of RECQL4 in HeLa cells. 4000 
HeLa cells were seeded per well in a 96 well plate and reverse transfected with RECQL4 siRNA pool (9 + 10) and the control 
Non-targeting siRNAs. 18 hours post transfection medium was changed with the addition of PHA-767491 at variable 
concentrations. Medium was replaced every 3 days with fresh medium containing the appropriate concentrations of PHA-
767491.  MTS absorbance was read at 490nm 7 days following initial PHA-767491 treatment.  Data represent means ± SEM 
of triplicates, western blot and graphs is a representative of one of two independent experiments. Cells were lysed 7 days 
following initial PHA-767491 treatment, the lysates were run on SDS PAGE and western blot performed.  Membrane was 
probed for Tubulin and RECQL4.   Loss of both RECQL4 and tubulin signal represents the loss of cells. a:NT (non-targeting) 
siRNA b:RECQL4 siRNA. RECQL4 knockdown did not demonstrate sensitivity to PHA-767491. 
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5.2.5 RECQL4 DNA damage  
We found evidence of DNA damage in ASC52telo cells treated in the PHA-model.  
RTS cell lines (AG05013tert, AG18375, and AG03587) were investigated for the 
same markers.   There was a significant increase seen in AG05013tert γH2AX and 
TRF2 expression intensity, with no significant changes seen in co-localisation of 
TRF2 and γH2AX foci (Figure 5.2-p)  
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Figure 5.2-p Expression of DNA damage and telomeric markers in RTS cell lines. AG05013tert P+15,16,17, AG18375 
P+4, 5, 6, AG03587 P+13, 14, 15, HS68tert P+35, 44,45, and MRC5 P+36, 45, 46, were seeded onto glass coverslips in 24 
well plate and allowed to reach around 80% confluency.  The cells were fixed in 4% paraformaldehyde, and stained for γH2AX 
and TRF2. Images were collected with a Leica SP8 confocal microscope and quantified using CellProfiler. Error bars represent 
SEM. Statistical values were calculated by the Tukey post hoc test following one-way ANOVA analysis, 
**P≤0.01,****P≤0.0001. Graph represents data combined from three independent experiments (n=3). An increase of γH2AX 
and TRF2 expression was shown in AG05013tert cells. 
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5.3 Isolation and identification of RECQL4 interacting partners. 
The established HeLa#2 and U2OS#15 clones were expanded, and 9 10cm petri 
dishes were used per treatment as follows. RECQL4-Emerald expression was 
induced with 2 µg/ml doxycycline. To enrich the isolated RECQL4 population for 
post-translational modifications (Im et al., 2015), the cells were treated with 2µM 
Suberoylanilide hydroxamic acid (SAHA), 4mM hydroxyurea (HU) or DMSO as 
control.  SAHA is an inhibitor of histone deacetylases (HDACs).  SAHA was included 
in the experiment to permit identification of posttranslational acetylation 
modifications of RECQL4 and protein-protein interactions that depend on it. 
Hydroxyurea (HU) treatment was employed to facilitate isolation of S-phase specific 
binding partners and post-translational modifications of RECQL4. HU blocks DNA 
synthesis by inhibiting ribonucleotide reductase, which limits the accumulation of 
deoxyribonucleotides required for incorporation at replication forks, holding the cells 
at S phase (Butler et al., 2000; Koç et al., 2004; Karnani and Dutta, 2011). The 
isolation of GFP-Emerald tagged RECQL4 was performed using Chromotek GFP-
trap®_A, then SDS PAGE and western blot was performed to determine efficiency 
of RECQL4-Emerald expression and pull-down.  RECQL4-Emerald expression was 
demonstrated in the input samples of the GFP-Trap, which then decreases 
expectedly with the non-bound samples (wash), with higher expression seen on the 
bound beads, demonstrating efficient immunoprecipitation (Figure 5.3-a).  
 
 
 
Figure 5.3-a GFP-trap pull-down of Emerald-GFP tagged RECQL4. RECQL4 expression was induced in the selected 
U2OS #15 cells with doxycycline in 10cm dishes. Post 3 days the cells were either treated with 2μm Suberoylanilide 
hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control with DMSO for 18 hours. GFP tagged RECQL4 was 
immunoprecipitated using GFP-Trap_A, then SDS-page and western blot were performed. The membrane was probed with 
RECQL4 (1:1000 in BSA blocking). 1 –Input, 2 – Non-bound, B – Bound; 2% input and unbound loaded. Bound lanes show 
strong signal of RECQL4-Emerald. 
 
The SDS gel was cut to segments, and sent for identification of protein content by 
mass spectrometry (Table 5.3-a). Co-precipitated binding partners from a 
subsequent pull-down experiment were separated on SDS PAGE.  A few previously 
identified positive ‘hits’ were also verified with western blot.  Presence of PP2A 
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(protein phosphatase 2A) was demonstrated in the lysate and wash, but very little 
to no signal was seen in the pull-down fraction in U2OS cells (Figure 5.3-b).  Little 
to strong expression was shown in HeLa cells (Figure 5.3-c). MCM10 is a known 
interacting protein of RECQL4.  Its expression was demonstrated in the pull-down 
following SAHA treatment in both cell lines, although somewhat weaker in U2OS 
(Figure 5.3-b and Figure 5.3-c).   
 
Cell treatment RECQ4 pull down ‘positive hits’ 
Blank- SAHA Serine/threonine-protein phosphatase 2A  
Control Homeobox protein engrailed-2  
Control Homeobox protein engrailed-1  
Hu ATP-dependent DNA helicase Q4 (RECQL4) 
SAHA ATP-dependent DNA helicase Q4 (RECQL4) 
 
Table 5.3-a A list of identified proteins from the RECQL4 pull down earmarked for follow-up analysis. RECQL4 
expression was induced in the selected U2OS #15 cells with doxycycline in 10cm dishes. Post 3 days the cells were either 
treated with 2μm Suberoylanilide hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control treated with DMSO 
(control), untreated (blank) for 18 hours. GFP tagged RECQL4 was immunoprecipitated using GFP-Trap_A, then SDS-page 
and the gel was cut into pieces and sent for mass spectrometry.   
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Figure 5.3-b Pull-down of RECQL4 interacting partners in U2OS clone #15 cells. RECQL4 expression was induced in 
the selected U2OS #15 cells with doxycycline in 10cm dishes. Post 3 days the cells were either treated with 2μm 
Suberoylanilide hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control treated with DMSO for 18 hours. GFP 
tagged RECQL4 was immunoprecipitated using GFP-Trap_A, then SDS-page and western blot were performed. The 
membrane was probed with PP2A (1:1000 in BSA blocking), RECQL4 (1:1000 in BSA blocking), and MCM10 (1:800), 1 –
Input, 2 – Non-bound, B – Bound; 2% input and unbound were loaded. PP2A expression is not seen in the RECQL4-bound 
fraction, but weak signal of MCM10 is shown. 
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Figure 5.3-c Pull-down of RECQL4 interacting partners from HeLa clone #2 cells. RECQL4 expression was induced in 
the selected HeLa #2 cells with doxycycline in 10cm dishes. Post 3 days the cells were either treated with 2μm Suberoylanilide 
hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control treated with DMSO for 18 hours. Immunoprecipitation using 
GFP-Trap_A, SDS-page and western blot were performed. The membrane was probed with PP2A (1:1000 in BSA blocking), 
RECQL4 (1:1000 in BSA blocking), and MCM10 (1:800), 1 –Input, 2 – Non-bound, B – Bound; 2% input and unbound loaded.  
PP2A and MCM10 expression shown in RECQL4 bound fraction.  
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A novel RECQL4 interacting protein: Highly divergent homeobox (HDX) had been 
previously identified in other experiments (data not shown here). To explore this, 
further, a HDX antibody, which was not available before, was first verified following 
reverse siRNA transfection. Reduced expression was demonstrated following 
siRNA knockdown (Figure 5.3-d).  RECQL4-GFP pulldown was performed, and the 
isolated proteins were analysed on western blot probed for HDX. HDX was found to 
be present in the GFP-bound fraction suggesting interaction with RECQL4 (Figure 
5.3-e and Figure 5.3-f).  The novel homeobox protein engrailed-2 (EN-2) was seen 
by mass spectrometry (Table 5.3-a), and was also found to be present in the 
RECQL4 bound fraction (Figure 5.3-e). 
 
Figure 5.3-d Verification of HDX siRNA and antibody. Reverse transfection was performed using 2µM siRNA (pooled 
molecules 1, 2, 3 and 4) with Non-targeting and Dharmafect only as controls. 12,000 U2OS FLIPINTREX cells were then 
seeded per well in a 96 well plate. 18 hrs post transfection the medium was topped up and the cells were incubated until day 
3.  Cell lysate was collected and an SDS PAGE and western blot was performed.  The membrane was probed with HDX 
antibody (abcam ab94475) at 1µg/ml in BSA blocking solution.  / Control - no treatment, Dharmafect – Dharmafect 1, delivery 
vehicle only, NT siRNA - non-targeting siRNA, HDX siRNA – HDX pool siRNA.  Reduced HDX expression was demonstrated 
following knockdown.   
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Figure 5.3-e Pull-down of RECQL4 interacting partners in U2OS clone #15 cells. RECQL4 expression was induced in 
the selected U2OS #15 cells with doxycycline in 10cm dishes. Post 3 days the cells were either treated with 2μm 
Suberoylanilide hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control treated with DMSO for 18 hours. GFP 
tagged RECQL4 was immunoprecipitated using GFP-Trap_A, then SDS-page and western blot were performed. The 
membrane was probed with Abcam anti-HDX antibody (ab94475) at 1µg/ml  in BSA blocking solution, RECQL4 (1:1000 in 
BSA blocking) and Engrailed 2 (1:10000). 1 –Input, 2 – Non-bound, B – Bound; 2% input and unbound were loaded. RECQL4: 
150kDa, HDX: 77kDa, EN-2: 42 kDa. HDX and EN-2 signal is shown in the RECQL4 bound fraction. 
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Figure 5.3-f Pull-down of RECQL4 interacting partners in HeLa clone #2 cells. RECQL4 expression was induced in the 
selected HeLa #2 cells with doxycycline in 10cm dishes. Post 3 days the cells were either treated with 2μm Suberoylanilide 
hydroxamic acid (SAHA), 4mM hydroxyurea (HU), or as a control treated with DMSO for 18 hours. Immunoprecipitation using 
GFP-Trap_A, SDS-page and western blot were performed. 2% input and unbound were loaded, 1 –Input, 2 – Non-bound, B 
– Bound. Membrane was probed for RECQL4 (Cell Signalling 1:1000) 150kDa, HDX -77kDa (Aviva Systems Biology 
ARP39832_P050), (top blots), and Abcam anti-HDX antibody (ab94475)(bottom blot) at 1µg/ml  in BSA.  HDX and EN-2 signal 
is shown in the RECQL4 bound fraction. 
 
5.4 Summary 
In summary, RECQL4 expression appeared variable in cell lines and RTS cells.  The 
AG05013 RTS cell line appeared to demonstrate evidence of DNA damage with an 
increase in γH2AX and TRF2 intensity not seen in the other RTS cell lines 
(AG03587, AG18375).  Further investigations are required to understand the 
reasons for this finding, perhaps sustained DNA damage from existing specific 
RECQL4 mutation.  Further comparison of other RTS cell lines could better our 
understanding of the apparent alterations of DNA damage response seen in these 
cells, such as cell morphology, aneuploidy, proliferative rate, and preferred DNA 
damage response pathway.   
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The shRNA constructs generated during this work are used for follow-on work in the 
laboratory. Lentiviral vectors have been generated and used for transduction of 
ASC52telo cells. Phenotypic changes induced by stable knockdown are currently 
being characterised as part of an MSc by Research project. 
 
We found a number of novel RECQL4 protein interactions that to date have not been 
reported.  These preliminary findings are currently under follow-up investigation in 
the laboratory and could lead to new roles and pathways that involve RECQL4.   
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6 Discussion  
 
6.1 Interfering with DNA replication initiation (chapter 1, section 3.1) 
 
We set out to establish a model based on replication initiation stress and reduced 
proliferative rate, which mimics the potential effects of RECQL4 mutations 
identifying any subsequent cellular changes, such as damage to the cells (Sangrithi 
et al., 2005; Lu et al., 2014a; Lu et al., 2016).   
PHA-767491 is a pyrrolopyrridinone molecule, the first well-characterized inhibitor 
of DBF4 dependent kinase (DDK) (Montagnoli et al., 2008; Vanotti et al., 2008).  It 
is a dual Cdc7/Cdk9 inhibitor, and consequentially inhibits firing of replication origins 
without affecting replication fork progression (Montagnoli et al., 2008), due to 
specific inhibition of both Cdc7 kinase and the phosphorylation of MCM2 at the 
Cdc7-dependent Ser40 site (Montagnoli et al., 2008). PHA treatment was found to 
abolish MCM2 phosphorylation in HCC1954 cells further corresponding to cell 
growth and viability effects (Sasi et al., 2014).  In normal cells Cdc7 inhibition arrests 
cell proliferation (Montagnoli et al., 2004; Tudzarova et al., 2010). The inhibition or 
depletion of Cdc7 leads to the triggering of the replication origin activation 
checkpoint, which generates a reversible G1 arrest, failure to progress to S phase, 
while the cells remain viable.  Active Cdc7 levels are restored following withdrawal 
of treatment (Tudzarova et al., 2010).   
An early study was the first to show that DDK depletion leads to the severe 
disruption of DNA replication in HeLa cells (Jiang et al., 1999).  Further studies have 
demonstrated the depletion of DDK by siRNA in HeLa cells led to p53-independent 
apoptosis, in comparison to a normal human dermal fibroblast cell line, in which it 
led to reversible cell cycle arrest. This effect was further confirmed in other cell lines 
(Montagnoli et al., 2004; Im and Lee, 2008; Tudzarova et al., 2010; Ito et al., 2012).  
PHA-767491 has also been demonstrated to reduce proliferation in a number of 
other cell lines (Sasi et al., 2014).  
Our aim was to establish a model of mild replication initiation inhibition in 
mesenchymal stem cells (ASC52telo) in culture using PHA.  ASC52telo cells have 
been employed in many studies (Wolbank et al., 2009; Hasebe-Takada et al., 2016; 
Nardone et al., 2017; Pitrone et al., 2017). Our results indicated the degradation of 
PHA during cell culture, and media changes with fresh addition of PHA at day 3 
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maintained inhibition. There is little information on the stability of PHA in the 
literature, as studies appeared to use short term treatment of around 24 to 72 hours 
(Montagnoli et al., 2008; Natoni et al., 2013; Fitzgerald et al., 2014; Sasi et al., 2014; 
Erbayraktar et al., 2016). There are many conditions which can lead to degradation 
of a substance, including time, and environmental factors (Blessy et al., 2014).   
A model of PHA-767491 was established in low and high passage ASC52telo cells 
with acute and chronic PHA treatment, and withdrawal of treatment in either case 
(‘recovery’).  This enabled us to further understand the effects of reduced replication 
over time and the potential cellular stress this generates, similar to the effect of 
RECQL4 mutations, and if and how the cells may recover following the cessation of 
treatment with PHA-767491. Interestingly, PHA-767491 treated cells appeared to 
lead to cell morphology changes, as the cells appeared larger, which is an indication 
of cellular morphological modifications that have been further explored in this study.  
Cells that are actively proliferating produce a range of proteins which can be utilised 
as markers using assays such as immunofluorescence.  Ki67 is a nuclear antigen 
expressed in cycling cells, and is not expressed in quiescent cells (Sobecki et al, 
2017). The role of Ki67 was not initially fully understood (Tsurusawa and Fujimoto, 
1995), however, a more recent study has found Ki67 may be involved in the 
organisation of heterochromatin in proliferating cells (Sobecki et al., 2016).   Early 
studies found levels of expression to appear in G1 phase, with a further increase 
during S phase and G2 phase, with the maximum level seen during mitosis at the 
surface of chromosomes (Gerdes et al., 1984; Sasaki et al., 1987; Manoir et al., 
1991; Tsurusawa et al., 1992; Scholzen and Gerdes, 2000; Ladstein et al., 2010). 
Absent expression is seen in resting cells in G0 phase of the cell cycle (Scholzen 
and Gerdes, 2000).  An early study, however, did find some tumour cells in G1 
phase negative for Ki67 progressed into S phase of the cell cycle, following a long 
G1 phase duration (Tsurusawa and Fujimoto, 1995).  We expected a decrease of 
Ki67 expression in PHA-767491 treated cells, as we have demonstrated reduced 
proliferation as reduced cell count.  Somewhat surprisingly, we observed some high 
levels of Ki67 expression in these cells.  This contradiction might be related to 
persisting Ki67 expression in G1; as described previously, PHA-767491 could hold 
the cells in G1 phase of the cell cycle. The reduced expression shown following long 
term PHA-767491 treatment could demonstrate increased sensitivity and/or more 
cells exiting the cell cycle into G0, as the cells were previously shown to demonstrate 
reduced proliferation via cell count.  A study by Montagnoli et al, (2008), 
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demonstrated an increase of Ki67 following PHA-767491 using 
immunohistochemistry in HCT116 xenografts, which also remained unexplained 
(Montagnoli et al., 2008).  
Topoisomerases are enzymes that hold important roles in uncoiling supercoiled 
DNA, and removing knots and catenates that form during DNA metabolism by 
causing transient breaks in the DNA double-helix (Wang, 1985; Wang, 2002). 
Topoisomerase 1 (TOP1) generates single-stranded breaks in double-stranded 
DNA, swivels the broken end around the non-scissile strand, then re-joins the break 
during transcription and replication (Bouwman and Crosetto, 2018). Camptothecin 
(CPT) inhibits topoisomerase I catalytic activity through the prevention of re-ligation, 
and stabilizes the TOP1-DNA cleavage complex (Hsiang et al., 1985; Huang et al., 
2004; Darzynkiewicz et al., 2012; Zhao et al., 2012; Berniak et al., 2013), leading to 
a G2 delay and cytotoxicity (Janss et al., 1998). Camptothecin has been reported in 
many studies as an attractive anticancer drug (Hafian et al., 2004; Zhou et al., 2010; 
Gaur et al., 2014).  At this stage of the study, we utilised CPT to demonstrate 
reduced cell proliferation, verified with reduced Ki67 expression, which has also 
been demonstrated in the literature (Zhou et al, 2010; Gaur et al, 2014).  
There are many methods for the analysis of cell proliferation, each with their own 
advantages and limitations (Jones et al., 2001; Ng et al., 2005; Hutmacher et al., 
2009; Mimeault and Batra, 2010; Quent et al., 2010).  The simplest method using a 
haemocytometer was utilised in our study, and with the combination of trypan blue 
cell viability was measured alongside.  Although simple and not expensive the main 
limitation can be human error and the same operator would introduce a constant 
level of this potential error (Pierre, 2002). We also utilised the indirect colorimetric 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-2H- 
tetrazolium) assay.  The MTS assay is based on the bioreduction of tetrazolium salts 
changing the colour from a pale yellow to dark blue dye by the formation of formazan 
catalysed by mitochondrial dehydrogenases, and measured by absorbance 
(Mosmann, 1983; Berridge et al., 2005).  Limitations include a variable metabolic 
behaviour found in cells and under variable culture conditions such as pH changes, 
and as an end-point assay further analysis of cell survival cannot be achieved.  High 
cell density has also been found to be inappropriate for measuring cell proliferation 
(Plumb et al., 1989; Hsu et al., 2003; Ng et al., 2005; Lopez‐Barcons, 2010; Rattan 
et al., 2011). Additional chemical treatments may also interfere (Wang et al., 2010). 
In our study PHA and DMSO treated wells without cells were utilised as controls, 
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and demonstrated no modification of signal. The assay measures enzyme activity 
of mitochondrial dehydrogenases, that is metabolic activity, rather than measuring 
the number of cells and viability (Mosmann, 1983; Quent et al., 2010).  
Nevertheless, this enzyme activity is proportional to the number of live cells as 
damaged or dead cells display no dehydrogenase activity (Mosmann, 1983; 
Jevprasesphant et al., 2003). The MTS assay has been utilised for analysing cell 
growth following PHA-767491 treatment in a recent study, and found inhibition of 
cell growth, as seen in our study (Liu et al., 2018).  A cell count alongside the MTS 
is necessary to verify the cell number is suitably represented within our study.    
6.1.1 PHA-767491 effect on osteocyte differentiation (chapter 1, section 
3.1.1) 
6.1.1.1 Differentiation of ASC52telo MSCs 
The MSCs utilised in our study were isolated from adipose tissue obtained 
commercially, and can differentiate in vitro into mesodermal lineages; osteocytes, 
chondrocytes, and adipocytes (Hampel et al., 2005; Strem et al., 2005; Zhang et al., 
2011), and non-mesenchymal lineages: skeletal myocytes (Strem et al., 2005), 
hepatocytes (Wang et al., 2014a), cardiomyocytes (Strem et al., 2005; Choi et al., 
2010), pancreatic (Timper et al., 2006), and neuronal cells (Safford et al., 2002; 
Kang et al., 2003; Strem et al., 2005). It is not clear whether all these terminally 
differentiated cell types represent true in vivo routes of differentiation. We 
concentrated on differentiating the cells into adipocytes, osteoblasts, and 
chondrocytes, which was verified in low and high passage ASC52telo cells. Re-
expression of hTERT in mesenchymal stem cells is also extensively studied 
(Wolbank et al., 2009), and in particular found that the ASC52telo cell line maintains 
mesenchymal surface markers, and osteocyte and adipocyte differentiation 
potential. However, adipocyte differentiation capabilities may become enhanced 
(Jun et al., 2004; Kang et al., 2004a; Wolbank et al., 2009). Other reports also found 
that hTERT immortalisation of ASCs leads to increased differentiation potential (Jun 
et al., 2004; Kang et al., 2004a), however, this may not be applicable to all 
transduced cell lines, as differentiation potential appears to be variable even across 
subclones derived from single adult stem cells (Guilak et al., 2006).   
As the fibroblast like MSCs differentiate into chondrocytes, their morphology 
changes into a large round shape.  The cells become surrounded by ECM that 
contains a highly organised network of collagens, proteoglycans and 
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glycosaminoglycans (Hardingham et al., 2006; Chang et al., 2008; Ding et al., 2010). 
The cells produce cartilage-related extracellular matrix molecules, including 
proteoglycans, collagen II and IV, PRELP and aggrecan (Caplan, 1991; Pittenger et 
al., 1999; Zuk et al., 2001; Erickson et al., 2002; Zuk et al., 2002; Dragoo et al., 
2003; Siitonen et al., 2003; Wickham et al., 2003). Alcian blue stains highly 
sulphated proteoglycans in nodules, a characteristic of cartilaginous matrix, a sign 
of chondrocyte differentiation (Zuk et al., 2002; Ogawa et al., 2004). 
The differentiation of adipocytes leads to changes of cell shape from the fibroblast 
like MSC, into spherical shape cells, expressing ECM proteins such as fibronectin, 
laminin, and collagen.  Fibronectin initially forms a network, which is replaced by 
collagen network (Elbrecht et al., 1996; Kubo et al., 2000; Rosen and Macdougald, 
2006; Vallee et al., 2009).  Differentiation then leads to the accumulation of 
intracellular lipid-rich vacuoles, identifying the final stage of adipocyte differentiation. 
These vacuoles stain positive using Oil Red O (Vater et al., 2011).  Oil Red O 
(C26H24N4O) is a fat-soluble diazol dye which detects neutral lipids and cholesteryl 
esters (Ramirez-Zacarias et al., 1992).  Oil Red O is a hydrophobic dye; minimally 
soluble in solvent which further decreases in water, associating with the lipids in 
tissue (Mehlem et al., 2013), or in our study with lipid droplets.  The lipid droplet 
production appears proportional to the extent of differentiation (Kuri-Harcuch and 
Green, 1978).  In our study, the outcome was determined using this method and 
qualitatively. To further this, data can be collected quantitatively by extracting the 
dye using isopropanol (Choi et al., 2008) or via measuring the activity of glycerol-3-
phosphate dehydrogenase (GPDH) (Pairault and Green, 1979; Tsuji et al., 2008).  
Following osteoblast differentiation, cell morphology modifies from fibroblast like 
cells into cuboidal shape, also demonstrated in our study.  The cells produce 
extracellular matrix (ECM) which is composed of mainly collagen type I, and late 
differentiation aggregates and nodules form.  Increased levels of alkaline 
phosphatase, and the accumulation of calcium is also seen during differentiation 
(Pittenger et al., 1999; Chamberlain et al., 2007).  We analysed these calcium levels 
qualitatively using Alizarin Red S staining, often used within the literature (Stanford 
et al, 1995; Yang et al, 2004; Håkelien et al., 2014;Aveic et al, 2019).     Alizarin Red 
S forms a chelate complex with calcium cations (Stanford et al., 1995).  Strong 
staining was observed demonstrating osteoblast differentiation within our study.  We 
often observed, although not always significant, stronger staining of the calcium 
deposits in differentiated ASC52telo cells with PHA-767491 treatment, which could 
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be investigated further by quantification to determine its significance.  The stain can 
be further analysed following extraction for semi-quantification (Stanford et al., 
1995), for example using acid extraction, which can be used to assay the kinetics of 
osteogenesis (Junqueira et al., 1998; Long, 2001; Gregory et al., 2004), and RNA-
Seq analysis to determine the extent of differentiation (Håkelien et al., 2014).   
 
Disrupting the balance of MSC differentiation into adipocytes and osteoblasts has 
been reported in many human diseases, with some physiological changes favouring 
adipocyte differentiation of bone marrow MSCs leading to loss of bone, and 
increased risk of bone fracture (Rodríguez et al., 2000; Sekiya et al., 2004; 
Muruganandan and Sinal, 2014). In aging an increase in bone marrow adipogenesis 
with decrease in bone marrow formation has been reported (Meunier et al., 1971; 
Burkhardt et al., 1987; Kajkenova et al., 1997; Nuttall and Gimble, 2000; Verma et 
al., 2002).  The link between increasing age and the loss of bone mass and strength 
has been long established, with some points mentioned previously (Parfitt, 1984; 
Zebaze et al., 2010; Almeida, 2012).   Reduced RECQL4 activity could be linked to 
reduced proliferation and impairment of osteoblasts, either directly, or providing a 
sensitised environment (Ng et al, 2015).     RTS patients demonstrate clinical signs 
of premature aging, which may be related to changes in aging of MSCs.  
Accumulation of pre-osteoblastic cells with a decrease of mature osteoblasts have 
been reported in rats with increasing age (Roholl et al., 1994).   
 
Genetic approaches have proposed that the committed osteoblast lineage is the cell 
of origin in OS (Berman et al., 2008; Walkley et al., 2008), which would explain 
previous studies as p53 deletion in pre-osteoblasts and osteoblast progenitors 
showed higher levels of OS compared to multi-lineage potential cells (Ng et al., 
2012).  Osteoblast progenitors have been found to be more committed than other 
mesenchymal stem cells, which correlates to lower levels of other sarcoma types 
observed (Lin et al., 2009).  A large early study found 81% of osteosarcomas were 
undifferentiated or poorly differentiated (Dahlin, 1957), which was also reported in 
later studies (Thomas et al., 2004; Tataria et al., 2006; Haydon et al., 2007).  We 
propose that mesenchymal stem cells or differentiating osteoblast may be the cells 
of origin of OS, which is also raised as a possibility by other laboratories (Conget 
and Minguell, 1999; Pittenger et al., 1999; Thomas et al., 2004; Tataria et al., 2006; 
Haydon et al., 2007; Deng et al., 2008). Many studies are in support of sarcomas 
being a differentiation disease, in support of our hypothesis, and suggest that 
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mutations that hinder differentiation are the cause, initiating different sarcomas 
depending on cell lineage and stage of differentiation. It is thought to be the reason 
for the many different subtypes seen in osteosarcoma as well (Tang et al., 2008).  
Studies in support of this model have demonstrated an overlap of gene expression 
signatures of differentiated stages of MSCs from normal tissues and sarcomas 
(Nielsen et al., 2002; Boeuf et al., 2008; Bovée et al., 2010; Mohseny and 
Hogendoorn, 2011).   Other studies propose another model: the sarcoma originates 
from primitive MSCs following the acquired mutations that direct sarcoma genesis 
(Rubio et al., 2005; Tolar et al., 2007; Li et al., 2009), as the overlap of signatures 
is thought to be generated due to similar stroma of different tissues (Wunder et al., 
2007; Li et al., 2009).  Sarcomas may generate from mutated MSCs which are 
vulnerable to further mutations (Yang et al, 2014).  
6.1.1.2 The role of RUNX2 in regulating MSC differentiation 
RUNX2 is essential in the regulation of osteoblast differentiation through the 
expression of bone-specific genes, such as collagen type 1α-1, Osterix and Bone 
sialoprotein (BSP) Nakashima et al., 2002; Rutkovskiy et al, 2016). The activity of 
RUNX2 is regulated via many post-translational modifications such as 
phosphorylation, methylation, acetylation, and ubiquitination (Bae and Lee, 2006; 
Rajgopal et al., 2007; Zagami et al., 2009).  The level of RUNX2 expression is cell 
cycle phase dependent, and variable depending on cell type and during 
osteogenesis in MSCs.  Maximum expression has been shown in preosteoblasts, 
and again in early mature osteoblasts.  A decline in expression occurs during 
osteoblast commitment, reducing further in mature osteoblasts and osteocytes 
(Ducy et al., 1997; Maruyama et al., 2007; Tang et al., 2008; Komori, 2010; Jönsson 
et al., 2012), which we also demonstrated in our study.  In osteoblasts the maximum 
peak is seen in early G1 phase of the cell cycle, which reduces in S and M phase 
(Galindo et al., 2005).   A decrease of expression is also seen at the G1/S transition 
of the cell cycle and during mitosis (Nimmo and Woollard, 2008). RUNX2 represses 
the transcription of p21CDKN1A/WAF1/CIP1, a cyclin-dependent kinase inhibitor that holds 
a role in cell cycle arrest at G1 (Westendorf et al., 2002; Galindo et al., 2005; Galindo 
et al., 2007). In our study, RUNX2 was increased in lower passage ASC52telo cells 
under PHA treatment upon osteoblast differentiation, however, this requires 
repeating to verify. As previously discussed, in normal cells PHA-767491 treatment 
would lead to the cells being held at G1 phase of the cell cycle (Rodriguez-Acebes 
et al., 2010; Tudzarova et al., 2010; Ahuja et al., 2016), which may explain the 
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increase in RUNX2 expression levels we observed.  Further analysis is required 
such as cell cycle sorting to determine this. 
Under genotoxic stress, RUNX2 interacts with the p53 tumour suppressor (Ozaki et 
al., 2013). Overexpression of RUNX2 leads to a downregulation of genes 
downstream of p53, while downregulation of RUNX2 leads to an elevation of these 
following DNA damage (Ozaki et al., 2013). RUNX2 may have an important role in 
DNA damage response (DDR) (Wysokinski et al., 2015). During differentiation some 
DDR-related factors may associate with RUNX2. The deficiency of p53 has been 
shown to enhance the ability of proliferation and differentiation of osteoblasts (An et 
al., 2010). An increased level of p53 upregulates RUNX2 in osteoblasts and inhibits 
osteoblast differentiation (Galindo et al., 2005; Lengner et al., 2006).  High levels of 
RUNX2 have also been found in osteosarcoma with loss of p53 (Pereira et al., 2009; 
San Martin et al., 2009). High expression level of RUNX2 is associated with bone 
metastasis (Vladimirova et al., 2008; Zagami et al., 2009; Pratap et al., 2011), 
suggesting an involvement in forming a microenvironment that encourages tumour 
invasion.   
 
RUNX2 and RECQL4 expression has been found to be increased in some OS 
patients (Martin et al, 2014).  The lack of functional RUNX2 in osteoblasts leads to 
a loss of growth restraint (Pratap et al., 2003).  Osteogenic differentiation leads to 
growth restraint and terminal cell cycle exit due to RUNX2- dependent induction of 
p27KIP1 (Drissi et al., 1999), and growth arrest following the inhibition of S-phase 
cyclin complexes in mature osteoblasts (Thomas et al., 2001; Thomas et al., 2004).   
6.1.1.3 The role of RECQL4 in bone morphogenesis 
Ng et al, (2015), using conditional alleles that specifically inactivated Recql4 in vivo 
in osteoblastic progenitor stages of differentiation, described shorter bone formation 
and reduced bone volume. RECQL4 knockdown in the osteoblastic cell lineage and 
in primary osteoblasts did demonstrate cell cycle arrest, apoptosis, impaired 
differentiation and failed proliferation (Ng et al., 2015). The cells displayed a 
‘flattened’ morphology, proliferation declined with a reduced Sca-1 expression, a 
marker of proliferation (Ng et al., 2015). Although other studies have observed 
senescence in human fibroblasts following RECQL4 knockdown (Lu et al., 2014a), 
this was not observed (Ng et al., 2015), however, some aspects of regulation of 
proliferation may be different between these cell types (Lu et al., 2014b).  There are 
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important differences to consider between this mouse model system and human 
patients. RECQL4 mutant proteins are expressed throughout the human body 
during all the stages of skeletal development, while the OSX-CRE mediated 
conditional allele will not deplete Recql4 from all bone forming cells (Ng et al., 2015).  
However, the study does suggest an important intrinsic function for Recql4 in 
skeletal growth (Ng et al., 2015).  Mice, that harbour Recql4 depleted cells 
committed to osteoblast differentiation, fail to produce mineralisation, as shown with 
alizarin red staining, while profiling revealed that all markers of osteoblastic 
maturation, except Runx2 were reduced in these cells (Ng et al., 2015). Interestingly 
the same depletion in more mature cell populations did not demonstrate this skeletal 
phenotype, suggesting that Recql4 may have a major role in pre-osteoblasts in mice 
(Ng et al., 2015).  High expression of Recql4 was reported in MC3T3.E1 mouse 
osteoblastic cells, and this level decreases as the cells differentiate in culture. 
Recql4 overexpression leads to increased proliferation, while siRNA-mediated 
depletion impeded growth (Yang et al., 2006). However, the decline of RECQL4 
mRNA was not demonstrated in human cells following in vitro differentiation of 
Fob1.19 human immortalised foetal osteoblast cells (Burks et al., 2007).  The 
authors suggest this variable outcome could be due difference in species, and 
method of induction of differentiation (Burks et al., 2007). 
 
Recql4 may play a role in the regulation of osteoprogenitor proliferation as its 
localization is observed in active osteoblasts surrounding the growth plates rather 
than differentiated osteocytes in adult mice (Yang et al., 2006).   High expression in 
actively forming bone, in osteoblasts lining the trabecular surface, and in bone lining 
cells, also suggests an important role for  RECQL4 in bone growth (Delagoutte and 
Von Hippel, 2003; Siitonen, 2008).  This is not too surprising as we know 
differentiation leads to reduced proliferative state of the cells, and a correlation 
between RECQL4 expression and proliferation activity has been demonstrated 
(Yang et al., 2006). Recql4 expression in mice is also abundant in proliferating 
intestinal enterocytes and in immature cells and in chondrocytes of developing 
bones and cartilage of the growth plate (Delagoutte and Von Hippel, 2003).  Yang 
and co-workers (2006) suggest that reduced RECQL4 expression may be required 
for full differentiation (Yang et al., 2006).  RTS patients may harbour mutations that 
generate C-terminally truncated RECQL4 proteins, which preserve function in 
replication, but helicase activity is either diminished or limited (Ng et al., 2015).  This 
suggests that tumour predisposition may be a feature of cells that retain the Sld2-
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homology regions of RECQL4, which leads to proliferation with genomic instability 
(Kitao et al., 1999a; Abe et al., 2011; Kohzaki et al., 2012).  In line with our thoughts, 
these genomic instabilities would lead to OS formation. Further to this, the 
previously mentioned study by Ng et al, (2015) suggests that tumourigenesis may 
require mutant Recql4 activity (Ng et al., 2015).  Double knockout mice that harbour 
deleted p53 and Recql4 in the osteoblastic lineage (Osx-Cre p53fl/flRecql4fl/fl) do not 
always develop OS. The study suggests that  mutant alleles of Recql4, and not null 
alleles, may lead to susceptibility to OS formation (Ng et al., 2015).   However, 
previous mouse models were unable to demonstrate that Recql4 mutations lead to 
OS in mice, due to transcription of the N-terminal region, and hypomorphic Recql4 
alleles (Hoki et al., 2003; Mann et al., 2005). 
 
6.2 Relationship between disturbance of DNA replication initiation and 
cellular transformation (chapter 1, section 3.1.2) 
 
Disruption of the process of differentiation can lead to severe diseases, such as 
cancer (Gray et al., 2004; Jögi et al., 2012).  We identified cellular changes indicative 
of cell damage in ASC52telo cells under PHA-767491 treatment.  Further to this, 
acquiring DNA damage may dysregulate differentiation.  Chronic PHA-767491 
treated cells demonstrated osteoblastic like characteristics, with increased RUNX2 
expression and mineralised calcium deposits observed during culturing in normal 
media. The same was not seen in acute PHA-767491 treated cells.  Interestingly, 
we would expect RUNX2 levels to be reduced with the evidence of calcium 
mineralisation, as it occurs at a later stage of differentiation (Stein et al., 2004; 
Rutkovskiy et al., 2016) Dysregulation of osteogenesis transcription factors could 
be establishing the features seen, and acquired over the long term PHA-767491 
treatment.  It is important to consider factors that regulate RUNX2, which also play 
a role in the regulation of osteoblast differentiation, as previously discussed (Long, 
2011; Rutkovskiy et al., 2016).  The induced overexpression of RUNX2 in adipose 
derived mesenchymal stem cells has been reported to enhance osteogenic activity 
and inhibit adipogenesis, with a significant increase in mineral deposition compared 
to control cells (Zhang et al., 2006).  RUNX2 is known to target other genes in 
osteogenesis, including osteocalcin (Li et al., 2012). Our results would be 
strengthened by the analysis of osteocyte specific gene expression, such as 
osteocalcin.  Wang et al. (2006) describes a method to measure the formation of 
calcified nodules with fluorescent dyes in living cells continuously without the 
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deleterious effects of Alizarin Red S.  This would be useful to determine the initial 
stages and proposed continual dysregulation observed in our study. Adipose-
derived stem cells may undergo spontaneous differentiation in vitro following aging 
or seeding at low density with concurrent RUNX2 expression, calcium 
mineralization, bone morphogenetic protein-2 and alkaline phosphatase activity (Liu 
et al., 2016).  In our study, the same was not seen in the control cultures.  Although 
the cells under continuous PHA-767491 treatment showed reduced proliferation 
rate, the same cell density was seeded for both treated and control cells.  Early 
studies were thought to demonstrate spontaneous differentiation, however, many of 
these were later retracted due to the inability to reproduce the results, and cross-
contamination (Rubio et al., 2005).  
6.2.1 Membrane potential maintained in PHA-767491 treated ASC52telo 
cells (chapter 1, section 3.1.3) 
Mitochondrial DNA (mtDNA) is important for mitochondrial function and biogenesis 
during development and differentiation (Larsson et al., 1998). mtDNA maintenance, 
expression and regulation is complex, including mtDNA replication, mtDNA 
transcription, RNA modifications, RNA stability, translation, and localisation of 
translated proteins (Hällberg and Larsson, 2014).  It is not too surprising that genetic 
defects of mitochondrial function can lead to human diseases (Archer, 2013; 
Magalhães et al., 2014; Singer, 2014).   RECQL4 has also been shown to have a 
regulatory role in mitochondrial DNA copy number (mtDNA) maintenance.   mtDNA 
copy number was found to increase in HEK293 cells following the elevation of 
RECQL4 expression, while knockdown in U2OS cells lead to a decrease in mtDNA 
copy number.  RECQL4 deficient human fibroblasts and RECQL4 suppressed 
cancer cells express elevated mitochondrial superoxide production with a decrease 
in repair function following oxidative DNA damage (Chi et al., 2012). Interestingly, 
mtDNA copy number was found to be significantly reduced in RTS cell line 
AG05013.  Reduced levels were also demonstrated in cells without mitochondrial 
localization signal and showing localisation to the nucleus.  Mitochondrial mass was 
also decreased and mitochondrial morphology was aberrant suggesting alterations 
in mitochondrial bioenergetics occur without RECQL4 localisation.  Increased 
invasive capabilities in these cells were further evidenced, which may be a 
contributing factor of the predisposition of tumourigenesis found in RTS patients 
(Kumari et al., 2016).  Interestingly, mitochondrial and metabolic changes are also 
regarded as hallmarks of differentiation of stem cells. During differentiation, 
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mitochondrial modifications occur (Folmes et al., 2011; Varum et al., 2011; Wanet 
et al., 2015). Osteoblasts have a high energy requirement, as they synthesize large 
amounts of extracellular matrix proteins (Esen and Long, 2014).  Mitochondrial 
activity has been found to be regulated during osteoblast differentiation, and at later 
stages of differentiation an increase in glycolysis is observed and may have a key 
role in mature osteoblasts.  This may enable the cells to become more adaptable to 
changes in O2 levels and energy changes (Komarova et al., 2000).  
The mitochondrial membrane potential, sometimes referred to as the protonmotive 
force, is a crucial parameter controlling respiratory rate, ATP synthesis, Ca2+ 
uptake and storage, ROS generation and detoxification, and may influence the 
regulation of mtDNA expression (Nicholls, 2004; Gustafsson et al., 2016). Usage of 
rhodamine 123 (R123), tetramethylrhodamine methyl ester (TMRM), and 
tetramethylrhodamine ethyl ester (TMRE) provides a simple method for analysis of 
membrane potential. These dyes bind to the inner and outer aspects of inner 
mitochondrial membrane due to their lipophilic cation properties, and accumulate by 
the mitochondria depending on membrane potential, which can then be measured 
as absorbance due to the exhibition of a red shift in excitation and emission (Vander 
Heiden et al., 1997; Scaduto and Grotyohann, 1999; Jayaraman, 2005; Masgras et 
al., 2012).  Viable cells exhibit high fluorescence, with low levels in apoptotic cells, 
and under pathological condition such as mitochondrial membrane potential 
impairment (Cottet‐Rousselle et al., 2011;Burbulla and Krüger, 2012). 
In our study, the mitochondrial membrane appeared viable and no significant 
changes were seen in permeability in the TMRE assay.  However, higher readings 
were demonstrated in higher passage cells under both normal conditions and PHA-
767491 treated cells, the reasons for which is unclear. Culturing cells for long period 
in vitro can generate alterations in gene expression, and differentiation potential, as 
a result of culture induced stress (Somaiah et al., 2015). In aging, a decrease in 
energy production and increased oxidative stress are considered as major 
contribution to age related pathologies. Defects in mitochondrial activity are also 
often seen (Di Lisa and Bernardi, 2005; Conley et al., 2007; Pi et al., 2007; Bratic 
and Larsson, 2013). Although differences in membrane potential reading between 
young and aged cells have been reported, some uncertainty remains due to 
methodological limitations (Nicholls, 2004).   
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The effect of PHA-767491 treatment on mitochondria is not intensively studied in 
the literature.  A study by Nantoni et al, (2011) showed that PHA-767491 induced 
Bax activation and a time-dependent increase in cells with low mitochondrial 
membrane potential in chronic lymphocytic leukemia (CLL) cells. They found the 
inhibition of Cdk9 lead to death of quiescent CLL cells through the intrinsic apoptotic 
pathway, suggesting a link with the transcriptional inhibition of McI-1 as a decrease 
of McI-1 protein was seen. Cdc7 inhibition caused a block of proliferation in CLL 
cells (Natoni et al., 2011).  Our study did not appear to show significant changes to 
mitochondrial membrane potential in response to chronic or acute PHA-767491 
treatment.   
To further verify our findings, methods such as flow cytometry and confocal 
microscopy can be used (Cottet‐Rousselle et al., 2011).  They offer the visualisation 
and analysis of morphological changes of mitochondria (Cottet‐Rousselle et al., 
2011).  We could also verify our findings with the use of oxygen electrodes to 
measure and analyse respiratory parameters.   
6.3 PHA-767491 generates DNA damage in ASC52telo cells (chapter 2, 
section 4) 
6.3.1 Morphological markers of genome instability 
The cellular architecture not only provides structural basis to cellular shape, but 
involves many functions necessary for the survival and maintenance of the cell 
(Takai et al., 2005).  In most cells under normal conditions the shape of nuclei is 
usually round or oval (Webster et al., 2009). Alterations can be seen during normal 
development and differentiation (Hampoelz and Lecuit, 2011), and during cell aging 
and genetic diseases (Khatau et al., 2009; Zwerger et al., 2011).   
 
Cellular morphological changes are utilised as markers of chromosomal instabilities; 
aberrant mitotic structures are typically associated with unfinished replication in 
somatic cells, indicative of replicative stress (Mankouri et al., 2013). These include 
abnormalities found within the literature, such as micronuclei, nuclear budding, 
chromatin bridges, and enlarged nuclei (Yoon et al., 2002; Zhen et al., 2002; Hida 
et al., 2004; Hong et al., 2009; El Ghamrasni et al., 2011; Mcgranahan et al., 2012; 
Chen et al., 2014a; Tyagi et al., 2015; Yadav and Bhatia, 2017). Cellular aging has 
been reported to be an influential factor of baseline of these markers, and 
demonstrated in our study (Khatau et al., 2009; Zwerger et al., 2011).  The initial 
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PHA treatment was sufficient to generate DNA damage which either maintained or 
increased with chronic treatment.    
Measurement of the frequency of micronuclei is often used to quantify genotoxic 
stress, and the diagnosis of malignant diseases (Offer et al., 2005; El-Zein et al., 
2006; Verma and Dey, 2014; Tyagi et al., 2015).  Micronuclei were first identified in 
erythrocytes (Dawson and Bury, 1961). They are formed when fragments or entire 
chromosomes separate from the mitotic chromosome ‘bundle’. A separate nuclear 
envelope, complete with nuclear lamina and Nuclear-pore complexes (NPCs), is 
formed around them after cytokinesis. Micronuclei are induced by genotoxic stress 
or loss of factors needed for chromosomal segregation, forming an independent 
nucleus like structure  (Walker et al., 1996; Goshima et al., 2003; Salina et al., 2003; 
Offer et al., 2005; El-Zein et al., 2006). Micronuclei themselves may hold a role as 
an origin of chromosomal instability, following the reincorporation of defective 
micronuclear chromatin into daughter nuclei.  The defects in micronuclei can affect 
DNA repair and replication, leading to the generation of genomic instability 
(Terradas et al., 2016).  Scoring of micronuclei was performed within the criteria set 
by Fenech (2000), who considered them to be morphologically identical to but 
smaller than the cell nucleus, at no more than one third of its diameter.  The 
boundary of micronuclei needs to also be easily distinguishable from the nuclear 
boundary as overlapping edges are referred to as blebs (Fenech, 2000).  To further 
our investigation, we could probe ASC52telo cells for centromeric DNA to identify if 
the observed bridges and micronuclei contain α-satellite DNA, to further identify if 
defects in centric/pericentric heterochromatin are present (Pageau and Lawrence, 
2006). We saw an increased expression of Ki67 in the micronuclei, which has also 
been observed by other laboratories, suggesting a faulty mitotic checkpoint leading 
to mitotic catastrophe, seen in carcinoma development with p53 overexpression 
(Caruso et al., 2011).  
Nuclear buds are another form of nuclear abnormalities, often forming following 
genotoxic stress and γ-irradiation.  They are also called ‘Blebs’ and ‘Nuclear 
protrusions’ (Zaharopoulos et al., 1998; Haaf et al., 1999; Serrano‐García and 
Montero‐Montoya, 2001; Fenech, 2009).   The initiation of bud formation usually 
occurs during S phase of the cell cycle.  They demonstrate the same morphology 
as micronuclei, however, they remain linked to the nucleus via a narrow or wide 
nucleoplasmic stalk (Fenech, 2006). Amplification of DNA becomes selectively 
localised to specific sites at the periphery of the nucleus, forming budding as the 
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surplus DNA is excluded via the nucleus, which can form micronuclei.  The amplified 
DNA may also be eliminated through recombination between homologous regions 
within the sequence, this then forms minicircles of acentric and a telomeric DNA.  
These localise to regions within the nucleus or following segregation localise to the 
nucleus at distinct regions (Shimizu et al., 1998; Shimizu et al., 2000). This suggests 
that the nucleus has an ability to sense excess DNA, and induce a potential DNA 
repair mechanism to eliminate these (Fenech, 2006; Black and Giunta, 2018).  
A further example of nuclear architecture defect is the formation of the doughnut-
shaped nuclei (Reichert et al., 2010; Verstraeten et al., 2011; Dreesen et al., 2013).  
They have been found to form during chromatin decondensation during late mitosis, 
suggesting the involvement of centrosome separation and organization defects 
(Verstraeten et al., 2011). However, Jagannathan et al (2012), did not find a relation 
with centrosomes and suggested an indirect cause following cell cycle perturbation 
(Jagannathan et al., 2012).  The observation of the doughnut-shaped nuclei has 
been linked to an increase of proteasomal degradation of pericentrin (Verstraeten 
et al., 2011). During cell division, the sister chromatids are often connected via DNA 
bridges, most apparently during anaphase.  A subset of these has been found in 
human cells to link to chromosomal fragile sites (Chan et al., 2009; Lukas et al., 
2011). These fragile sites can be susceptible to chromosome breakages, 
translocations, deletions, and associated often with genetic disorders and cancer 
(Durkin and Glover, 2007; Gandhi et al., 2010). The mis-repair of double stranded 
DNA breaks could generate dicentric chromosomes and forming bridges (Fenech, 
2006; Black and Giunta, 2018), which may be the mechanism behind the 
chromosome bridges observed in our study.  
PHA-767491 treated lung cells from p53R172H-KI mice demonstrated inhibition of 
origin firing and reduced micronuclei formation (Singh et al., 2017). However, these 
cells hold a Tp53 mutation, supporting the relationship between p53 expression 
levels and the induction of micronuclei and level of p53 association with 
chromosomal damage reported in other studies (Driessens et al., 2003; Salazar et 
al., 2009).   The study by Huggett et al (2016) did not report cell morphology changes 
using phase contrast light microscopy, and nuclei analysis using DAPI, in human 
(foetal) IMR90 lung fibroblast cells treated with acute PHA-767491, or CDC7 siRNA 
knockdown.  Arrested growth was observed as smaller population of cells, 
consistent with G1 cell cycle arrest (Huggett et al., 2016), which was also 
demonstrated in other studies (Montagnoli et al., 2004; Rodriguez-Acebes et al., 
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2010; Tudzarova et al., 2010).  However, treatment in cancer cells showed 
detachment and cells floated into the media (Huggett et al., 2016).   Altered 
morphology has been reported following PHA-767491 on pluripotent mesenchymal 
progenitor C3H10T1/cells.  CDC7 reportedly holds an important role in α-actin 
filament reorganization and SMC morphology. Acute PHA-767491 treatment (10 
hours) led to an inhibition of α-SMA expression, reduced actin filament-formed 
stress fibres in cells induced with TGF-β (Shi et al., 2012). 
6.3.2  Protein markers of DNA damage 
The micronuclei appeared to be stained positive for γH2AX, indicating they may 
have been generated following double stranded DNA breaks (Rogakou et al., 1998).  
Activation of H2AX can also occur as a result of typical DDR activation seen in 
senescent cells. In fibroblasts these foci were termed Persistent DNA Damage Foci 
(PDDF) (Rodier et al., 2009).  Senescence analysis is required to determine PDDF 
as influential factor within our study.  
We observed induction of γH2AX foci in response to acute and chronic PHA-767491 
treatment.   H2AX phosphorylation occurs in the chromatin structure surrounding 
the DSB site, and near the DSBs the chromatin rapidly de-condenses to allow 
efficient repair (Rogakou et al., 1998; Celeste et al., 2003a; Helt et al., 2005; Kruhlak 
et al., 2006; Heo et al., 2008; Li et al., 2010a).  γH2AX foci start to form at the DSB 
site around 10-30 mins following damage, and remain there until the damage is 
repaired, reaching a plateau within 30 minutes (Nakamura et al., 2006).  
The intrinsic low levels of γH2AX observed in the control cells represent H2AX 
phosphorylation that primarily occurs normally during DNA replication, initially 
reported as a result of stalled and collapsed replication forks (Yoshida et al., 2003).  
Induction can also occur in mitotic cells where they form nuclear foci that are not 
due to DNA damage, and importantly do not induce a DNA damage response via 
downstream proteins (Mcmanus and Hendzel, 2005; An et al., 2010). This suggests 
the cell cycle may play a role in γH2AX induction, and also a decrease seen may 
not accurately reflect reduced DNA damage (Ichijima et al., 2005; Tu et al., 2013).  
To verify our findings, cell cycle analysis would be performed using flow cytometry, 
to verify levels of H2AX found in proportion to intrinsic histone content, and cell cycle 
specific expression, particularly important in cells treated with PHA-767491 
(Macphail et al., 2003; Kataoka et al., 2006).    
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γH2AX levels have been reported to increase with PHA-767491 treatment of Capan-
1 pancreas adenocarcinoma, and PANC-1 pancreatic ductal epithelial carcinoma 
cells, but not in IMR90 lung fibroblasts cells.  The cells were treated for 96 hours, in 
contrast to our prolonged treatment. Cancer cells maybe more sensitive; increased 
Cdc7 and Dbf4 has been demonstrated in many human malignancies (Bonte et al., 
2008; Huggett et al., 2016);  however, not all cancer cells demonstrate a similar 
effect (Montagnoli et al., 2004).  Importantly, as we suspect within our PHA-767491 
model, the expression levels of Cdc7-Dbf4 may hold a role in aiding survival of some 
cancer cells by enhancing replication stress tolerance following the induction of 
ssDNA and dsDNA breaks (Bonte et al., 2008; Cheng et al., 2017). Taken together, 
this suggests that some human malignancies may require a certain level of CDC7 
expression to aid tumorigenesis. 
A common way to measure γH2AX foci is performed by immunofluorescence, other 
methods include western blotting, or flow cytometry (Nakamura et al., 2006).  The 
use of CellProfiler software to quantify foci excludes qualitative factors such as 
variation of the foci due to cell cycle phase, giving a further advantage of counting 
individual foci as opposed to overall intensity. We indeed observed discrepancies 
between data obtained with foci counts and intensity measurements. Nevertheless, 
analysis with flow cytometry alongside would verify our findings, and would be used 
to further our study.  
TRF2 and other members of the shelterin protein complex prevent the recognition 
of telomeres as a DNA break that would lead to repair, repressing the repair at 
chromosomes ends.  This is very important for maintaining genome organization 
into separate chromosomes.  If repression does not occur this leads to chromosomal 
fusions and genomic instability (Reddel, 2014).  Reduced levels of TRF2 observed 
in our work could represent TRF2 degradation following DNA damage, as reported 
in the literature (Saha et al., 2013). Changes of nuclear morphology indicative of 
chromosomal instability were shown to increase with both acute and chronic PHA 
treatment. A study by Saha, (2013) reported a link with TRF2 intensity with the 
degree of nuclear morphology changes (Saha et al., 2013).  To further our study, 
nuclear contour ratios could be calculated to determine if a correlation between 
these markers occurs in our system.  
DNA damage foci that occur at uncapped telomeres and identified by DNA damage 
response factors (53BP1, γH2AX, Rad17, ATM, and MRE11) that co-localise with 
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telomeres and shelterin proteins are referred to as Telomere dysfunction-Induced 
Foci (TIFs) (Karlseder et al., 1999; De Lange, 2002; Takai et al., 2003; Zhang et al., 
2017a).  In our study we determined TIFS by analysing the colocalization of γH2AX 
and TRF2 to identify damage at the telomeres. γH2AX foci have been demonstrated 
in many studies showing robust correlation with replicative telomere shortening 
reflecting age-dependent telomere dysfunction-induced foci  (Takai et al., 2003; 
Sedelnikova et al., 2004; Sharma et al., 2012).  Significant co-localisation was 
shown in low passage cells, however, the same was not seen in high passage cells.  
High passage control cells appeared to generate similar TRF2 levels in comparison 
to low passage control cells.  In all cell passages and treatments, the evidence that 
not all γH2AX foci colocalised with TRF2 foci suggests that the DNA damage 
generated is not concentrated to the telomeres. There could also be reduced 
response, degradation of TRF2 over time, or reduced maintained telomerase (Chu 
et al., 2016).   The damaged telomeres may fuse with broken DNA ends as the cell 
progresses through the cell cycle, generating a dicentric chromosomes (Vukovic et 
al., 2007).  The consequent breakage of the anaphase bridge leads to new 
chromosome free ends, which fuse again with exposed DNA, initiates breakage-
fusion-bridge cycles (Zheng et al., 1999) and could lead to the morphological signs 
of genome instability we also observed in or model.  TIFs can be more easily 
detected by analysing the co-localisation of 53BP1 foci with TRF1 (Takai et al., 
2003), Nevertheless, our model uses hTERT immortalised cells and telomerase 
expression may be an influential factor.   
The DNA damage evidence in PHA-767491 cells led to analysing a DNA damage 
response by looking at expression levels of effector proteins CHK1, phosphorylated 
CHK1 and 53BP1. CHK1 holds many roles, including checkpoint control, a direct 
role in cell survival, and the regulation of DNA repair (Sanchez et al., 1997;Sørensen 
et al., 2005; Dai and Grant, 2010; van Jaarsveld et al., 2019), and has been shown 
to be important for cell proliferation (Takai et al., 2000; Shimada et al., 2008).   
Disruption can lead to cell death or cellular defects, or human disease following 
monoallelic loss of CHK1 (Zhang et al., 2005; Tang et al., 2006; Boles et al., 2010).  
Decrease in CHK1 levels under normal conditions or cellular stress is mainly due to 
proteasome-dependent degradation (Merry et al., 2010), which can be further 
influenced by nutrient restriction, histone deacetylase inhibition, and other 
interacting proteins (Xu et al., 2004; Zhang et al., 2005; Brazelle et al., 2010; Li et 
al., 2010b). Reduced levels can also be due to stresses that lead to the activation 
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of p53-dependent G1/S arrest, which inhibits E2F-dependent transcription of CHK1, 
found to be important in the rise of levels during G1 / S transition (Gottifredi et al., 
2001).  Genotoxic stress can lead to a delay of progression through S or G2 phases 
of the cell cycle, and is caused by the phosphorylation of CDC25A and CDC25C 
phosphatases by CHK1, which inhibits their activity, consequently inhibiting the 
dephosphorylation of cyclin-dependent kinases CDK1 and CDK2 ( Bartek et al., 
2004; Sørensen et al., 2005; Goto et al., 2019), thus delaying mitotic entry and 
allowing DNA repair mechanisms to follow (Sanchez et al., 1997;  Brown and 
Baltimore, 2003). If CHK1 is inhibited, it can enable the cell to continue the cell cycle 
with sustained DNA damage, potentially leading to cell death (Sørensen et al., 
2005).   
The activation of CHK1 stabilizes the CDC7-DBF4 kinase complex, assisting in 
replication (Yamada et al., 2013), and is important for intra-S and G2/M cell cycle 
checkpoints  (Sanchez et al., 1997; Zhao et al., 2002; Brown and Baltimore, 2003; 
Petermann et al., 2006; Heffernan et al., 2007; Segurado and Diffley, 2008).  Certain 
number of the ASC52telo cells would be reversibly arrested at G1 phase within the 
cell cycle due to the PHA-767491 (Rodriguez-Acebes et al., 2010), therefore, we 
could expect this may influence CHK1 activity, also due to the inhibition of Cdc7 be 
it mild.  Interestingly, Montagnoli and co-workers observed that PHA-767491 does 
not lead to a sustained DNA damage response (Montagnoli et al., 2008b). They did 
not detect CHK1 phosphorylation at Ser345, and only low levels of CHK2 
phosphorylation at Thr68, following PHA-767491 treatment in HeLa cells. Although 
an increase in γH2AX expression was seen, they suggested this may be a 
secondary effect.. In our study, slight increase of phosphorylated CHK1 at 
endogenous levels was only seen in low passage chronic PHA-767491 treated cells, 
which requires further verification. 
53BP1 has been shown to initiate the phosphorylation of H2AX and other proteins, 
to proceed a DNA repair response (Ward et al., 2005; Lee et al., 2010; Noon et al., 
2010), and promotes DNA end linking during chromosome remodelling (Manis et 
al., 2004; Ward et al., 2004).  53BP1 has a role in the early event of tumour 
progression, influencing proliferation, apoptosis and cell cycle (Nuciforo et al., 2007; 
Bi et al., 2015).  An increase of 53BP1 expression in cells under acute PHA-767491 
could demonstrate an initial response; however, expression appears to be reduced. 
Nevertheless, in some chronic treated cells a significant increase was seen, 
suggesting that the long-term DNA replication interference could still generate 
Page | 185  
 
53BP1 response.  Apoptosis or senescence often follows as a response to 
irreparable DNA damage (Elmore, 2007).  The acute treated cells could be more 
sensitive to the initial treatment and induce cells into apoptosis as an alternative to 
repair.  Quantifying apoptotic and senescent could determine if this is an influential 
factor within our study. Although not significant, reduced expression was seen in 
high passage chronic PHA-767491 cells under recovery, which could indicate during 
long term treatment these cells lost the capability to initiate a 53BP1 mediated 
response, indicating a reduced DNA damage response.  The lack of expression may 
relate to the increase in genomic instabilities seen in these cells. If 53BP1 can 
activate CHK1 (Bartek and Lukas, 2003), we may have expected to see a correlation 
between them, which may be the case in high passage cells.    
Deregulation of cell proliferation has been found to lead to DNA damage response 
activation mainly via the ATM and ATR pathways (Hahn et al., 1999) (Bartkova et 
al., 2005; Gorgoulis et al., 2005; Bartkova et al., 2010). Interestingly, this activation 
in normal cells would lead to a barrier against uncontrolled cell growth, a hallmark 
of cancer cells.   In tumour cells this activation however leads to removal of this 
barrier through one or more losses of DNA damage response capabilities, 
increasing genomic instability, and the higher dependency on the remaining DNA 
damage response (Halazonetis et al., 2008; O’connor, 2015). A cancer cell acquires 
a number of central genetic lesions that enable alterations to the normal multicellular 
development and expansion of cells, allowing intratumoral diversification and the 
development of cancer subclones. These cells harbour variations of genomic 
modifications, which differ from the surrounding tumour cell population. Patients who 
present this heterogeneity show poor prognosis and increase in relapse following 
cancer treatment, which is a feature of OS (Landau et al., 2013; Landau et al., 2015; 
Andor et al., 2016; Mcgranahan et al., 2016). A driver of this process is chromosomal 
instability (Bakhoum and Landau, 2017).  
6.3.3 Interference with DNA replication initiation leads to cellular 
transformation (chapter 2 section 4.2) 
The degree of chromosomal instabilities is not the only influential factor for 
tumourigenesis.  To assess whether the chromosomal instability we observed 
following chronic PHA treatment correlated with the acquisition of tumourigenic 
characteristics, we further analysed the cells for anchorage-independent growth and 
loss of contact inhibition, hallmarks of tumour cell development.  Modification of 
adhesion is classed within the first change of cellular adaptation and is also involved 
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in the metastasis stage (Jinka et al., 2012).  In normal cells the detachment from the 
extracellular matrix, or cell adhesion to an inappropriate location induces a type of 
apoptosis, often termed as anoikis, triggered by the loss of interaction between the 
cell and the extra-cellular matrix (ECM) that mediates cell death (Frisch and 
Ruoslahti, 1997; Frisch and Screaton, 2001; Lee et al., 2016).  Anoikis was first 
described in epithelial and endothelial cells and protects cells when adherent on 
permissive ECM proteins (Frisch and Francis, 1994).  Anoikis is a Greek word 
meaning loss of “home” or “homelessness”, and holds an important role in the 
prevention of detached cells adhering to new locations and potentially initiate 
dysplastic growth.  The failure of this regulation can lead to adherent cells detaching 
from supportive matrix due to loss of survival signals from cell-ECM interactions, are 
able to survive under suspension conditions or capable of proliferation with 
alternative ECM proteins at ectopic sites. Tumour cells, including osteosarcoma, are 
able is to resist anoikis, and to grow and survive without anchorage to ECM (Liu et 
al., 2008; Taddei et al., 2012; Zhu et al., 2013; Gao et al., 2018). Osteoblasts secrete 
ECM that is a major component for mature bone, and important mechanical 
receptors that signal bone matrix formation and the promotion of mineralization 
following mechanical strain (Wozniak et al., 2000; Simmons et al., 2003). Secreted 
ECM-related proteins include osteonectin, osteopontin (OPN), osteocalcin (OCN), 
bone morphogenetic protein 2 (BMP-2), and type I collagen, and promote vascular 
endothelial growth factor (VEGF) synthesis (Bhatt et al., 2007). 
Adult tissue derived MSCs retain adherence to plastic dishes in laboratory culture 
(Da Silva Meirelles et al., 2006). Adipose derived MSCs also hold this characteristic 
(Grossmann, 2002). Cell clump (spheroids) formation was observed in our PHA 
model indicating potential anchorage-independent cell growth. Although a few small 
spheroids were seen in some of the control conditions on ultra-low attachment 
plates, these appeared rare and indicated a growth rate significantly lower than the 
chronic treated high passage cells. 
MSC spheroids have been shown to maintain differentiation, and allow a novel 3D 
culture model in comparison to adherent monolayer systems (Baraniak and 
Mcdevitt, 2011).  Long term culturing of ASCs as 3D spheroid culture leads to 
efficient and enhanced proliferation, with unaltered adhesion capacity demonstrated 
with re-attachment.  Alterations of cell-to-ECM interacting protein expression have 
also been found in MSC spheroids compared to scraped or trypsinised MSCs, 
Page | 187  
 
suggesting that spheroid growth leads to cellular changes advantageous to 
proliferation and growth (Lee et al., 2016).    
The soft agar method has been the gold-standard, sensitive assay for many years 
for exploring anchorage-independent growth (Macpherson and Montagnier, 1964; 
Conery and Harlow, 2010; Hasebe-Takada et al., 2016); however, the soft agar 
assay is unsuitable to demonstrate tumourigenic conversion from hTERT 
transduction (Jiang et al., 1999; Wolbank et al., 2009; Zhang et al., 2017c). Instead, 
we grew the cells in plates treated to reduce attachment surface (Fukazawa et al., 
1995).  The ultra-low attachment plates used in our study have a neutrally charged, 
hydrophilic surface with covalently bonded hydrogel layer that minimises attachment 
(Corning 3474), (Basu-Roy et al.; Douma et al., 2004; Boschelli et al., 2008; Dottori 
et al., 2010; Neri et al., 2013). Several studies have used similar techniques and 
observations as to our study, to determine malignant transformation (Ward et al., 
2013; Giannakouros et al., 2015). 
To further our analysis staining using crystal violet dye can be used, binding to 
proteins and DNA, and indicating cell viability, colony formation (Zhang et al., 
2017c), and anoikis in vivo  (Pedanou et al., 2016).  It is a method used often in the 
literature, however, similar to using the MTS assay, as the cell clumps appear large 
the permeability of the stain would be a concern.  Another methodology for cell 
clump quantification would be the flow cytometry-based pulse-width assay, which is 
reported to show high level of accuracy, and sensitivity (Hickerson et al., 2014; Cui 
et al., 2016),    Quantifying the clumps alone could be used, however, in our study, 
the treated cell clumps appeared larger, therefore the cells appeared to favour 
grouping together rather than producing smaller and many clumps.  It would be 
interesting to analyse our PHA-767491 treated cells for anoikis in vivo, to determine 
if reduced regulation may be leading to the potential anchorage-independent growth 
observed (Kang et al., 2007; Rago et al., 2008).  
Another cellular transformation hallmark includes the loss of contact inhibition.  Our 
findings initially showed that acute PHA-767491 treatment reduced cell proliferative 
rate, however, we wanted to investigate if the cellular modifications that we 
observed, including anchorage-independent growth, led to a loss of contact 
inhibition in these cells. ASC52telo cells have been reported to display normal 
contact inhibition properties (Wolbank et al., 2009).  In confluent adherent cell lines, 
contact inhibition is defined as a major decrease in cell mobility and mitotic rate in 
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relation to increasing cell density, and a stationary state insensitive to nutrient 
renewal following confluency, in spite of the availability of growth factors and 
nutrients (Levine et al., 1965; Huttenlocher et al., 1998; Halbleib and Nelson, 2006; 
Takai et al., 2008; Zeng and Hong, 2008; Heckman, 2009). In particular, fibroblast 
cells display density-dependent inhibition and the extent of quiescence is 
proportional to serum growth factor concentrations within the growth medium in 
culture (Cooper and Hausman, 2000).   
The formation of cell clumping observed in our study in PHA-767491 treated cells 
could lead to under-represented cell quantity, as individual cells could not be 
quantified within the cell clumps.  Grzesiak and co-workers (2011) observed similar 
cell clump formation following culture of equine adipose derived primary cells  
(Grzesiak et al., 2011).  Undifferentiated adipose derived stem cells form spheres, 
thought to be neurospheres, spontaneously when cultured at high density (Kang et 
al., 2004b; Ivascu and Kubbies, 2007; Meyer and Walter, 2016; Schmidt et al., 2016; 
Zhang et al., 2017b).  Chronic PHA treatment did cause more variable cell viability 
over the culture time measured by trypan blue; however, it remained above 95%, 
demonstrating good rate of cell survival in culture (Ribeiro et al., 2006).   
 
We used protein concentration measurements to gain a better insight of cell growth.  
However, protein concentrations may alter due to conditions of the cell, and changes 
may occur when cells are under stress (Gasch et al., 2000; Brauer et al., 2008; 
Keren et al., 2013; Barenholz et al., 2015), or are in different cell cycle phase 
(Cookson et al., 2009).  Changes in protein concentrations also relate to the 
proliferative state of the cell, an increase in bio-synthesis machinery genes leads to 
faster growth.  Barenholz et al, (2015) suggested a model where cell growth leads 
to production of proteins at the same rate as protein degradation.  These 
suggestions could explain the variable protein concentrations we observed.  
Nevertheless, results obtained with cell count and protein concentration 
measurements show some correlation. An increase was shown in general in acute 
PHA-767491 treated cells, although this did decrease following further culturing. 
High passage chronic treated cells following recovery demonstrated overall 
significant increase in proliferation over the 21 days of culture.  Repeats are required 
to verify this finding, as not always seen, but suggests continual growth in these 
cells.  We do need to consider that the cells may catch up following release of 
treatment.  Further culturing and other analysis are required.   
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The RealTime-Glo MT cell viability assay (Promega) is a nonlytic assay. It 
measures the reducing potential of viable cells in an ATP-independent manner, is 
well tolerated by cells and luminescence signal can be retaken up to 72 hrs of 
incubation, which provides kinetic data allowing the possibility to monitor cellular 
changes over time. The assay utilises a pro-substrate, and an engineered luciferase 
added to the media. The MT cell viability pro-substrate is cell-permeant and diffuses 
into the cells in culture.  This is reduced by metabolically active cells forming a 
NanoLuc® substrate that diffuses out of the cells, and rapidly used by A NanoLuc® 
Enzyme that is also added to the media, producing a luminescent signal (Hall et al., 
2012).  The assay result correlates with the quantity of metabolically active viable 
cells, and is affected by the number of cells per well, and their overall metabolic 
activity.  High number of cells, however, results in loss of linearity (Riss et al., 2015).  
Our study showed the initial reading (day 21) appeared sufficient as demonstrated 
high cell density across the cultures, treated and controls, although no significant 
differences at time of reading. However, a high reduction of signal was observed 
after 72 hours in all cells, which was unexpected and could suggest loss of cell 
viability. When viewed microscopically the cells, however, appeared viable 
suggesting this was not the case. To verify cell viability, I performed an MTS assay 
following further culture time on the same cells, which demonstrated cell viability, 
and further that high passage cells released from chronic PHA treatment showed 
increased cell numbers.  The same was not shown in low passage cells, suggesting 
potential cellular changes may occur following chronic treatment.  There are a 
number of possible reasons for the reduced luminescence readings obtained with 
the RealTime-Glo MT kit, which occurred following experimental repeats.  As a 
luminescent assay, exposure to sources of light could have led to the reduction of 
output.  High light intensity may also lead to an increase in the decay rate of the 
reaction (Deluca et al., 1979). Further repeats and potential experimental design 
modifications would enable the use of the RealTime-Glo MT kit in further 
investigations in our study, but in this instance, it did not meet expectations. 
Nevertheless, the finding that chronic PHA-767491 recovery cells continue to 
proliferate was generally confirmed with each technique.  Extending the time in 
culture would be important, and  to distinguish between the loss of contact inhibition 
and slow growth further studies are required.  β-galactosidase activity assay would 
highlight the cells under senescence, and contact inhibition as both are associated 
with lysosomal activation (Knecht et al., 1984; Severino et al., 2000; Leontieva et 
al., 2014). It would be important to determine if PHA-767491 treatment generates 
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senescent cells alone.  Modifying the methodology by seeding the cells initially at 
high density has been used within the literature (Leontieva et al., 2014), and would 
enable further verification of our results.   
A study by Røsland et al (2009), was the first to report spontaneous malignant 
transformations that occurred in 45.8% of long term cultured bone-marrow derived 
human mesenchymal stem cells (hMSC), followed by a number of other reports. 
However, contamination was admitted generating artefactual results and suggested 
to be the ‘cause’ of transformation (Rubio et al., 2005; Røsland et al., 2009; Torsvik 
et al., 2010). A more recent study, however, observed tumorigenic transformation 
during long-term culture, and was confirmed not to be due to contamination with 
other human cell lines (Pan et al., 2013). Due to risk of contamination during long 
term culturing it is therefore crucial that rigorous aseptic working procedures are 
followed to reduce artefactual results indicating transformation, observed in early 
reports.  This also highlights the need to characterise the cell type, discussed in the 
next chapter.  
In summary, our model of replicative stress in ASC52telo cells verified our thoughts 
as DNA damage was shown.  In particular, prolonged replicative stress may lead to 
a reduced or impaired response leading to sustained DNA damage and cell 
transformation, as depicted in Schematic 6.3-1.    
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Schematic 6.3-1 cell damage response in ASC52telo cells treated with PHA-767491.  ASC52telo cells under PHA model demonstrate increased DNA damage following replicative stress induced by PHA-767491. 
Chronic treatment appears necessary for sustaining DNA damage and developing features seen in cellular transformation. 
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6.4 ASC52telo genotype verified (chapter 2, section 4.3).   
Throughout my investigations, to ensure cellular changes in high passage cells were 
considered, we used matched high passage number cells as a control to the long 
term treated cells, to demonstrate the cellular changes were due to conditions of 
treatment rather than passage.  
Short tandem repeats (STRs) contain 3-7 base pair long sequence units repeated 
in tandem, dispersed across the genome.  The number of repeat units at the same 
locus varies between individuals, and the haplotype of several loci combined 
together can identify individuals (Jeffreys et al., 1985b; Litt and Luty, 1989; Weber 
and May, 1989; Edwards et al., 1991; Rassmann et al., 1991; Moretti and Budowle, 
1998), and as in our case cells and cell lines, at an astonishingly high power of 
probability. When amplified with PCR they can be differentiated using fluorescent 
primers that flank the repeat sequences at hypervariable regions (Jeffreys et al., 
1985a; Jeffreys et al., 1985b; Saiki et al., 1985; Edwards et al., 1991; Warne et al., 
1991; Edwards et al., 1992).  It is crucial to determine origin, phenotype, and 
contamination in cell lines. The method utilised (GenePrint® 10 System) enabled 
co-amplification and detection of 10 human loci, following the amplification of STR 
regions of human genomic DNA with ILS, and run by capillary electrophoresis to 
determine the size of the amplified samples.  The random match probability of the 
system is 1 in 2.92*109 (Promega).  Our ASC52telo cells at different stages of 
passage and treatment have been verified, and the possibility of contamination with 
other (tumour) cell lines was ruled out.  Cell line authentication has been set as an 
important standard of the literature (Masters et al., 2001; Dunham and Guthmiller, 
2009; Stacey et al., 2014; Yu et al., 2015). Standards have been issued regarding 
the authentication of the use of human cell lines by the American Tissue Culture 
Collection Standards Development Organization Workshop.  To further our analysis 
the European Medicines Agency reported the analysis of senescence in vitro 
following several passages could be utilised to indicate the absence of 
immortalized/tumourigenic cells, aiding the quality control of MSCs, and highlighting 
cross contamination (Emea, 2009).    
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6.5 RECQL4 expression and proliferation (chapter 3, section 5) 
The role of RECQL4 in DNA replication, repair and telomere maintenance is well 
documented, therefore, we would assume that loss leads to an effect on cellular 
growth and lifespan (Ghosh et al., 2012; Davis et al., 2013; Ferrarelli et al., 2013).  
RECQL4 expression has been found to correlate with cell proliferation activity 
(Bachrati and Hickson, 2003; Yang et al., 2006; Lu et al., 2014a).   The study by 
Yang et al, (2006) demonstrated decrease of proliferation in MC3T3.E1 cells 
following the knockdown of Recql4 using siRNA silencing.  On the other hand, 
overexpression was shown to lead to cell growth in mouse osteoblastic cells (Yang 
et al., 2006).   A more recent study found that the disruption of Recql4 reduced 
proliferation in mouse osteoblasts (Ng et al., 2015), and in Drosophila (Xu et al., 
2009a).  Tissue and cell specific expression patterns have also been shown for 
RECQL4 mRNA with northern blotting analysis.  High expression correlates to 
higher number of intensively proliferating cells. It is not surprising, therefore, that 
tissues and organs with the highest expression are strongly affected contributing to 
the pathological features seen in RECQL4 related syndromes (Larizza et al., 2010; 
Wang and Plon, 2016). The expression profile of RECQL4 has been found to be 
consistent with the skeletal defects most often seen in patients with RTS (Larizza et 
al., 2010; Wang and Plon, 2016).  Interestingly, RTS patients usually have a normal 
lifespan in the absence of cancer despite presentations of premature aging  (Hofer 
et al., 2005; Jin et al., 2008; Larizza et al., 2010).  
In our study, RECQL4 expression levels appeared variable during cell culture 
between U2OS and HeLa cell lines.  The study was small and repeats are needed, 
however, we employed different indicators of proliferation and viability to verify our 
findings. Nevertheless, a steady increase and decrease in RECQL4 expression in 
U2OS cells was found correlating to cell count levels.   
In cancer cell lines, we would not expect to find contact inhibition. HeLa cells 
demonstrate rapid growth and a lack of contact inhibition (Stephenson, 1982).   
Other authors report that HeLa cells in culture maintain contact inhibition (Schwab, 
2008), however, it might reflect clonal variability of this cell line that is used in 
laboratories all over the world.  We observed reduced but apparently continual 
growth rate following confluency under our conditions.  Other studies have reported 
long term culture leading to continual growth as cells pile up and detach in batches 
(Delinasios et al., 2015).   
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There are a few similarities in the expression pattern of RECQL4 involving ubiquity, 
showing higher levels in proliferating cells, and cell cycle phase specific distribution. 
Peak of expression is seen at S-phase of the cell cycle (Bachrati and Hickson, 2003; 
Dietschy et al., 2009; Croteau et al., 2012b).  Certainly, there appears a correlation 
between RECQL4 expression with Ki67 expression and the proliferative state of the 
cells, however, repeats and further analysis are required to confirm.  
 
We did experience difficulties culturing the AG03587 cell line; it appears to 
proliferate very slowly and goes into senescence more readily than the other RTS 
cells lines. Cell viability measurements alongside are also required to ensure this is 
not a contributing factor to the results obtained.   The AG18375 cell line harbours a 
confirmed RECQL4 mutation at chromosomal location 8q24.3 (g.2626G>A and 
g.2886delT), and the patient presented with OS at 21 years of age (Gupta et al., 
2013).  RECQL4 mutations are thought to lead to partially active protein in some 
RTS cases (Ouyang et al., 2008).  In our study, the effect on proliferation in culture 
could be due to cell specific features, or specific RECQL4 mutation.  
6.6 Generation of Emerald-GFP tagged RECQL4 expression constructs 
(chapter 3, section 5.2) 
RECQL4-emerald tagged HeLa and U2OS cells were established successfully, and 
following signal analysis, the induced expression appeared to be localised mainly in 
the nucleus, but also to cytoplasm in HeLa and U2OS cells.  Of the RecQ helicase 
family, RECQL4 is the only one known to be found both in the nucleus and 
cytoplasm (Yin et al., 2004; Petkovic et al., 2005; Burks et al., 2007). There are 
contradicting results within the literature relating to RECQL4 localisation, which 
could be due to the antibodies and methods used, and could explain the diverse 
results (Yin et al., 2004; Petkovic et al., 2005: Schurman et al., 2009; Chi et al., 
2012; Monaghan and Whitmarsh, 2015).  RECQL4 has two signals regulating its 
presence in the nucleus. A nuclear localisation signal (NLS) is located at the N-
terminus (amino acids 363-492) (Yin et al, 2004,  (Burks et al., 2007), while the C-
terminus harbours a functional nuclear export signal (NES), which may be important 
for cytoplasmic localisation and for mitochondrial maintenance. Diminished 
cytoplasmic localization was observed following the deletion of this NES (Chi et al., 
2012). Localisation of RECQL4 may also be influenced by cell cycle phases 
(Petkovic et al., 2005). The phosphorylation of the NLS has been found to be 
important for many cell cycle related proteins for nuclear localisation (De et al., 2012; 
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Bauer et al., 2015), while acetylation has been reported to influence recognition of 
localisation signal. RECQL4 is acetylated by p300, a histone acetyltransferase, 
leading to localisation to the cytoplasm (Dietschy et al., 2009).   
Interestingly, a recent study further suggests RECQL4 main activity may be located 
within the mitochondria, and re-location to the nucleus allowing nuclear genome 
maintenance.  Mitochondrial localisation of RECQL4 has been found in a few other 
studies as well (Chi et al., 2012; Croteau et al., 2012a; De et al., 2012; Gupta et al., 
2013; Wang et al., 2014b), which could explain some of the phenotypic features 
seen in RTS patients (De et al., 2012).  RECQL4 intracellular distribution and 
dynamic re-localization to sites of DNA damage has suggested to be a possible 
contribution to phenotypes and associated heterogeneity, which has been found in 
RECQL4-associated diseases (Croteau et al., 2012b).  
Tagging of proteins with the small and versatile GFP provides a scalable method to 
study localisation and protein-protein interactions (Leonetti et al., 2016).  Using the 
same direct method utilised in our study, GFP-tagged RECQL4 was also reported 
to be predominantly localised to the nucleus in U2OS cells, however, a small 
percentage was observed localised to the cytoplasm.  Additionally, mitochondrial 
localisation was also seen  (Woo et al., 2006; Chi et al., 2012).  The GFP tag may 
influence the localisation of the protein. It has been reported that GFP translocates 
to the nucleus itself (Seibel et al., 2007), although it may be mediated by its 
capability diffusing through the nuclear pores passively. Overexpression of tagged 
proteins can lead to effects on structure, function, and localisation of the protein 
(Agbulut et al., 2006; Das et al., 2009), which also depends on whether the tag is 
on the amino or the carboxy terminus (Simpson et al., 2000; Giraldez et al., 2005). 
The promoter used on the plasmid vectors for transient transfection, such as CMV, 
can increase the protein amount present within the cell (Deer and Allison, 2004; Qin 
et al., 2010), which has been found to also influence sub-cellular localisation and 
function.  Cells expressing low levels of fluorescent tagged protein under inducing 
conditions are ideal for further work, (Watanabe and Mitchison, 2002; Taylor et al., 
2011), and in our study we chose low expressing clones.    
6.6.1 siRNA 
The study by Abe et al, (2011) suggests that a complete loss of RECQL4 in humans 
would be lethal (Abe et al., 2011).  Knockdown of RECQL4 has been shown to 
correlate with reduced proliferation in primary fibroblast (Lu et al., 2014).  
Page | 196  
 
Senescence was detected without an increase of apoptosis (Lu et al., 2014), 
consistent with studies in the literature of senescent cells being resistant to 
apoptosis (Hampel et al., 2005), however, an increase in cell death was 
demonstrated suggesting another pathway may be involved.  Development of 
senescence could be a result of oxidative stress (Lu et al., 2014).  Senescent cells 
have been shown to be irreversibly arrested in G1/G0 cell cycle phase (Sherwood 
et al., 1988), and RECQL4 knockdown was shown to lead to accumulation of cells 
in G0/G1 (Lu et al., 2014).  Senescence induced by replication defects usually leads 
to cell cycle arrest during G1 or G2 of the cell cycle (Mao et al., 2012).  Considering 
this, RECQL4 knockdown appears to lead to stress induced cell cycle arrest (Lu et 
al., 2014).  In both mouse and human cells RECQL4 dysfunction generated an 
increase in DNA damage, and increases senescence  (Lu et al., 2014).        
RECQL4 siRNA 9 and 10, targets the 3’ untranslated region of the RECQL4 mRNA.  
This mode of targeting found to be more effective than targeting the open reading 
frame (ORF) (Forman et al., 2008; Gayral et al., 2014).  The targeting of these 
sequences occurs following perfect and imperfect complementarity.  The direct 
cleavage and degradation of the mRNAs follows perfect complementarity, while 
imperfect complementarity leads to blockage of transcription and inhibition of protein 
synthesis from the target mRNA (Zhang et al., 2015),  both leading to reduced 
protein content. Factors affecting these processes include flanking sequence, 
location within the 3’-UTR, and the accessibility of target mRNA (Grimson et al., 
2007).  A key issue described in the literature is off-target gene silencing which may 
also involve other influential factors (Jackson and Linsley, 2004; Birmingham et al., 
2006; Jackson et al., 2006). In our work we used siRNA molecules that had been 
designed by the supplier, Qiagen using a novel algorithm that minimizes the risk of 
off-target effect (Li and Zamore, 2019).  
Primary RTS fibroblasts (AG05013tert) demonstrated sensitivity to PHA-767491, 
not seen in HeLa and U2OS models. Repeats are needed to verify our initial 
findings, but this may not seem unexpected when taking into account that siRNA 
mediated knockdown did not reach 100%, and the effects are often reversed over 
time as previously described, compared to AG05013 cell line that carries an 
inactivating mutation of RECQL4.  We also need to consider that these two cell lines 
originate from malignant cancers.  Depleting RECQL4 in fibroblast cell lines such 
as hTERT immortalised HS68 might provide answers to this contradiction  
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6.6.2 shRNA 
A long-term aim of our work is to interfere with RECQL4 expression in mesenchymal 
stem cells under standard culturing conditions or during osteogenic differentiation 
to establish why people with biallelic RECQL4 mutations develop osteosarcomas. 
To achieve this, we established a rescueable siRNA mediated knockdown system 
in standard laboratory cell lines, and vectors for lentivirus mediated transduction for 
shRNA knockdown. Unlike synthetic siRNA, which are effector molecules 
introduced directly into the cells, short-hairpin RNAs (shRNAs) are introduced 
indirectly. The constitutive expression of shRNA molecules can be achieved by RNA 
polymerase II or III -driven expression cassettes (Scherer and Rossi, 2003).  shRNA 
integration via viral vectors into mammalian cell lines have been demonstrated to 
induce stable transduction, and long-term gene knockdown (Taxman et al., 2010).  
The recombinant constructs generated in our study were verified using standard 
protocols employed by a number of other laboratories successfully (Inouye et al., 
1981; Roberts, 1987; Woollard et al., 1994; Yu et al., 2003; Seo et al., 2015; Yu et 
al., 2016).  In the literature successful use of RECQL4 knockdown using shRNA 
have also been reported (Croteau et al., 2012a; Ghosh et al., 2012). 
6.7 RECQL4 expression and DNA damage markers (chapter 3, section 5.24) 
RECQL4 has an important role in replication initiation, and chromosomal instabilities 
could occur if altered RECQL4 expression leads to an extension in the time of 
exposure of single stranded DNA, whereas high expression could cause unmatched 
annealing, and depletion could lead to impaired reannealing (Macris et al., 2006). 
Maire and co-workers (2009) found a correlation between RECQL4 expression 
levels and a higher frequency of structural chromosomal changes (S-CIN) 
associated with OS, however they did not observe a relationship with N-CIN 
(numerical chromosomal instabilities) (Maire et al., 2009). RTS patients have been 
found to demonstrate both N- and S-CIN (Der Kaloustian et al., 1990; Ying et al., 
1990; Orstavik et al., 1994; Lindor et al., 1996; Miozzo et al., 1998).  Chromosomal 
instabilty in vivo may lead to neoplastic transformation of cancer stem/progenitor 
cells which are sensitive to RECQL4 mutations.  Mesenchymal cells may be 
especially sensitive, which are thought to give rise to tumours in RTS patients 
(Larizza et al, 2010). Cells isolated from a mouse model of RTS type II showed 
aneuploidy due to defects in sister-chromatid cohesion, which suggested a role for 
the RECQL4 helicase in sister-chromatid cohesion and mitotic chromosome 
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segregation, a potential source of chromosomal instability and cancer predisposition 
(Mann et al., 2005).  
RTS fibroblast cell lines showed slightly reduced growth rate, and appeared to be 
moderately sensitive to gamma-irradiation and generated higher levels of H2AX 
and 53BP1 foci, in comparison to control fibroblasts (GM00323 and GM00969), 
suggestive of defective repair of DSBs (Singh et al., 2010). RECQL4 also found to 
colocalize with γH2AX, suggesting RECQL4 binds to DSB (Singh et al., 2010). 
H2AX foci count has also been found to be increased, suggesting that deficiency 
of RECQL4 activated a DNA damage response using ATM (Lu et al, 2014);  
however, was not found to be significantly increased in our study.  Our findings could 
be extended by probing for other markers of DNA damage, for example 53BP1.   
The RECQL4 helicase resolves telomeric D-loop structures with the help of shelterin 
proteins TRF1, TRF2, and POT1, which stimulate its helicase activity.  RECQL4 
may also work synergistically with WRN by unwinding telomeric D-loops, and may 
assist WRN and BLM following oxidative stress.  RECQL4 depletion induces crisis 
sites at telomeres via the activation of 53BP1 DNA damage response protein, 
although the cause could be due to replicative stress (Ghosh et al., 2012).  The 
promotion of telomeric maintence may involve RECQL4 and the repair of the 
thymine glycol lesions that block DNA metabolism (Ferrarelli et al., 2013).  A high 
level of fragile telomeres were observed in the AG05013 and AG18371 RTS cell 
lines (Ghosh et al., 2012). It is possible that binding of DNA repair factors or other 
proteins involved in telomere replication are inhibited in RECQL4 mutated cells 
(Ghosh et al., 2012).  However, the fact that we were not able to show increase of 
telomeric damage in RTS cell lines, that is co-localisation of γH2AX and TRF2, does 
not support the above findings of the literature. The lack of co-localisation seen in 
our work could be due to short telomeres being scored as non-telomeric; chromatid 
ends in pre-senescent human cells that have extremely short telomeres may lack 
TRF2 foci (Nakamura et al., 2008). This is especially relevant to the data obtained 
where co-localisation was not observed and reduced or low TRF2 foci were also 
seen.  Although, unlikely relevant as short telomeres should not be present in the 
AG05013tert cells, and low passages were utilised for all RTS cell lines.      
Page | 199  
 
6.8 Isolation and identification of RECQL4 interacting partners (chapter 3, 
section 5). 
With the generated inducible RECQL4-Emerald tagged HeLa and U2OS clones, 
analysis of protein interactions was performed using the GFP-pulldown. RECQL4 
has been found to interact with many proteins involving different pathways (Table 
6.8-a), a few of which are discussed in detail below. GFP pulldown is a widely used 
technique (Trinkle-Mulcahy et al., 2008; Emmott and Goodfellow, 2014), however, 
there are limitations to be considered such as the influence the GFP tag fusion may 
have on the protein, discussed previously (see section 5.2.4.1).   
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Table 6.8-a Interacting protein with RECQL4.  Adapted from (Croteau et al., 2012b)  
Location Protein Recql4 region 
of interaction 
Interaction activity Reference 
Nuclear MCM10 1-200aa Helicase inhibition, 
replication complex. 
(Xu et al., 2009b) 
 RAD51 unknown DSBs repair (Reinhardt and 
Schumacher, 2012) 
 XPA unknown Nucleotide excision 
repair 
(Yin et al., 2004), (Fan 
and Luo, 2008) 
 POL  unknown DNA Polβ primer 
extension stimulation 
and activity 
(Fan and Luo, 2008) 
 APE1 unknown Stimulation of APE1 
endonuclease 
(Fan and Luo, 2008) 
 RPA unknown Stimulation of RECQL4 
helicase 
(Rossi et al., 2010) 
 BLM 1-471aa Stimulation of BLM  (Singh et al., 2012) 
 p300 1-408aa Cellular location of 
RECQL4 regulation 
(Xu and Liu, 2009) 
 Nucleophosmin 
(NPM) 
Unknown unknown (Wang et al., 2014b) 
Mitochondria TOM20 13-18aa Import into mitochondria (Croteau et al., 2012a) 
 p32  Promotes nuclear 
localization of RECQL4 
(Wang et al., 2014b) 
 TFAM Unknown unknown (Singh et al., 2010) 
 p53 270-400aa Silencing of RECQL4 
and p53 nuclear 
location signals 
(Croteau et al., 2012a) 
Nuclear / 
telomere 
TRF1 Unknown Stimulation of RECQL4 
helicase and telomere 
maintenance  
(Werner et al., 2006) 
 TRF2 Unknown Stimulation of RECQL4 
helicase and telomere 
maintenance 
(Werner et al., 2006) 
 WRN unknown Stimulation of WRN on 
telomeric D-loop 
(Werner et al., 2006) 
Unknown Cut5 unknown DNA replication (Burks et al., 2007)
  
 PARP1 833-1208aa Base excision repair (Petkovic et al., 2005),  
(Schurman et al., 
2009). 
 URB1/2 Unknown Unknown  (Yin et al., 2004), 
(Woo et al., 2006) 
Cytosolic Protein 
Phosphatase 2A 
(PP2A) 
unknown unknown (Wang et al., 2014b) 
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As an inhibitor of histone deacetylase, SAHA was used in our study to identify 
RECQL4 interacting proteins which rely on posttranslational acetylation 
modifications, for regulating protein activity and transmitting signals throughout the 
cell (Cohen, 2000).  The study by Dietschy et al, (2009), was the first to demonstrate 
post-translational modifications of RECQL4, and following the acetylation of 
RECQL4 by p300, a significant proportion of RECQL4 protein was shifted from the 
nucleus to cytoplasm in vivo. We employed extended HU treatment to induce fork 
collapse and new origin firing (Park et al., 2006; Ghosh et al., 2012; Kohzaki et al., 
2012; Sidorova et al., 2013) and to see if it influences interactions and modifications 
of RECQL4.  
We found PP2A/A α and β isoforms in the pulldown from U2OS cells, however, we 
could not verify the interaction with western blot analysis. A low amount of PP2A 
was detected in the pulldown from SAHA treated HeLa cells.   We were also able to 
detect MCM10 in the bound fraction of the pulldown, however, its abundance was 
mainly reflected by levels of RECQL4, and was not always seen. Wang et al (2014) 
suggested RECQL4 was transported to the mitochondria, and although MCM10 can 
also be found there, it mainly remained at the outer mitochondrial membrane.  
RECQL4 may dissociate from MCM10 via other protein interactions.   
6.8.1 Novel RECQL4 interacting proteins (chapter 3, section 5.3) 
Excitingly, novel RECQL4 protein interactions were detected; Engrailed-1 (EN-1), 
Engrailed-2 (EN-2), and Highly Divergent Homeobox (HDX).  HU treatment 
appeared to induce an increase in HDX levels in the complex. HDX is a hitherto 
uncharacterised protein, also known as CXorf43. It belongs to the POU-class 
homeobox genes, which contains 16 related genes in the human genome. HDX, 
unlike the other members, does not encode a POU-specific domain, for which it has 
been placed into a new class within this family. HDX encodes a highly divergent 
atypical homeodomain (Holland et al., 2007).  It has been found to be significantly 
enriched during embryonic development (Dennis et al., 2003), while its expression 
is reduced in breast and other cancer cells (Yamamoto et al., 2011).  Missense 
mutations in HDX could be involved in the pathogenesis of acute promyelocytic 
leukemia (APL) (Greif et al., 2011).  Homeobox transcription factors have a role in 
the regulation of cell identity, and are involved in normal and malignant 
haematopoesis; the dysregulation of the ‘Hox code’ may play an important role in 
myeloid malignancy development (Eklund, 2007).  Following the knockdown of 
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osterix, HDX was found to be upregulated in mouse chondrogenic ATDC5 cells 
(Park and Kim, 2013).  Another study suggested HDX may be relevant in mental 
retardation (Honda et al., 2010). Other homeobox gene mutations have also been 
linked to mental retardation, epilepsy, or other movement disorders (Wigle and 
Eisenstat, 2008).  
Two further Homeobox proteins, EN-1 and EN-2 were detected by mass 
spectrometry.  EN-2 was further analysed by western blot, and was confirmed to be 
present in RECQL4 bound fractions, however, this finding requires verification.  
SAHA treatment may cause an increase in the level of EN-2 in the complex.  
Homeobox genes are a superfamily of regulatory genes and encode homeodomain-
containing transcription factors.  The homeobox itself is a 183-bp DNA sequence 
that encodes a 61 amino acid homeodomain within the HOX proteins.  The 
homeodomain recognises and binds sequence-specific DNA motifs (Mcginnis and 
Krumlauf, 1992).  In humans 39 HOX genes have been identified, and shown to 
have roles in apoptosis, differentiation, receptor signalling, motility, and 
angiogenesis (Shah and Sukumar, 2010).   
Engrailed is a member of the homeobox gene family, characterised first in 
Drosophila (Wedeen and Weisblat, 1991). The human genome contains two copies 
of Engrailed, EN-2 and EN-1, which hold important roles in early embryonic 
development and in normal human neuronal development (Sillitoe et al., 2008; 
Morgan et al., 2011; Mcgrath et al., 2013).  The overexpression of EN-2 has been 
found in cancers, and it is suggested as a potential oncogene in breast cancer.  
Following the suppression of EN-2 in a human breast cancer cell line, a significant 
decrease in proliferation was found (Martin et al., 2005).  Similarly, a decrease in 
prostate cancer cell proliferation was observed following siRNA mediated 
knockdown of EN-2, which in turn decreased PAX-2 expression (Martin et al., 2005; 
Bose et al., 2008).  Hypermethylation of EN-1 has also been seen in colorectal 
cancer, prostate cancer, and astrocytoma (Mayor et al., 2009; Wu et al., 2010; 
Devaney et al., 2011).   A number of homeodomain containing proteins of the HOX 
family were found to play roles in replication (De Stanchina et al., 2000; Comelli et 
al., 2009; Salsi et al., 2009; Falaschi et al., 2010; Marchetti et al., 2010; Miotto and 
Graba, 2010). Interestingly, a study found the N-terminus of RECQL4 to adopt a fold 
similar to homeodomains, and the domain is involved in the interaction with TopBP1 
(Ohlenschläger et al., 2012).    
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7 Conclusion 
 
RECQL4 holds an important role in DNA replication, further demonstrated by its 
known interactions with DNA replication factors crucial for the initiation of DNA 
replication (Im et al., 2009; Xu et al., 2009; Thangavel et al., 2010). To enable a 
model of mild replication interference, to an extent expected in RTS patients, PHA-
767491 was used in our study to reduce the activity of CDC7/DBF4, a kinase with a 
key role upstream of RECQL4 in replication initiation.  Reduced proliferative rate 
was demonstrated in PHA-767491 treated ASC52telo cells (under acute as well as 
chronic treatment), in agreement with literature results (Montagnoli et al., 2008; 
Vanotti et al., 2008; Natoni et al., 2013; Fitzgerald et al., 2014; Sasi et al., 2014; 
Erbayraktar et al., 2016). 
RTS patients present predominantly osteoblastic OS (Sim et al., 1992; Werner et 
al., 2006; Hicks et al., 2007; Zils et al., 2015).  Our findings using ASC52telo cells 
under PHA-767491 model did appear to influence osteoblastic markers; calcium 
and RUNX2, following osteocyte differentiation. Using qualitative methods, we 
found that calcium levels appeared to increase following PHA treatment post 
osteocyte differentiation, despite reduced cell numbers due to the mild proliferation 
inhibition.  High calcium levels can lead to cellular disruption, and may influence 
cancer cell progression (Mundy, 2002; Santini et al., 2012; Daft et al., 2015).  High 
calcium levels have also been reported in osteosarcoma patients (Kharb et al., 
2012).  Quantification methods are required to determine if the qualitative data within 
our study is a true representation of calcium levels.  The expression of RUNX2 is 
suggestive of MSCs commitment towards differentiation into osteoblasts (Ducy et 
al., 1997; Komori et al., 1997; Tang et al., 2008; Komori, 2010). Interestingly, our 
findings suggest an elevation of RUNX2 expression following acute PHA-767491 
treatment in ASC52telo osteocyte differentiated cells. An elevation of RUNX2 levels 
have been observed in OS cells (Nathan et al., 2009; Martin et al., 2014).  The 
overexpression of RUNX2 has been reported as potentially leading to disrupted 
osteoblast differentiation.  Impaired osteoblast differentiation can lead to genomic 
instability, and OS (Andela et al., 2005; Lu et al., 2008; Tang et al., 2008; Pereira et 
al., 2009; San Martin et al., 2009; Won et al., 2009; Kurek et al., 2010; Martin et al., 
2010; Martin et al., 2014).  We investigated further if these cells underwent cellular 
transformation.  Our findings showed that PHA-767491 treated ASC5telo cells 
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demonstrate these osteoblastic differentiation markers under normal (non-
differentiating) media, showing significant increase of RUNX2 levels and 
observation of high calcium levels. The data obtained suggest the dysregulation of 
osteoblast differentiation drivers under acute and chronic PHA-767491 treatment, 
however, further verification is required to support this conclusion.    
 
The dysregulation of mitochondrial function can lead to diseases (Archer, 2013; 
Magalhães et al., 2014; Singer, 2014). Therefore, we considered mitochondrial 
maintenance in our PHA model.  Our findings showed no significant changes of 
mitochondrial activity, measured by membrane potential, in acute and chronic PHA-
767491 treated cells, demonstrating lack of mitochondrial alterations in these cells.  
However, RECQL4 may hold a role in mitochondrial maintenance (Croteau et al., 
2012), which is likely to be independent of its role in replication initiation. 
 
We found that ASC52telo cells under acute and chronic PHA-767491 treatment 
demonstrated the presence of DNA damage,  with an increased occurrence of 
changes in nuclear morphology, suggestive of genomic instability.  Phosphorylation 
of H2AX (γH2AX) occurs as a localised response to DSB (Rogakou et al., 1998). 
γH2AX forms foci rapidly (Rothkamm and Horn, 2009), and remains until the DNA 
damage is repaired (Nakamura et al., 2006). As expected from literature data, we 
found that ASC52telo cells responded to Camptothecin treatment with the 
generation of γH2AX foci. ASC52telo cells with acute and chronic PHA-767491 
treatment demonstrated significantly high levels also, with levels returning to 
background in low passage cells released from treatment.  Importantly, the same 
degree of return to normal levels was not seen in high passage cells released from 
PHA-767491 treatment under the same recovery conditions.   Effect of inhibition of 
replication initiation on telomere maintenance only appeared to be present in low 
passage ASC52telo cells under acute and chronic PHA-767491 treatment.  Not all 
of the DNA damage appears telomeric.    We found signs of activated DNA damage 
response with Phospho-CHK1 following chronic PHA treatment in low passage 
ASC52telo cells, suggesting the involvement of the ATR pathway (Bartek et al., 
2004; Dai and Grant, 2010).    Interestingly, in correlation to this, the significant 
activation of 53BP1 was shown in low passage chronic PHA treated cells.  However 
in acute treated cells the level of 53BP1 appeared reduced, compared to control 
cells, suggesting a lack or impairment of 53BP1 response in these cells.  Taken 
together, our findings suggest, cells under chronic replicative stress lead to signs of 
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sustained DNA damage, which may generate cells susceptible or sensitive to 
transformation during sustained PHA-767491 treatment or post recovery. To gain 
further insights into this process, transformation characteristics were investigated.   
ASC52telo cells under the PHA model were cultured over a prolonged time reaching 
a high cell density.  Our findings suggest continual cell growth in ASC52telo high 
passage cells released from chronic PHA-767491 treatment, which indicates 
impaired or loss of contact inhibition, a hallmark of cancer cells (Abercrombie, 1979; 
Hanahan and Weinberg, 2000). Although we would expect these cells to recover 
from PHA-767491, which would lead to an increase of proliferation, the level of 
continual growth was not observed in low passage cells and controls.  Further to 
this, high passage chronic PHA-767491 treated cells demonstrated signs of 
anchorage-independent growth, with spheroid cultures forming following the 
detachment from the extracellular matrix, which is another sign of transformation. 
The cells may have acquired resistance to anoikis or programmed cell death (Kang 
et al., 2007).    
In conclusion, we developed a model of replicative stress in ASC52telo cells that 
induced cellular changes indicative of DNA damage following chronic PHA-767491 
treatment. These changes were sustained following recovery and may lead to the 
development of transformation characteristics, as depicted in Figure 7-1 (blue 
arrows), alongside our hypothesis. RECQL4 mutations could generate 
chromosomal instabilities causing disruption to osteocyte differentiation.  The 
dysregulation is likely to have pathological consequences, and may be relevant to 
characteristics of RTS disease and the predisposition to OS.   
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Figure 7-1 DNA damage resulting in dysregulation of osteoblast differentiation and OS development. Sustained DNA 
damage occurs following chronic mild inhibition of DNA replication initiation (PHA-767491 model) which may lead to 
dysregulation in osteogenesis regulator factors (our findings, blue arrows), which could lead to differentiation dysregulation 
and osteosarcoma.  We suggest RECQL4 mutations lead to chromosomal instabilities causing the dysregulation of osteocyte 
differentiation and osteosarcoma development (red arrows).     
 
The AG05013tert fibroblast cell line, a TERT immortalized RTS cell line with 
documented RECQL4 mutations (Kitao et al., 1999b), demonstrated sensitivity to 
acute PHA-767491 treatment, however, the same was not observed following the 
siRNA knockdown of RECQL4 in U2OS an HeLa cells.  The lack of sensitivity to 
PHA-767491 in these cells could be explained by incomplete depletion of RECQL4 
levels, or the reduction of siRNA efficiency over time (Jacobsen et al., 2004). Further 
investigations using other RTS cell lines would verify our findings.  With the use of 
PHA-767491 treatment in ASC52telo we established an in vitro cell culture model 
under acute and chronic replicative stress, and recovery.   
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Our findings demonstrate induced chromosomal instabilities due to mild inhibition of 
DNA replication.  Some of these markers were further investigated in a group of 
RTS cell lines: AG05013tert, AG18375, and AG03587 cells, to link to RECQL4 
mutations. Patients with RTS have been found to demonstrate genomic instabilty 
(Der Kaloustian et al., 1990; Ying et al., 1990; Orstavik et al., 1994; Lindor et al., 
1996; Miozzo et al., 1998).  Although there appears to be variation of reports in the 
literature, an association has been suggested between RECQL4, S-CIN and OS 
(Maire et al, 2009), with  truncating RECQL4 mutations associated with a higher risk 
(Wang et al., 2003).   We found significant increase of γH2AX intensity in the 
AG05013tert RTS cell line, suggesting greater extent of DSB damage in these cells. 
An increase of telomeric DNA damage was observed in AG05013tert cells, but was 
not evidenced in AG18375 and AG03587 RTS fibroblasts, suggesting a potential 
role of RECQL4 in TERT mediated telomere maintenance, which warrants further 
investigations given the presence of DNA damage markers in this cell line.  Overall, 
it is difficult to suggest a reason for the evidence of DNA damage in the RTS 
AG05013 cells, which is not found in the other RTS cell lines (AG18375 and 
AG03587), as some mutation characteristics known are shared.  Similarly, 
proliferative rate was also found variable between specific RTS cell lines.  We found 
variability of DNA damage response between RTS cell lines as well, which has also 
been reported in the literature (Smith and Paterson, 1982; Shinya et al., 1993; Kerr 
et al., 1996; Lindor et al., 2000), reflecting heterogeneity of these cells (Schurman 
et al., 2009). Further studies are required to perhaps identify if specific mutations 
are generating or providing a sensitised environment for DNA damage and 
tumorigenesis, conceivably through interacting proteins and pathways.    
We investigated RECQL4 interacting proteins and identified known binding partners 
of RECQL4; MCM10, and low levels of Protein phosphate 2 A (PP2A), previously 
reported in the literature (Xu et al., 2009; Wang et al., 2014).  The co-localisation of 
PP2A and RECQL4 was reported to be restricted to the cytosolic RECQL4 complex 
(Wang et al., 2014).  This could explain the lack/low efficiency of pulldown of PP2A 
seen in our study, as RECQL4 expression was primarily observed in the nucleus of 
our cells.   We found novel interactions with highly divergent homeobox (HDX) and 
homeobox protein EN-2.  Although there is little information on HDX in the literature, 
HDX may have a role in human disease, and tumourigenesis (Honda et al., 2010; 
Greif et al., 2011; Yamamoto et al., 2011).  EN-2 has been reported to play a role in 
proliferation and human disease, including cancer (Bose et al., 2008; Rissling et al., 
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2009).  Pulldown levels appeared variable following SAHA and HU treatment, which 
may be influenced by other parameters.  These novel findings could lead to 
furthering our understanding of RECQL4 and potential novel pathways and roles.  
6.9 Overall findings and future directions 
Our study (Schematic 6.3-1), demonstrated the accumulation of chromosomal 
changes that may be required to drive tumourigenesis, and are acquired over 
several cell cycles in long term culture with cellular stress generated by chronic 
PHA-767491 treatment. Further to this, our findings suggest that chronic PHA-
767491 treatment leads to the development of transformation characteristics, which 
become permanent, as after withdrawal of treatment the transformed phenotype is 
not reversed.  Further investigations involving other markers of osteocyte 
differentiation would verify our findings and perhaps the dysregulation of 
differentiation regulation. 
To verify our hypothesis, the ASC52telo cell line would be transduced using the 
generated RECQL4 shRNA lentiviral vector, enabling a model of ASC52telo cell line 
with stable and long term RECQL4 knockdown to be established, differentiated into 
osteoblasts, while analysing for DNA damage, during and post differentiation.  We 
know from a recent study that adipose derived mesenchymal stem cells (ASCs) may 
play a role in OS development (Wang et al., 2017).  It would be interesting to 
establish if impaired ASCs following RECQL4 knockdown may provide the 
microenvironment forming a niche that supports OS development (Hanahan and 
Coussens, 2012; Turley et al., 2016).  This will enhance our understanding to 
establish a direct link between impaired replication initiation due to RECQL4 
mutations, consequential chromosomal abnormalities and the development of 
malignancies, in particular osteosarcoma.  
The novel protein interactions found with RECQL4 are exciting and verification of 
these could lead to new pathways or RECQL4 roles.  Literature data suggest that 
RECQL4 is a double-edged sword, and perhaps RECQL4 depletion alone may not 
be the only driving force of osteosarcoma development.  Depleting RECQL4 with 
lentivirus delivered shRNA in mesenchymal stem cells could verify our hypothesis 
of its involvement in osteoblast differentiation, and if dysregulation and/or 
impairment can lead to osteosarcoma.  
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